














Structural and Functional Investigation of Bacterial Membrane Biosynthesis 
 
 


















Submitted in partial fulfillment of the requirements  
for the degree of Doctor of Philosophy  













































Meagan Belcher Dufrisne 
 










Structural and Functional Investigation of Bacterial Membrane Biosynthesis 
Meagan Belcher Dufrisne 
 
 Integral membrane enzymes contribute a unique repertoire to the cell, as they are 
capable of synthesizing products from substrates of different chemical character at the 
membrane-water interface. Membrane-embedded enzymes are often responsible for the 
synthesis of important components of the cellular membrane and contribute to the structural 
integrity of the cell, maintenance of cellular homeostasis and signal transduction. One of the main 
focuses of Dr. Filippo Mancia’s laboratory is understanding how enzymes complete these 
functions by investigating, at an atomic level, the determinants of substrate binding and catalysis 
within the membrane and at the membrane surface. Here I will present my investigation of two 
such integral membrane enzyme systems, which are responsible for the synthesis and processing 
of membrane-embedded molecules in bacteria.  
 
Phosphatidylinositol-phosphate Synthase (PIPS) 
Phosphaitylinositol (PI) is an essential lipid component in mycobacteria, demonstrated 
by loss of viability when PI is reduced to 50% of wild-type levels. Phosphatidylinositol (PI) is 
required for the biosynthesis of key components of the cell wall, such as the glycolipids 
phosphatidylinositol-mannosides, lipomannan and lipoarabinomannan. For these molecules, PI 
serves as a common lipid anchor to the membrane. In Mycobacterium tuberculosis, the disease 
causing pathogen of tuberculosis, these glycolipids function as important virulence factors and 
modulators of the host immune response. Therefore, the enzyme responsible for PI synthesis in 
this organism is a potential target for the development of anti-tuberculosis drugs.    
	
	
The defining step in phosphatidylinositol biosynthesis is catalyzed by a member of the 
CDP-alcohol phosphotransferase enzyme family. The enzyme uses CDP-diacylglycerol as the 
donor substrate, and either inositol in eukaryotes or inositol-phosphate in prokaryotes as the 
acceptor alcohol of the synthesis reaction. In prokaryotes, phosphatidylinositol-phosphate 
synthase (PIPS; a member of the CDP-alcohol phosphotransferase family) catalyzes this reaction 
to yield phosphatidylinositol-phosphate, which is then dephosphorylated to PI by an 
uncharacterized enzyme.   
Structures of PIPS from Renibacterium salmoninarum (RsPIPS), with and without 
bound CDP-diacylglycerol, have revealed the location of the acceptor site as well as molecular 
determinants of substrate specificity and catalysis of the enzyme. However, RsPIPS has low 
activity relative to PIPS from Mycobacterium tuberculosis (MtPIPS) and the two share only 40% 
protein sequence identity. Therefore, these initial structures have limited potential for meaningful 
homology modeling and drug design. Presented here are the structures of PIPS from 
Mycobacterium kansasii (MkPIPS), which is 86% identical to MtPIPS, in an apo state to 3.1 Å 
resolution, in a nucleotide-bound state to 3.5 Å resolution, and in a novel ligand-bound state to 
2.6 Å resolution. This work provides a structural and functional framework to understand the 
mechanism of phosphatidylinositol-phosphate biosynthesis in the context of mycobacterial 
pathogens.    
 
RodA-PBP2 Complex 
 The cell wall of most gram-negative and gram-positive bacteria (excluding atypical 
bacteria such as members of Mycoplasmataceae) is composed of peptidoglycan, a mesh of 
repeating carbohydrates (N-acetylmuramic acid, MurNAc, and N-acetylglucosamine, GlcNAc) 
cross-linked by small peptides. Peptidoglycan is essential for growth, division and viability of the 
organism. Any disruption of the biosynthesis of peptidoglycan, whether by genetic mutation, 
	
	
inhibition with antibiotics or degradation by lysozyme, results in bacterial cell lysis. Peptidoglycan 
helps maintain cell shape and serves as an anchor for accessory proteins and other cell wall 
components. As essential components of the cell wall, enzymes contributing to the peptidoglycan 
biosynthetic pathway can be exploited as antibiotic targets.  
 After a hydrophilic peptidoglycan precursor (UDP-MurNAc-pentapeptide) is 
synthesized in the cytosol, it is attached to the lipid carrier undecaprenyl phosphate (UndP). The 
lipid-linked precursor (undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide or Lipid I) is modified 
further to undecaprenyl-pyrophosphoryl-MurNAc-(pentapeptide)-GlcNAc (Lipid II) by addition of 
a GlcNAc moiety. Lipid II is then flipped across the membrane to the periplasm where its sugars 
are polymerized to form the glycan strands of the peptidoglycan mesh. SEDS proteins, essential 
for maintaining bacterial processes that determine shape, elongation, cell division and 
sporulation, are integral membrane enzyme that have been implicated in this process as either 
Lipid II flippases, glycosyltransferases responsible for sugar polymerization, or both. SEDS 
proteins are also known to form a functional complex with type b penicillin-binding proteins 
(PBPs), which are known as transpeptidase enzymes, responsible for the crosslinking of peptides 
in the formation of the peptidoglycan mesh.  
 Though structures of both RodA (a SEDS protein involved in bacterial growth and 
elongation) and type b PBPs are available, the interaction between the two proteins and their joint 
enzymatic activity is poorly characterized. Here, I present the preliminary structural 
characterization of a RodA-PBP2 protein complex by single-particle cryo-electron microscopy 
(cryo-EM). We hope this ongoing work will contribute to the understanding of these enzymes and 
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     Membrane-embedded enzymes achieve crucial cellular functions, including the 
synthesis of membrane components, preservation of cell structural integrity, maintenance of 
cellular homeostasis and signal transduction. The specialized lipid environment of integral 
membrane enzymes facilitates their unique function. Existing in a lipid suspended state that 
partitions aqueous solutions, these enzymes are poised for their unique roles catalyzing the 
movement or synthesis of molecules of mixed chemical character. The question of how this is 
achieved is one of the main focuses of Dr. Filippo Mancia’s laboratory. We seek to characterize 
the determinants of substrate binding and catalysis of this type of enzyme. In my Ph.D., I was 
encouraged to pursue a number of projects in parallel and was included in the characterization of 
several bacterial membrane enzymes using structural biology as the main tool of investigation. 
As a result, my dissertation will be focused on two main projects. I will be addressing them in two 
sections.  
      First (Chapters 1-4), I will be discussing the structural and functional characterization 
of the enzyme Phosphatidylinositol-phosphate Synthase (PIPS) from Mycobacterium, which 
synthesizes a precursor of phosphatidylinositol, an important scaffolding lipid for several key 
components of the mycobacterial cell wall. Chapter 1 will be dedicated to background and 
significance of the completed work and Chapters 2-4 will focus on methods, results and 
discussion of different aspects of the project, as well as the future direction of this research. 
 Second (Chapters 5-7), I will be discussing the preliminary structural and functional 
characterization of a RodA-PBP2 protein complex, known to play a key role in synthesis of 
peptidoglycan during cell growth and elongation. Chapter 5 will give background and context to 
the completed work and Chapters 6 and 7 will detail methods, results, conclusions and an outline 




Finally, in Chapter 8, I present a published review for which I am the main contributor. It 
details the current structural landscape of enzymes that catalyze reactions with substrates of 
mixed chemical character at the interface of the lipid membrane and aqueous environment, thus 









Phosphatidylinositol-phosphate Synthase: Background and Significance 
 
1.1 Threat of tuberculosis 
 In 2016, tuberculosis (TB) disease claimed the lives of approximately 1.3 million 
people, making it the deadliest infectious disease in the world ahead of even HIV and malaria and 
one of the top ten causes of death worldwide (Figure 1.1 B). It is estimated that one third of the 
world’s population is infected with Mycobacterium tuberculosis, the disease-causing pathogen of 
TB (Figure 1.1 C), in a latent or active form, and there were approximately 10.4 million cases of 
active disease in 2016 (Figure 1.1 A)[1]. The most common form of TB is pulmonary tuberculosis, 
which is spread by the inhalation of M. tuberculosis expelled into the air by the coughing or 
sneezing of a diseased patient. M. tuberculosis is then taken up by macrophages where M. 
tuberculosis is able to arrest phagosome maturation, allowing the bacterium to successfully evade 
the immune system and wait latently, often for years, to present pathogenically. TB flourishes in 
crowded or unsanitary conditions and still plagues much of the developing world [2, 3].  
 
1.2 Available treatments for tuberculosis 
The Bacillus Calmette-Guérin (BCG) vaccine has been widely implemented since its 
development in 1921 as a prophylactic measure against pulmonary TB and other extra-pulmonary 
TB diseases. It is still commonly used in areas of high TB occurrence and in children who are at 
a higher risk for exposure to M. tuberculosis. A recent meta-analysis reported that BCG has a 
protective rate against infection between 19 and 28% in children. Of those infected, progression 
to active disease was reduced 58% in vaccinated individuals [4]. BCG is more effective against 




manifestations of the disease [5]. BCG is known to be less effective in adults and reports of 
vaccine efficacy do not take into account HIV co-infection [6, 7]. 
 
Figure 1.1 Tuberculosis (TB) prevalence. A) World map colored according to incidence of active TB 
in population per 100,000 in 2016 (increasing incidence light green to dark green). B) Top ten causes of 
death worldwide. Grey section of bar indicates deaths from cases of TB and HIV co-infection. C) Electron 






 Antibiotics to treat TB are also widely available, but long treatment courses and 
unpleasant side effects can make patient compliance difficult. For example, the first line of 
defense to treat a naïve patient infected with non-resistant TB is a course of four different drugs 
(isoniazid, ethambutol, rifampin, and pyrazinmide) taken every day for six months [1]. With drug 
resistant TB, treatment courses only get longer and more complex, using more expensive drugs 
with worse side effects. The treatment of TB has also been plagued historically with supply issues, 
which can make compliance impossible [8].  
 The development of anti-tuberculosis drugs is becoming more of a global priority. After 
a 40-year span in which no novel anti-tuberculosis drugs were approved by the FDA [9], two drugs 
have been recently approved, bedaquiline (2012) [9] and delamanid (2014) [10]. There are also 
many therapeutics in the drug development pipeline [11], but the usefulness of approved drugs 
can be limited by negative drug interactions with other anti-tuberculosis therapies or 
antiretrovirals, and can be impractical for broad use if they cannot be taken orally [11, 12]. Though 
were are seeing a revitalization in drug development efforts, the need for novel drug targets 
remains high, in part due to the ever-increasing threat of drug resistant TB.    
 
1.3 Emergence of drug resistant M. tuberculosis 
 The global problem of TB is further exacerbated by the emergence of drug resistant, 
multi drug resistant (MDR), extensively drug resistant (XDR) and totally drug resistant strains of 
M. tuberculosis. The prevalence of MDR-TB is increasing in both number of cases and as a 
percentage of all tuberculosis cases (Figure 1.2 A and B). In 2016, 4.1% of all TB cases and 20% 
of recurring cases were identified as MDR. XDR-TB is also on the rise. The WHO global 
tuberculosis report notes a 17% rise in XDR-TB cases from 2015 to 2016 to a total of 8511 
reported cases worldwide. The WHO global tuberculosis report also emphasizes that drug 




in many areas, highlighting an even larger tuberculosis burden [1]. Many challenges of TB 
treatment have contributed to the emergence drug resistant M. tuberculosis.  
 Patient compliance is most often cited as a major factor in the emergence of drug 
resistant TB, however this is only part of the picture. M. tuberculosis tends to accumulate 
resistance through mutation or genetic rearrangement of drug targets, drug efflux enzymes, or 
enzymes responsible for processing pro-drugs. These mutations vary widely, making the drug 
resistant landscape of M. tuberculosis incredibly complex. The variation in genetic mechanism of 
resistance changes the needs of treatment. Lack of resources in many endemic areas can limit 
the sophistication of diagnostics used in identifying the resistance profile. Because of this, 
resistant strains can be mistreated, adding cyclically to the problem of antibiotic resistance [13].  
 HIV co-infection can also limit treatment options due to a patient’s altered ability to 
tolerate drugs and unique drug interactions that have to be considered [14]. This often leads to 
the use of less efficacious medications, which can contribute to emerging resistance. Infection 
with HIV and subsequent suppression of the immune system also dramatically increases the 
chance of developing active TB. This in turn gives more opportunity for patients to spread the 





 The complexity of this problem demands solutions coming from all fronts. To battle 
this problem, research is focusing on development of new diagnostics, drugs and vaccines. Later 
in this chapter, I will present one potential drug target, Phosphatidylinositol-phosphate Synthase 
(PIPS), the structural and functional characterization of which is a main focus of this thesis.  
 
Figure 1.2 Emergence of drug-resistant TB. A) World map indicating estimated incidence of multi-
drug resistant (MDR) and rifampin resistant (RR) TB. *for countries with a minimum of 1,000 incident 
cases. B) New cases of pulmonary TB detected as being MDR as percentage of new cases (right) and 





1.4 Cell wall of mycobacteria 
 The waxy cell wall of mycobacteria is a exhibits a more complex structure than in other 
bacteria (Figure 1.3 A, B, and C) and is a significant hurdle in anti-tuberculosis drug development. 
It forms a barrier with low permeability, preventing the cellular entry of external molecules, such 
as antibiotics [16]. For anti-tuberculosis drugs to be successful, they must infiltrate this cell wall. 
The cell wall of mycobacteria has an inner lipid bilayer, which is decorated with peptidoglycan 
similar to gram-negative and gram-positive bacteria. However, the peptidoglycan mesh of 
mycobacteria is covalently attached to another sugar layer made up of arabinogalactan branched 
sugars, which in turn are covalently attached to mycolic acids, forming the inner leaflet of the outer 
membrane. The outer leaflet of the outer membrane made up of a lipid array uncommon in gram-
positive and gram-negative bacteria [17].  
 Some of these uncommon lipids include complex glycolipid classes, such as 
phosphatidylinositol mannosides (PIMs), lipomannans (LMs) and lipoarabinomannans (LAMs), 
which are essential for cell growth and viability and can act as virulence factors and modulators 
of the host immune system (Figure 1.3 D)[18].  There is evidence that mannose-capped LAM and 
PIM6 (phosphatidylinositol modified with six mannose moieties, Figure 1.3 D) mediate binding to 
receptors on macrophages and dendritic cells, initializing phagocytosis [19]. In virulent species, 
after cell entry, the mycobacterium can prevent the maturation of the phagosomes to a lysosome, 
allowing for its survival in these cellular compartments where it can lay dormant for years before 





Figure 1.3 Cell wall of mycobacteria compared to gram-positive and gram-negative bacteria. A) 
Illustration of the cell wall of gram-positive bacteria. B) Illustration of the cell wall of gram-negative 
bacteria. C) Schematic of the cell wall of mycobacteria. D) Schematic of key cell wall factors, different 
Phosphatidylinositol Mannosides (PIM) species, lipomannan (LM) and lipoarabinomannan (LAM) in its 
mannose-capped form (ManLAM). Figure made with reference to ([20] and [17]). Structural components, 




 PIMs, LM and LAM share a common phospholipid anchor, phosphatidylinositol. 
Furthermore, biosynthesis of phosphatidylinositol has been shown to be essential for growth and 
viability of Mycobacterium smegmatis [21].  The enzyme responsible for the biosynthesis of 
phosphatidylinositol in mycobacteria is phosphatidylinositol-phosphate synthase (PIPS), a 
member of the CDP-alcohol phosphotransferase enzyme family [21]. PIPS catalyzes the reaction 
between CDP-diacylglycerol (CDP-DAG) and inositol-phoshpate (IP), producing 
phosphatidylinositol-phosphate (PIP), which is dephosphorylated to PI by an uncharacterized 
enzyme (Figure 1.4). PI is synthesized by an alternative mechanism in eukaryotes, including 
humans, where PI is synthesized directly from CDP-DAG and inositol [22]. For these reasons 
PIPS may be a promising target for the development of novel anti-tuberculosis drugs. It’s potential 
for medical application encouraged our laboratory to pursue structural and functional 
characterization of this enzyme, including the work described in this thesis.    
 
Figure 1.4 Reaction catalyzed by Phosphatidylinositol-phosphate Synthase (PIPS) in 
mycobacteria. PIP-synthase, or PIPS, catalyzes the reaction between lipid substrate cytidine-
diphosphate diacylglycerol (CDP-DAG) and soluble substrate Inositol-phosphate (InsP; IP) in the 
presence of a divalent cation, to produce phosphatidylinsotiol-phosphate (PIP) and cytidine-
monophosphate (CMP).  
 
1.5 Phospholipid biosynthesis by CDP-alcohol phosphotransferase family of enzymes 
 CDP-alcohol phosphotransferases (CDP-AP) are integral membrane enzymes 
present across all levels of life. Members of the CDP-AP family share a conserved enzymatic 




acceptor in the presence of a divalent cation, resulting in a phosphodiester linked product (Figure 
1.5 A). These enzymes accommodate a variety of substrates of different character (Figure 1.5 B). 
For example, they can accommodate two soluble substrates (as is the case with Di-inositol-
phosphate-phosphate synthase (DIPPS); using substrates inositol-1-phosphate and CDP-
inositol), two lipidic substrates (as is the case with cardiolipin synthase; using substrates 
phosphatidylglycerol (PG) and CDP-DAG) or one soluble and one lipidic substrate (as is the case 
with eukaryotic PI synthase; using substrates CDP-DAG and inositol) [22-24]. Though the enzyme 
family is responsible for the synthesis of many diverse metabolites under this conserved 
mechanism, we are particularly interested in are those that synthesize glycerophospholipids such 
as phosphatidylinositol (PI), phosphatidylglycerol (PG), phoshatidylethanolamine (PE), cardiolipid 
(CL), and phosphatidylcholine (PC). These lipids are essential for maintenance of the lipid bilayer, 
which is the scaffold of the bacterial cell wall [25]. PI is particularly important to the mycobacterial 
membrane as previously discussed in this chapter (section 1.4). 
 CDP-APs share an eight amino acid signature sequence 
(D1xxD2G1xxAR…G2xxxD3xxxD4), which is absolutely conserved across all levels of life (Figure 
1.5). It was initially identified as a seven amino acid signature sequence excluding D1 of the 
sequence above. However more recent biochemical characterization and bioinformatics analysis 
has identified a preceding conserved aspartic acid residue that is also important for enzyme 
function and lengthening the CDP-AP signature motif to 8 amino acids [23]. 
 Though the reaction is well defined and conserved among the members of the CDP-
AP family, early biochemical characterization has produced some variation in reports of the 
chemistry of catalysis. Many studies of CDP-APs have identified an ordered bi-bi reaction 
mechanism, where both substrates must bind sequentially before the product is made ([26], [27], 
[28], [29], [30]). This is the generally accepted catalytic mechanism of this family of enzymes. 




and is catalyzed to an intermediate product before binding of the second substrate. Many of these 
enzymes, though catalyzing identical reactions forming the same phosphodiester-linked product, 
turned out to be part of different enzyme families which share an alternative consensus sequence 
(HxK(U)4D(x)4UUGO) [31], [29], [32]. However, there is still evidence of a ping-pong mechanism 
in at least one case of a CDP-AP enzyme. A bacterial phosphatidylcholine synthase (PCS) was 
shown to hydrolyze the CDP-linked product, releasing CMP prior to product formation and 
independent of the alcohol substrate binding, [33]. The ordered sequential bi-bi mechanism is 
widely accepted for CDP-AP enzymes, however these enzymes are far from being completely 
understood. More recent structure-function studies of CDP-alcohol phosphotransferases have 





Figure 1.5 CDP-alcohol phosphotransferase enzymes. A) Common reaction scheme for all CDP-AP 
enzymes in which the reaction between a CDP-linked donor and an alcohol-acceptor is catalyzed to form 
a phosphodiester-linked product and CMP in the presence of a divalent cation. B) Table of CDP-AP 
enzymes, substrates and products. Lipidic substrates in bold type. DIPP, di-inositol-phosphate-
phosphate; PI, phosphatidylinositol; PGP, phosphatidylglycerol-phosphate; PC, phosphatidylcholine; 
PE, phosphatidylethanolamine; CL, cardiolipin; PS, phosphatidylserine; PIP, phosphatidylinositol-
phosphate. C) The conserved eight amino acid signature motif characteristic of CDP-AP enzymes. 




1.6 Af2299 and IPCT/DIPPS: structure and function 
 Two structures of CDP-APs from hyperthermophile bacteria were published at the 
same time – one from the Mancia Lab – and gave the first glimpses into enzyme architecture, 
substrate binding and catalysis.  
 Af2299 is a representative CDP-AP from Archaeoglobus fulgidus of unknown function, 
though by homology it is thought to catalyze the reaction between two water-soluble substrates 
inositol-phosphate and CDP-glycerol to synthesize glycerol-phospho-inositol (GPI), a metabolite 
found in extremophile (hyperthermophiles) bacteria [34, 35]. Structures of Af2299 were 
determined in our laboratory by crystallization in meso (also known as lipidic cubic phase; LCP) 
to 1.9 Å resolution with CMP bound in one active site (PDB 4O6M), to 2.1 Å resolution with CDP 
bound in both active sites (PDB 4O6N), and to 3.1 Å resolution bound to CDP-glycerol (PDB 
4Q7C). The structures show that it is a dimer with each monomer being made up of a soluble 
cytidylyltransferase-like domain (CTD), a juxtamembrane helix, and six transmembrane helices, 
which surround a polar cavity that is open to the cytosol (Figure 1.6 A and B). The presence of 
the soluble CTD is unique to CDP-AP enzymes of archea and is observed in other instances to 
function with the CDP-AP as a bifunctional enzyme, such is the case with IPCT/DIPPS (discussed 
later in this section). In the case of Af2299, the CTD is thought to be an evolutionary relic, because 
when compared with active cytidylyltransferase enzymes, the active site of the Af2299 CTD is 
mutated and expected to be non-functional.  
 The Af2299 structure allowed the location of the CDP-AP eight amino acid signature 
motif between TM2 and TM3 (Figure 1.7 A). Structures of the enzyme bound to CDP-glycerol 
(PDB 4Q7C) and CDP (PDB 4O6N) elucidated the conserved CDP chemical group binding in the 
area flanked by this signature motif (Figure 1.7 B). The structure also identifies D1, D2 and D3 of 
the CDP-AP signature motif as residues responsible for coordinating the phosphate groups of 




site and putative acceptor site, is more likely central to catalysis. The Af2299 paper proposes a 
mechanism in which D4 activates the alcohol group of the acceptor, prompting a direct 
nucleophilic attach on the CDP-liked donor. The conclusions drawn about function and catalysis 
are based solely on structural interpretation, so it was not possible to make a conclusion whether 
this enzyme functions by an ordered bi-bi mechanism or a ping-pong mechanism (Figure 1.7 C).  
 IPCT/DIPPS, also from Archaeoglobus fulgidus, is a dual function enzyme with a 
cytidylyltransferase domain that acts first to synthesize CDP-inositol from CTP and inositol-
phosphate (inositol-phosphate cytidylyltransferase; IPCT) to be used in the reaction of the CDP-
AP DIPPS with inositol-phosphate to synthesize di-inositol-phosphate-phospahte. The structure 
of IPCT/DIPPS was determined to 2.65 Å resolution in its apo state (PDB 4MND) and shares a 
very similar architecture to the Af2299 enzyme (Figure 1.6 C and D) [23]. It also forms a dimer 
with each monomer being made up of a soluble domain, juxtamembrane helix (connector helix 2) 
and six transmembrane helices. The authors were also able to show that mutation of any one of 
the conserved residues caused a considerable ablation in enzyme function. This abrogation of 
function was especially marked when D2 of the signature sequence was mutated to an alanine, 
suggesting this mutation may disrupt metal binding essential for enzyme function. Based on 
previous characterization of CDP-APs, this paper proposes a sequential bi-bi mechanism, also 
with D1 or D4 acting as a catalytic base to facilitate a direct nucleophilic attack on the ß-






Figure 1.6 Structures of Af2299 and IPCT/DIPPS. The overall architecture of the Af2299 dimer (A; 
PDB 4O6M) is shown in ribbon representation superimposed over a transparent spacefill model. One 
monomer is colored, the transmembrane enzyme in rainbow with the putatively inactive CTD in grey. 
The other monomer is colored in grey. The Af2299 monomer is presented below (B) with a slice through 
the TM portion demonstrating the TM organization. IPCT/DIPPS dimer (C; PDB 4MND) is represented 
similarly, with the active IPCT domain in blue and the DIPPS enzyme colored by rainbow. The monomer 




 These structures have advanced our understanding of CDP-APs in general and have 
given a detailed framework for future studies. Analysis of the crystal packing of both enzymes 
also revealed that the CTD of each enzyme was essential for forming crystal contacts. Without 
the soluble domain, there is not much protein mass physically available outside of the detergent 
micelle or lipid environment, which is why early attempts to crystalize CDP-APs lacking this 
domain failed to produce diffracting crystals. The structures of these enzymes inspired the crystal 
engineering approach that led to the structure determination of the RsPIPS enzyme [36] as well 
as the work described in Chapter 2 to Chapter 6 of this thesis.  
 
Figure 1.7 CDP-AP motif and proposed catalytic mechanism. A) The Af2299 dimer is shown with 
monomers colored in blue and grey. Conserved signature motif is found at the cytosolic side of TM2 and 
TM3 (purple with eight conserved residues in green) where CDP is bound. B) Schematic representation 
of CDP binding, highlighting the role of conserved residues (red). C) The proposed catalytic mechanism 
based on the Af2299 structure involves D4 acting as a catalytic base, activating the acceptor substrate 
(R2-OH) to attack the beta-phosphate of the CDP group (pale green). This forms a phosphodiester-linked 





1.7 PIPS from Renibacterium salmoninarum 
 The structure of PIPS from Renibacterium salmoninarum (RsPIPS) was reported from 
our laboratory [36]. The structure of RsPIPS was solved using a crystal engineering approach, in 
which the N-terminal CTD domain of Af2299 was genetically fused to the N-terminus of the PIPS 
gene to promote the formation of crystal contacts. This approach worked well, allowing us to 
determine the structures of RsPIPS with and without bound CDP-DAG lipid to 3.6 and 2.5 Å 
resolution, respectively. The structure shows a similar topology to Af2299 and IPCT/DIPPS, 
containing a short juxtamembrane helix (JM1) at the cytosolic face of the membrane and six 
transmembrane helices (Figure 1.8). The organization of the conserved CDP binding pocket is 
the same, however, the space between TM2 and TM5 forms a hydrophobic groove, which acts to 
accommodate the acyl lipid tails of CDP-DAG, a feature not seen in the two previous structures 
that catalyze reaction between soluble substrates only (Figure 1.9). We were also able to identify 
a putative inositol-phosphate binding site based on the binding of sulfate, oriented near the 
catalytic aspartic acid residue.  
 
 
   
 
Figure 1.8 Structure of RsPIPS. The structure of PIPS reveals a dimeric architecture, with each 
monomer made up of a juxtamembrane helix (JM1, dark blue) and six transmembrane (TM, light blue, 





RsPIPS has low activity, so a homology model of MtPIPS was employed to design 
mutants, which were then functionally characterized using a radiolabel-based enzymatic assay to 
determine the role of specific residues in substrate binding and catalysis (all residue numbering 
is according to the MtPIPS enzyme). We identified D93 (D4 in the CDP-AP signature motif) as 
the catalytic residue. When it is conservatively mutated to an asparagine, all enzyme function is 
lost without losing substrate binding. Along with the classic signature motif residues, P153, M69 
 
Figure 1.9 CDP-DAG binding to RsPIPS. RsPIPS structure colored as in Figure 1.8 overlayed on a 
transparent spacefill model. CDP-DAG is shown in purple and detailed panels are shown below 
highlighting the hydrophobic groove coordinating the acyl chain (left) and the CDP binding pocket (right). 




and D31 were identified as having a role in CDP-DAG binding (Figure 1.10). R155, R195, S132 
and K135, were identified as having a role in IP binding (Figure 1.10). In addition, phosphate 
(PO43-) and sulfate (SO43-) were shown to be inhibitors of the enzyme. We observed a CDP-DAG 
dependent reaction mechanism, where IP binding is dependent on the presence of CDP-DAG. 
This is evidence of a bi-bi reaction mechanism, consistent with most previous characterization of 
CDP-AP enzymes (see section 1.6 of this chapter). 
This structural characterization brings PIPS into focus, however RsPIPS, shares only 
40% sequence identity to PIPS from Mycobacterium tuberculosis (MtPIPS). And as previously 
mentioned, RsPIPS exhibits low activity in functional assays, so it is arguably not an ideal model 
for an in-depth understanding the enzyme. In Chapters 2-6 of this thesis, I report the structural 
and functional characterization of PIPS from Mycobacterium kansasii (MkPIPS), an active 
enzyme, which shares 86% sequence identity with MtPIPS. MkPIPS is a better framework for 
more thorough functional characterization in the context of a pathogenic species and will be more 
useful in future application to in silico inhibitor discovery or docking experiments, which are the 






1.8 PIP-synthase from Mycobacterium: Significant work presented in this thesis 
             In Chapters 2-6 of this dissertation, I will describe the approaches and methods and 
report the results and interpretations of our structural and functional studies of a 
Phosphatidylinositol-phosphate synthase enzyme from Mycobacterium. I was able to employ 
structural genomics coupled with crystal engineering to solve the structure of a PIPS enzyme from 
Mycobacterium kansasii. Comparison of this structure with that of RsPIPS has produced 
hypotheses, which may explain the difference in activity exhibited by the two enzymes. I was also 
 
Figure 1.10 MtPIPS homology model used to probe function. A) and B) show MtPIPS homology 
model based on the RsPIPS structure with one monomer in light blue and the other in grey. Red indicates 
residues near CDP-DAG binding site, all but L70 seem to have a direct role in CDP-DAG binding. Blue 
indicates residues surrounding the putative IP binding site. Green indicates the catalytic base (D93). 
CDP-DAG in purple and Inositol-phosphate (InsP) in black. C) Activity of MtPIPS mutants, colored as the 




able to solve the structure of the enzyme bound to its substrates, first to CDP-DAG and then with 
both CDP and inositol-phosphate. These additional structures have also contributed to a better 
understanding of the molecular determinants of substrate binding in an active enzyme. I will 
describe our efforts to characterize the function of this enzyme using radiolabeled inositol-
phosphate in an enzymatic assay. Lastly, I will present ongoing experiments to validate structure-






A structural genomics and crystal engineering approach to structural studies of PIPS 
from Mycobacterium  
 
2.1 Hurdles in membrane protein structure determination 
 Membrane-embedded proteins serve incredibly important roles within all cells. They 
maintain the structural integrity of the cell membrane barrier and are also essential for detection 
of extracellular stimuli, signal transduction and maintenance of cellular homeostasis.   
Furthermore, more than half of available drugs target membrane proteins, so our understanding 
of them has a direct effect on human health [37]. Structural biology is an incredible tool to 
understand the molecular machinery of the cell at the atomic level. This degree of detail can help 
understand membrane protein function, any disease-causing mutations or may even aid in drug 
development. Approximately 20-30% of the human proteome is made up of membrane proteins 
[38], however structural biology of membrane proteins is especially challenging, and as a result 
less than 2% of the unique structures available in the PDB are of membrane proteins (according 
to the most recent data from the Stephen White laboratory at UC Irvine, 
http://blanco.biomol.uci.edu/mpstruc/, and the PDB, https://www.rcsb.org; data retrieved August 
25, 2018).  
 There are many hurdles to membrane protein structure determination and functional 
characterization. First, membrane proteins tend to be expressed at a low level in cells, even in 
recombinant systems, so structure determination requiring high amounts of pure sample (in the 
case of X-ray crystallography) can be difficult. Second, structural characterization requires the 
membrane protein to be extracted from the lipid bilayer with detergents or other membrane-
disrupting polymers, which can readily destabilize the native fold and cause aggregation. Even if 




up occluding the protein, preventing the growth of protein crystals, which is a significant bottleneck 
in structure determination by crystallography [38]. Nevertheless, advancement in many 
techniques for studying membrane protein structure has led to a steep increase in the number of 
membrane protein structures determined in the last 15 years (Figure 2.1). This is in part due to 
the recent technological advancements in the field of single particle cryo-electron microscopy 
(cryo-EM), which has begun to match the structural output of X-ray crystallography, the historically 
dominant technique to study membrane protein structure [39]. However, for many smaller 
membrane proteins, cryo-EM is still suboptimal for producing high resolution structures, keeping 
crystallographic techniques relevant. In the following sections, I will describe approaches 
developed to overcome the hurdles listed above, which I have employed to determine the 







2.2 Approaches to optimize expression and crystallization of PIPS from Mycobacterium 
2.2.1 Structural genomics 
 The increased success in membrane protein structure determination, demonstrated in 
Figure 2.1, is in part due the development and utilization of a high-throughput methods for protein 
 
Figure 2.1 Unique membrane protein structures over time. In the 33 years since the first membrane 
protein structure was determined in 1985—(photosynthetic reaction center from Rhodopseudomonas 
viridis [40]—we have seen incredible technical advancement leading to greater and greater number of 
membrane proteins being determined. The increase in unique membrane proteins structures is 
especially notable in the last 15 years. For the most recent statistics, figure retrieved from Stephen 
Whites Membrane Proteins of Known Structures Database  http://blanco.biomol.uci.edu/mpstruc/ on 




expression, purification and crystallization, known as structural genomics. Structural genomics is 
a powerful approach to increase the probability of structure determination by selecting across 
different species and screening close orthologs of the membrane protein of interest for expression 
and stability in detergents compatible with structural (or functional studies). This methodology, 
comprising bioinformatics analysis to select orthologs, high-throughput approaches, and robotic 
technology has advanced the field of membrane protein structural biology [41].  
 The formation of a stable, well-diffracting crystal relies on repeating protein-protein 
contacts, which allow a complex macromolecule to form an ordered (hence capable of diffracting 
X-rays) matrix. The difference of a few amino acids in a protein sequence can be enough to 
facilitate the formation of crystal contacts under the correct thermodynamic environment. Using 
structural genomics, one can exploit the naturally-occurring species to species variation that 
millions of years of evolution has afforded. By screening orthologs in a high throughput fashion, 
one can filter targets first by expression (small scale screening) and then by monodispersity as 
can be assessed by size exclusion chromatography (SEC), indicating a pure protein in a single 
structural state. This can then be followed by optimizing stability in different detergent or buffer 
conditions suitable for crystallization [41, 42].  
 Our lab worked closely with the New York Consortium for Membrane Protein Structure 
(NYCOMPS) from its inception to its completion in 2016 and we continue to work with the Center 
on Membrane Protein Production and Analysis (COMPPÅ) housed at the New York Structural 
Biology Center (NYSBC) in New York, New York. NYCOMPS developed a high throughput 
pipeline for target identification, cloning, expression and detergent screening with the aim of 
improving outcomes for membrane protein structure determination (Figure 2.2) [42]. This pipeline 
has resulted in the determination of many membrane protein structures, even within Dr. Mancia’s 
laboratory [34, 36, 43-46]. The support of NYCOMPS (and now COMPPÅ) was instrumental in 








Figure 2.2 Schematic representation of NYCOMPS pipeline. Structural genomics methods in this 
dissertation are based on the NYCOMPS pipeline depicted here. The process starts with the nomination 
of membrane protein targets of interest, which is used as a “seed” in bioinfomatic processing to identify 
and compile clusters of homologous targets. These expanded targets are then cloned and screened 
using high throughput technologies to find the most promising targets for further structural and 
biochemical characterization. Figure adapted from [42]. 
 
2.2.2 High throughput crystal optimization 
 Initial crystallization experiments of a protein are typically performed with commercially 
available precipitant screens or matrices, which tend to sample a large array of buffer type, pH, 
salt type, size of polyethlylene glycol (PEG) and other chemical additives. These screens are 




formulated from the literature based on precipitant compositions in which proteins have been 
previously crystallized. Over the years since its first introduction, these screens have become 
more and more diverse and specialized. Because these are sampling a vast chemical space, it is 
rare that the first crystals grown from commercial screens will diffract optimally for the 
determination of a high-resolution structure, so rounds of optimization must be undertaken. 
Traditional approaches for optimizing crystal growth and diffraction include 1) growing crystals at 
different temperatures, 2) optimizing protein concentration, 3) varying components of the 
precipitant solution (buffer, pH, salt, PEG, additives), 4) varying the lipid used for in meso 
reconstitution (in the case of lipidic cubic phase), and 5) varying cryo-protectant used when 
freezing crystals in preparation for x-ray diffraction [49].  
 Even small fluctuations in the precipitant solution or protein concentration can lead to 
a large difference in whether crystals are obtained or not, and on their diffraction quality. With so 
many variables to test, the task of optimization can seem daunting. However, using liquid handling 
robots and automated imaging systems, we are able to efficiently design and make in-house 
optimization screens, and we are able to set up hundreds to thousands of optimization conditions 
for crystallization in a single afternoon for crystals grown in both vapor diffusion and lipidic cubic 
phase (LCP; in meso) [50, 51]. The advancement and implementation of robotics in this respect 
makes the optimization task much more efficient, allowing the researcher to get the most out of a 
precious membrane protein sample. 
 
2.2.3 The use of crystallization chaperones 
 Another methodology used to improve the likelihood of crystal formation is the use of 
crystallization chaperones [52].  A crystallization chaperone is another protein or domain, usually 
with high crystallization potential, that is added to your protein of interest to facilitate 




in the structure determination of soluble proteins or nucleic acids, as they are able to stabilize 
flexible regions or multi-unit complexes [53, 54]. For membrane proteins, crystallization 
chaperones can extend available crystal-forming protein beyond the membrane or micelle border 
(Figure 2.3) [55] [56]. This is especially helpful for membrane proteins that may only be stable in 
detergents that form a larger micelle, which can sterically hinder protein-protein interactions or for 
proteins with very little extra-membrane surface area. With membrane proteins, crystallization 
chaperones can also increase the solubility of your target protein [55]. This technique can utilize 
a non-covalently attached chaperone, which can be anything that readily binds to your protein of 
interest non-covalently, or a covalently attached chaperone, requiring genetic manipulation of the 
recombinantly expressed protein through molecular biology.  
 
 
Figure 2.3 Crystallization chaperones. ß2AR has been successfully crystallized using several 
different crystallization chaperones and is used here to illustrate how crystallization chaperones 
facilitate crystallization. A) ß2AR (yellow) covalently fused to T4 lysozyme (blue) and B) non-covalently 




 The use of an antibody fragment (Fab) is the classic example of a crystallization 
chaperone (illustrated in Figure 2.3 B) [56]. Fabs were first successfully utilized to improve 
membrane protein crystallization for the structure determination of a bacterial cytochrome c 
oxidase [57] published in 1995, and their popularity as crystallization chaperones has not wavered 
since.  Their wide application is in part because Fabs can exhibit tight binding, stability, and have 
great potential for optimization [56]. Fabs are also useful in trapping proteins in specific states, 
aiding in crystallization and biological interpretation. This was seen in the determination of the 
open and closed states of KcsA K+ channel [58, 59]. Fabs can also be used to stabilize subunits 
enabling the formation of protein complexes, as seen in the determination of the HIV gp120 in 
complex with human CD4 [60]. More recently, camelid nanobodies have been similarly applied 
as crystallization chaperones for the structure determination of membrane protein [55]. 
Nanobodies are smaller single chain antibodies naturally produced in camelid species, such as 
llamas and camels. They have the advantage of accessing different epitopes that are not 
accessed by larger Fabs [61, 62]. The use of binding partners as crystallization chaperones can 
also function to immobilize loop regions, which were the source of heterogeneity without the 
presence of the chaperone. 
 Covalently attached chaperones for crystallization were introduced after the success 
of Fabs and have also become an incredibly useful technique. Here, targets are genetically 
altered to include extra protein domains at termini or within loop regions. Successful use of a 
covalently attached chaperone is demonstrated by the structure of human ß2 Adrenergic Receptor 
(ß2AR) G-protein Coupled Receptor (GPCR), one of the first successful applications of a covalent 
crystallization chaperone [63].  Here, T4 lysozyme was recombinantly fused into a loop region of 
the protein [63, 64] (Figure 2.3 A). Since this success, many other protein domains have been 




determination [36, 65, 66]. For a more thorough review of the use of crystallization chaperones 
for membrane protein structure determination, please see [55].  
 
2.2.4 Mutations, deletions and truncations 
 Increasing conformational homogeneity in your protein sample is paramount to the 
growth of well-ordered crystals. Incorporation of proteins into a stable crystal matrix requires that 
the same intermolecular contacts can be made, and this is less reliable in proteins exhibiting high 
disorder or instability [67]. Other methods to increase protein homogeneity include introducing 
stabilizing mutations, deleting flexible loops or truncating flexible termini. These approaches tend 
to work best when there is some a priori knowledge of the protein’s structure (and function), even 
if limited, so that a more efficient and targeted approach can be taken. Stabilizing mutations can 
be introduced in many ways. An example of a rigorous approach, is the introduction of a range of 
mutations, such as alanine scanning, assessed by testing mutants for relative thermostability. 
Here, thermostabilty is used as a general metric for overall protein stability to predict ease of 
crystal formation [67]. This approach was used, for example, in attempts to find the structure of 
an agonist-bound adenosine A2A receptor [68]. However, this approach is generally very labor 
intensive and not very practical. The more a priori structural information you have, the more 
targeted and precise your engineering attempts can become. For example, you can introduce 
stabilizing salt bridges, hydrophobic interactions or cysteine pairs for crosslinking to increase 
uniformity. A great example of this is the introduction of cysteine pairs in the bacterial glutamate 
transporter. When crosslinked, the cysteine pair trapped the glutamate transporter in the inward 
facing state, helping to resolve its mechanism of transport [69].  
 Flexible loops or termini can also be removed or truncated to limit interference in 
crystallization. This is similar to the stabilization of flexible regions sometimes seen when using 




can be used simultaneously, as in the determination of the structure of TRPV6, which utilized C-
terminal truncation, loop deletions, and extensive screening of mutants to find an optimally 
crystallizing construct [70]. It is important to note that any changes engineered in the protein must 
be taken into account when interpreting structural information and making biological conclusions. 
For example, if truncated or mutated regions are functionally important, this may limit your 
interpretation of the resulting structural information. On the other hand, if truly flexible, these 
regions may not be resolved by a crystal structure even if left intact. There is always a cost-benefit 
ratio to consider in engineering attempts.   
 
2.2.5 Application of these approaches in the structure determination of PIPS from 
Mycobacterium 
 The structure of Af2299 [34] was the result of a structural genomics approach applied 
to solving a structure of a member of the CDP-AP family of enzymes. From this, and the closely 
related structure of IPCT/DIPPS [23], it was apparent that the presence of a soluble domain in 
both proteins – unique to this subset of CDP-APs - was essential for the formation of crystal 
contacts (Figure 2.4). Therefore, an approach combining the principles of structural genomics 
with the implementation of the soluble cytidylyltransferase-like domain from Archaeoglobus 
fulgidus (AfCTD) as a crystallization chaperone was used to solve the structure of PIPS from 
Renibacterium salmoninarum (RsPIPS) [36]. At the time, l14 fusions were expressed and 
screened for crystallization, yielding preliminary crystals of PIPS from Mycobacteirum tuberculosis 
(MtPIPS) and Mycobacterium abscessus (MaPIPS). However, optimization attempts on these 
crystals were not successful (this work was performed by David Tomasek). Obtaining diffracting 
crystals of RsPIPS also required producing truncations in the linker region joining the PIPS 
enzyme with the AfCTD and introducing mutations designed to stabilize the PIPS-AfCTD interface 




discussed (See Chapter 1, section 1.7), we maintained an interest in solving the structure of a 
PIPS enzyme from the genus Mycobacterium. It was at this point that I took the leading role in 
the project. After I strugged to reproduce diffracting crystals of MtPIPS and MaPIPS, I pursued 
crystallization applying several techniques outlined in section 2.2.  
 
 As an initial approach to crysatllize MtPIPS, I again utilized the principles of structural 
genomics by varying the CTD crystallization chaperone. I replaced the AfCTD domain of the 
MtPIPS fusion with soluble domains from closely related CDP-AP enzymes from Ferroglobus 
placidus and Archaeoglobus veneficus, the only two targets identified by NYCOMPS 
bioinformatics processing.  
 
Figure 2.4 Essential crystal contacts in Af2299 and IPCT/DIPPS. Crystal packing and symmetry of 
Af2299 (top) and IPCT/DIPPS (bottom) visualized in Coot [71]. This illustrates that the CTD of Af2299 
and IPCT soluble domain of IPCT/DIPPS were both essential for the successful crystallization of these 




 In parallel, we performed a micro-genomics expansion of PIPS enzymes from genus 
Mycobacterium, to expand our search to previously untested genes. These mycobacterial targets 
were cloned with and without the AfCTD N-terminal fusion, and tested for expression, stability 
and crystallization using the NYCOMPS/COMPPÅ structural genomics pipeline. 
 Crystal optimization was performed iteratively between rounds of target cloning, 
expression, crystallization, and assessment of diffraction qualities when crystals were obtained. 
However, when my initial attempts at traditional crystal optimization failed to improve crystal 
diffraction, I turned to mutagenesis to optimize the construct of the PIPS fusion protein. I 
introduced mutations in key points of the protein seeking to rigidify the constructs based on 
structural information from AfCTD-RsPIPS fusions (for detailed methods see section 2.3.6).  
 After the determination and analysis of the first structure of MkPIPS (Chapter 3, section 
3.4.1), we identified the long C-terminus as an element that may be limiting or interfering with 
crystallization. So several truncations of the C-terminus were made in an attempt to further 
improve reproducibility and diffraction of LCP crystals.  
 Many of these mutational approaches were combined to try to find the optimal 
expression construct for crystallization. Detailed methods of this experimental overview are 
provided in section 2.3.  
 
2.3 Methods 
2.3.1 Target identification and cloning of PIPS from mycobacteria 
 PIPS enzymes from 12 mycobacterial species were identified and cloned from 
genomic DNA (provided by NYCOMPS/COMPPÅ) into a pET-based expression vector 
(pMCSG7) with an N-terminal decahistidine tag separated from the gene with a Tobacco Etch 
Virus (TEV) protease cleavage site [72]. These were cloned using Gibson assembly [73], both in 




alcohol phosphotransferase enzyme (cytidylyltransferase-like domain; AfCTD; residues 1-135 of 
UniProt O27985) recombinantly fused at the N-terminus separated by a GSGS linker (Figure 2.5). 
Three mutations were then introduced into each fusion construct in an attempt to replicate the 
minimal interface between the AfCTD and TM domains observed in the structure of RsPIPS [36]. 
These mutations were based on sequence alignment with Af2299 and RsPIPS and include 79F, 
77L, 17L (numbering of MtPIPS). This was accomplished using the QuickChange site-directed 
mutagenesis kit (Agilent). The Uniprot IDs and species of the sequences identified were as 
follows: 1: P9WPG6, Mycobacterium tuberculosis H37Rv; 2: A0A1M8UW79, Mycobacterium 
abscessus L984; 3: B2HM76, Mycobacterium marinum (strain ATCC BAA-535 / M); 4: 
A0A202FYW3, Mycobacterium avium ssp. paratuberculosis; 5: A0A0J6YQ88, Mycobacerium 
chubuense; 6: A4TD07, Mycobacterium gilvum; 7: X8CIT8, Mycobacterium intracellulare; 8: 
X7Y109, Mycobacerium kansasii; 9: A0A024QPA5, Mycobacterium neoaurum; 10: A1T870, 
Mycobacterium vanbaalenii; 11: S4ZCZ8, Mycobacterium yongonense; 12: A0A0H3MFZ3, 





Figure 2.5 Cloning of Mycobacterial PIPS fusions by Gibson Assembly. To make seamless fusion 
proteins with precise joining regions, we used the Gibson Assembly cloning technique [73, 74]. Linear 
DNA fragments were PCR amplified from vectors containing PIPS coding sequence (A) and Af2299 
coding sequence (B) with primers designed to produce homologous ends. In the Gibson reaction, a 
exonuclease, a polymerase and a ligase act to stitch the linear DNA together via the homologous ends 
(C) producing a seamless fusion construct (D).   
 
2.3.2 Expression and purification of mycobacterial PIPS 
 To express the target protein, E. coli was transformed with PIPS native and fusion 




culture (2xYT containing 100 µg/ml Ampicillin and 35 µg/ml Chloramphenicol). Starter cultures 
were grown overnight at 37°C. The next day, 2xYT containing 100 µg/ml Ampicillin and 35 µg/ml 
Chloramphenicol was inoculated with 250 µl of starter culture. Cultures were grown to an OD600 
between 0.8 and 1.0. Cultures were cooled to room temperature and induced by adding a final 
concentration of 200 µM IPTG. Cultures were incubated overnight at 22°C. In the morning cultures 
were harvested at 4°C and 4000 rpm.  
 The volume of culture grown varied with experiment, 20 ml for small-scale expression 
tests (SDS-PAGE analysis), 250 ml for mid-scale purification (HPLC detergent screening) and 
minimum of 800 ml for large-scale purification aimed at crystallization experiments. Pellets were 
normalized by weight and 80 mg of E. coli cell pellet was taken to use for the small-scale 
purification procedure and expression assessment. As a quick note, we refer to the initial 
screening step after cloning as “small-scale expression” screening, however this is a slightly 
misleading term. It is not a true assessment of expression alone. Since we purify in small scale, 
it is an assessment of expression levels, as well as of our ability to extract the target protein from 
the membrane, access of the affinity tag for purification, and overall stability. For our purposes of 
crystallization, purification of the protein in detergent is essential, so this assessment is more 
important than pure expression alone. 
 For all purification procedures, cell pellets were resuspended in lysis buffer (20 mM 
HEPES, pH 7.5, 200 mM NaCl, 20 mM MgSO4, RNase, DNase, PMSF, Complete protease 
inhibitor cocktail (Roche) and 1mM TCEP) and lysed by sonication with a tip sonicator (small and 
mid-scale) or by pressure using an Avestin Emulsiflex C3 (large scale). DDM was added to lysed 
samples to a final concentration of 1% to solubilize and extract the target proteins from the 
membrane. Solubilization was carried out for 1-1.5 hours at 4°C with gentle agitation or rotation. 
Samples were then spun at 13,200 rpm at 4°C for 15 minutes (small scale) or 34,000 rpm at 4°C 




added to Ni-NTA resin, which had been pre-equilibrated with buffer containing 20mM HEPES, pH 
7.5, 200 mM NaCl and 0.1% DDM. Imidazole was added to a final concentration of 40mM to 
reduce non-specific binding to the nickel resin. Samples were incubated for 1-2 hours at 4°C with 
gentle agitation or rotation to facilitate protein binding to the resin. Samples were incubated on 
ice to settle the resin. The supernatant was removed and discarded. The remaining resin was 
washed with 10 column volumes (C.V.) of wash buffer (20 mM HEPES, pH 7.5, 200 mM NaCl, 60 
mM Imidazole, 0.1% DDM) and eluted with 3-4 C.V. of elution buffer (20 mM HEPES, pH 7.5, 200 
mM NaCl, 300 mM Imidazole, 0.05 % DDM). For small scale, eluates were collected and stored 
for analysis by SDS-PAGE.  
 For mid-scale and large-scale purifications, His tagged SuperTEV protease [75] was 
added to the samples to remove the His tag from PIPS. SuperTEV protease is an TEV protease 
variant optimized for stability that cleaves the site included between the enzyme and the histidine 
affinity tag. SuperTEV is prepared in house based on established protocols [76]. After TEV 
protease is added, the samples were dialyzed overnight against buffer containing 20 mM HEPES, 
pH 7.5, 200 mM NaCl and 0.05% DDM to remove the Imidazole. After overnight dialysis, samples 
were added to fresh pre-equilibrated Ni-NTA resin to remove TEV protease, any uncleaved target 
protein and free His-tags from the solution as well as any contaminant proteins that bind naturally 
to the nickel resin without a histidine tag. Samples with resin are incubated for 30 minutes to 1 
hour at 4°C with gentle agitation or rotation. Samples are added to a disposable column and the 
flow through containing the cleaved target protein is collected for analysis by size exclusion 
chromatography (SEC) or for use in crystallization experiments, further discussed in section 2.3.4 







2.3.3 Screening for suitable detergents by buffer exchange 
 Protein purified in mid-scale, as described in the previous section, was filtered using 
0.2 µm PVDF centrifugal filters (Millipore) and 30 µl of filtered protein per detergent was injected 
onto an analytic high-performance liquid chromatography (HPLC) system and exchanged to 
buffers containing different detergent compositions. The buffers contained 20 mM HEPES, pH 
7.0, 200 mM NaCl, 1mM TCEP and one of the following detergent concentrations: 0.025% n-
Dodecyl-ß-D-Maltopyranoside (DDM), 0.2% n-Decyl-ß-D-Maltopyranoside (DeM), 1.2% n-Octyl-
ß-D-Maltopyranoside (OM), or 0.06% Lauryldimethylamine-N_Oxide (LDAO) (all detergents used 
are from Anatrace; structures of detergents found in Figure 2.6). Peaks were assessed based on 
monodispersity, retention time of the peak, presence of any peak coming out at the void volume 
(apparent aggregation), and comparative peak height, as a smaller peak may be indicative of 
protein loss or instability even if it does not show up in the void volume as an aggregate.   
 
Figure 2.6 Detergents and their chemical structures. Here is illustrated the detergents used in stability 
screening of PIPS from Mycobacterium. The chemical name is found on the left with the common name 
in parentheses, followed by the chemical structure. Chemical structures from Anatrace, the commercial 






 Proteins purified in large scale, as described in section 2.3.2 of this chapter, were used 
for crystallization either after SEC analysis for vapor diffusion or without SEC analysis to prevent 
further delipidation of the proteins. It is known that structural or annular lipids can play an important 
role in membrane protein function and stability [77] and though proteins are being removed from 
the membrane, lipids may be still playing an important role even within the detergent micelle. 
Reducing the manipulation and buffer exchanging steps may help prevent stripping these lipids. 
After purification, proteins were concentrated to between 10 and 60 mg/ml using a centrifugal 
concentrator with a 100 kDa cutoff (Amicon) at 10,000 x g at 4°C. The concentrated protein 
sample was centrifuged at 16,100 x g at 4°C to clear any insoluble aggregates. For crystallization 
by vapor diffusion, protein was set up in sitting drop 96 well plates (Axygen) using a Mosquito 
robot (TTP Labtech) with 200 nl of protein and 200 nl of precipitant. Vapor diffusion trays were 
stored in a Rock Imager 1000 (Formulatrix) storage and imaging system at either 4°C or 22°C 
and automatically imaged at periodic, predefined intervals. For lipidic cubic phase (LCP; in meso; 
Figure 2.7) crystallization, the protein was then mixed with monoolein (Sigma) in a 1:1.5 protein 
to lipid ratio (w/w). Using the LCP Mosquito (TTP Labtech) 80 nl of protein-lipid mix was deposited 
on a glass LCP plate, covered with 750 nl of precipitant solution (from a commercial screen or in-
house screen) and sandwiched with a glass coverslip. Commercial screens used include 
MemGold, MemGold II, MemMeso, and Wizard Cubic LCP from Molecular Dimensions, as well 
as JCSG+ and NeXtal CubicPhase II from Qiagen. Crystals usually appeared after 2-3 days, but 
plates were stored at 22°C until crystals were at optimal size and quality, generally 3-4 weeks. 
When ready to freeze and ship to the synchrotron, a tungsten carbide glass-cutter (Hampton 
Research) was used to cut open the glass cover slip and crystals were harvested using 35-100 





Figure 2.7 Crystallization in Lipidic Cubic Phase (LCP). Lipidic cubic phase is a technique in which a 
membrane protein in an aqueous environment is mixed with a lipid matrix to crystallize a membrane 
protein in a more favorable environment closer to the native membrane. This is achieved by the mixing 
of the protein and lipid in coupled syringes (a, b and c). After mixing to homogeneity, the lipid mixture is 
dispensed onto a plate with a perforated spacer, covered with precipitant solution and closed with a 
coverslip (d and e). This allows for the growth of crystals in a lipidic cubic phase or mesophase (f). Figure 




additional cryoprotectant. All diffraction data were assessed and collected at APS NE-CAT 
beamlines 24-ID-E and 24-ID-C using their remote access system. For more information about 
data processing, please see Chapter 3 section 3.2.  
 
2.3.5 Optimization of crystals 
 Optimization screens were designed by varying concentrations of components from 
the initial crystallization condition. Generally, pH and PEG concentration were increased and 
decreased around the initial condition in a 96 well array. Generally, repeats of these screens 
would be made with varying salt concentrations as well. Other optimization strategies were also 
used, such as varying the identity of the PEG or salt counter ion. Optimization screens were 
designed using the Dragonfly Designer software and made using the Dragonfly liquid handling 
robot (TTP Labtech). Crystal optimization was performed iteratively, reassessing the optimization 
strategy depending on the quality of crystallization and diffraction of such crystals from any given 
screen.  
 
2.3.6 Design and production of mutants for crystal optimization 
 To optimize preliminary crystals of AfCTD-MtPIPS previously grown by David 
Tomasek, the AfCTD was replaced with soluble domains from closely related enzymes. These 
included amino acids 1-136 of a CDP-alcohol phosphotransferase enzyme from Ferroglobus 
placidus (UniProt D3RX14) and amino acids 1-136 of a CDP-alcohol phosphotransferase enzyme 
from Archaeoglobus veneficus (UniProt F2KMH0). The corresponding genes were synthesized 
(GenScript) and cloned into existing vectors for MtPIPS expression by Gibson assembly, as 
described in Figure 2.5. Three mutations were made to mimic the CTD-PIPS interface observed 
in RsPIPS (79F, 77L, 17L in MtPIPS), two of which (79F and 77L) are in the TM2-3 loop region 




Table 2.1. The rationale for this is described in more detail below. This approach was only 
attempted with the PIPS enzyme from Mycobacterium tuberculosis in early stages of this project, 
but was not applied more widely to PIPS from all the mycobacterial species tested as described 
below.    
 
Table 2.1 CTD-MtPIPS variants made for crystal optimization.  
Construct Name CTD Species Linker-PIPS TM2-3 Loop 
AvCTD-MtPIPS Archaeoglobus veneficus GSGS-SKLP ERGGGTR 
AvCTD-MtPIPS-F79 Archaeoglobus veneficus GSGS-SKLP LRFGGTR 
FpCTD-MtPIPS Ferroglobus placidus GSGS-SKLP ERGGGTR 
FpCTD-MtPIPS-F79 Ferroglobus placidus GSGS-SKLP LRFGGTR 
Red indicates changes in loop region from native MtPIPS sequence. 
 
 Mutants to stabilize the PIPS-AfCTD interface were designed using homology models 
based on the RsPIPS structure. It was observed from the RsPIPS structure that a key 
phenylalanine residue (F77 in RsPIPS numbering) made contacts essential for stable interface 
formation (Figure 2.8 B and C). We recapitulated this in early crystallization trials by mutating the 
homologous residue in the mycobacterial PIPS enzymes to phenylalanine along with two key 
leucine residues (described in section 2.3.1). However, in later optimization on the PIPS enzyme 
with the best diffracting crystals (MkPIPS), we decided to vary this residue and surrounding 
residues also within the TM2-TM3 loop region that were hypothesized to have an effect on the 
formation of this interface (Figure 2.8). It was also taken into consideration that the form of RsPIPS 
that yielded the apo structure (PDB 5D91; RsPIPS-∆6N) and the best diffracting crystals was a 
truncation mutant missing 6 residues at the N-terminus with a shorter linker between AfCTD and 
RsPIPS. Because of this previous success, we reasoned that increasing or decreasing the linker 
length and even attempting a similar truncation at the N-terminus may favorably affect PIPS-




 After having determined the first MkPIPS structure it was noted that the long C-
terminus seemed to be interfering with the formation of the previously observed PIPS-AfCTD 
interface. Based on this, we made different C-terminal truncations, including AfCTD-MkPIPS-
∆30C, AfCTD-MkPIPS-∆24C, and AfCTD-MkPIPS-∆21C. All truncations were made using site 
directed mutagenesis to introduce a stop codon after the indicated residue (202 for ∆30C, 208 for 
∆24C, and 211 for ∆21C). Please see Table 2.2 for a complete list of MkPIPS mutants made in 
the optimization phase.  
 All point mutants were generated using the site directed mutagenesis Quick Change 
Lightening Kit (Agilent) and transformed into XL10 Gold Ultracompetent E. coli cells (Agilent). 
Variations of the linker region were cloned using Gibson Assembly (in house enzyme mix) [74] 
with just one amplicon with overhang regions containing the altered linker. Mutations, deletions 





Figure 2.8 Design of mutants for MkPIPS crystal optimization. A) Sequence alignment of two 
crystallized RsPIPS fusion proteins with MkPIPS fusion protein before any mutations are introduced, 
highlighting the two regions focused on for optimization, the linker region (yellow) and the TM2-3 loop 
(green). Below shown the AfCTD-RsPIPS-∆6N monomer to demonstrate the linker region (A) and the 
loop region (B) with detailed images in panels below. These detail panels also point out the JM region, 
which was also manipulated in optimization attempts of MkPIPS. Residues thought to be important for 
AfCTD-RsPIPS interface formation are shown in green and residues of linker shown in red. Figure 




Table 2.2 MkPIPS variants cloned for crystal optimization with RsPIPS constructs for reference. 
Construct Name Linker-PIPS TM2-3 Loop JM alterations Truncation 
AfCTD-RsPIPS-FL GSGS-LNKY LLFREGP   
AfCTD-RsPIPS-∆6N GS-RGLF LLFREGP   
native fusion GSGS-SKVP QRGGGTR --- --- 
F79 GSGS-SKVP LRFGGTR --- --- 
F79-GS GS-SKVP LRFGGTR --- --- 
F79-GS∆6N GS-SRAA LRFGGTR --- --- 
W79 GSGS-SKVP LRWGGTR --- --- 
Y79 GSGS-SKVP LRYGGTR ---  
M79 GSGS-SKVP LRMGGTR ---  
N79 GSGS-SKVP LRNGGTR   
R79 GSGS-SKVP LRRGGTR ---  
I79 GSGS-SKVP LRIGGTR ---  
E79 GSGS-SKVP LREGGTR ---  
F79-long-link GSGSGG-SKVP LRFGGTR ---  
F79-L∆3N GSGSL-SKLS LRFGGTR ---  
F79/E81 GSGS-SKVP LRFGETR ---  
F79-GS∆7 GS-RAAF LRFGGTR ---  
F79/E81-L∆3N GSGSL-SKLS LRFGETR ---  
F79/E81-GS∆6N GS-SRAA LRFGETR ---  
F79/E81-GS∆7N GS-RAAF LRFGETR   
F79/E81-long-link GSGSGG-SKVP LRFGETR   
F79/E81-GS GS-SKVP LRFGETR   
RsJM-short-GS GS-RGLF LRFGGTR RsPIPS --- 
RsJM-long GSGS-LNKY LRFGGTR RsPIPS --- 
RsLoop GSGS-SKVP LLFREGP RsPIPS --- 
RsJM-long-RsLoop GSGS-LNKY LLFREGP RsPIPS --- 
RsJM-short-RsLoop GS-RGLF LLFREGP RsPIPS --- 
Q77/F79/E81 GSGS-SKVP QRFGETR --- --- 
Q77/F79/R80/E81 GSGS-SKVP QRFRETR --- --- 
S79 GSGS-SKVP LRSGGTR --- --- 
T79 GSGS-SKVP LRTGGTR --- --- 
F79-∆30C GSGS-SKVP LRFGGTR --- at residue 202* 
F79-∆24C GSGS-SKVP LRFGGTR --- at residue 208* 
F79-∆21C GSGS-SKVP LRFGGTR --- at residue 211* 
S79-∆30C GSGS-SKVP LRSGGTR --- at residue 202* 
S79-∆24C GSGS-SKVP LRSGGTR --- at residue 208* 
S79-∆21C GSGS-SKVP LRSGGTR --- at residue 211* 
Catalytically Inactive 
Variants 
    
F79-D93N GSGS-SKVP LRFGGTR   
S79-D93N GSGS-SKVP LRSGGTR   
S79-∆24C-D93N GSGS-SKVP LRFGGTR  at residue 208* 
S79-∆21C-D93N GSGS-SKVP LRSGGTR  at residue 211* 
Yellow rows highlight RsPIPS constructs used for design on MkPIPS mutants. Red indicates changes in 






 Structural genomics, high throughput robotics and crystal engineering are powerful 
tools that have greatly advanced the field of membrane protein structural biology. These 
techniques have been implemented in this project toward the main goal of solving the structure 
of a PIPS enzyme from Mycobacterium. Specifically, we have implemented structural genomics 
and high throughput screening for expression and stability. We have utilized crystallization 
chaperones and in an attempt to stabilize the interface of the protein of interest and the 
crystallization chaperone we have used mutational crystal engineering. We have also used high 
throughput crystallization and crystal optimization strategies to improve data outcomes. Here, I 
will discuss the results of the approaches and techniques described above.  
   
2.4.1 Small scale expression tests of PIPS 
 PIPS constructs cloned as previously described (section 2.3.1) were tested for 
expression in small scale (section 2.3.2). Figure 2.9 shows the results of a small-scale expression 
test run on an SDS-PAGE containing 12% acrylamide and stained with Coomassie.  
 MtPIPS fused to alternative CTD from Archaeoglobus veneficus (AvCTD-MtPIPS) 
expressed at lower levels than MtPIPS fused to AfCTD (Figure 2.9 C), however expression was 
still promising enough to continue with this construct into larger scale purification. On the other 
hand, MtPIPS fused to alternative CTD from Ferroglobus placidus (FpCTD-MtPIPS) expressed 
even lower according to my small scale expression tests. Because of this, I did not take FpCTD-
MtPIPS any further.  
 Generally, mycobacterial PIPS constructs did not express as well with a N-terminal 
10x His tag alone (“native”; Figure 2.9 D). Of these native constructs, MtPIPS and MabPIPS had 





Figure 2.9 Small scale expression of PIPS from Mycobacterium. Mycobacterial PIPS constructs were 
expressed in small scale and purified as described in section 2.3.2 of this chapter. The resulting purified 
protein was run on SDS-PAGE containing 12% acrylamide. Results of small scale expression from 
MtPIPS (A), MabPIPS (B) and MtPIPS CTD variants (C) are shown in the top panel. These were the first 
constructs cloned and so were expressed separately from the remaining mycobacterial PIPS enzymes, 
the results of which are shown below. D) Small scale expression results for remaining Native 
mycobacterial PIPS enzymes.  “Native” refers to no fusion constructs, however were still expressed with 
a recombinant 10x histidine tag and TEV cleavage site. Illustrated by the blue RsPIPS no-fusion 
monomer (E). F) Small scale expression results from AfCTD fusion constructs, illustrated in (G) by the 
fusion of RsPIPS (blue) and AfCTD (orange). Pure protein bands of PIPS enzymes are accentuated by 




expression, however even less prevalent. Fortunately, the expression was boosted dramatically 
in the same vector with the same 10x His tag when the AfCTD was recombinantly fused to the N-
terminus (Figure 2.9 F). AfCTD-McPIPS and AfCTD-MvPIPS showed especially promising results 
from the small-scale expression test. Many of the targets run at a lower molecular weight than 
expected, which is common for membrane proteins, which tend to be more resistant to SDS 
denaturation. Table 2.3 provides details on protein constructs and expression results. Ten of the 
AfCTD fusions were scaled up for mid-scale expression and detergent screening (section 2.3.3). 
 
Table 2.3 Mycobacterial PIPS constructs cloned and tested for expression.  







NATIVE     
MtPIPS Mycobacterium tuberculosis 217 23.3 low 
MabPIPS Mycobacterium abscessus 220 23.0 yes 
MmPIPS Mycobacterium marinum 234 24.7 no 
MavPIPS Mycobacterium avium 213 22.2 no 
McPIPS Mycobacterium chubuense 223 23.6 low 
MgPIPS Mycobacterium gilvum 220 23.0 low 
MiPIPS Mycobacterium intracellulare 210 22.0 no 
MkPIPS Mycobacterium kansasii 232 24.4 no 
MnPIPS Mycobacterium neoaurum 220 22.8 no 
MvPIPS Mycobacterium vanbaalenii 223 23.4 low 
MyPIPS Mycobacterium yongonense 210 22.0 no 
MbPIPS Mycobacterium bovis 217 23.3 N/A 
FUSION     
AfCTD-MtPIPS Mycobacterium tuberculosis 355 39.2 yes 
AfCTD-MabPIPS Mycobacterium abscessus 358 38.9 yes 
AfCTD-MmPIPS Mycobacterium marinum 372 40.6 yes 
AfCTD-MavPIPS Mycobacterium avium 351 38.1 yes 
AfCTD-McPIPS Mycobacterium chubuense 361 39.5 yes 
AfCTD-MgPIPS Mycobacterium gilvum 358 38.9 yes 
AfCTD-MiPIPS Mycobacterium intracellulare 348 37.9 yes 
AfCTD-MkPIPS Mycobacterium kansasii 370 40.3 yes 
AfCTD-MnPIPS Mycobacterium neoaurum 358 38.7 yes 
AfCTD-MvPIPS Mycobacterium vanbaalenii 361 39.3 yes 
AfCTD-MyPIPS Mycobacterium yongonense 348 37.9 yes 
AfCTD-MbPIPS Mycobacterium bovis 355 39.2 N/A 
     
AvCTD-MtPIPS Mycobacterium tuberculosis 356 39.2 yes 





2.4.2 Mid-scale expression and detergent screening of PIPS from Mycobacterium 
 Of the 12 AfCTD-PIPS fusions initially cloned, 10 were successfully purified in mid-
scale and screened for suitable detergents. PIPS from M. bovis was found to be identical in 
sequence to PIPS from M. tuberculosis after cloning, so was not pursued further. Also, M. 
tuberculosis PIPS had been extensively screened previously by David Tomasek, and was known 
to be stable in DDM and DM. The 10 remaining targets gave protein yields between 0.3 and 0.7 
milligrams per gram of E. coli cells with AfCTD-MkPIPS giving the highest yields. Of the 10 PIPS 
fusions that were screened with buffer exchange on HPLC, six yielded notable results (AfCTD-
MabPIPS, AfCTD-McPIPS, AfCTD-MkPIPS, AfCTD-MvPIPS, AfCTD-MyPIPS, and AfCTD-
MgPIPS; Figure 2.10). AfCTD-MabPIPS and AfCTD-McPIPS gave promising monodisperse 
peaks in only DDM. AfCTD-MkPIPS and AfCTD-MvPIPS were much more consistent across 
different detergents. AfCTD-MkPIPS showed sharp monodisperse peaks in DDM and DeM, with 
less optimal peaks in OM and LDAO. AfCTD-MvPIPS showed sharp monodisperse peaks in all 
four detergents tested. AfCTD-MyPIPS was a little less favorable, showing a “shoulder” to the left 
of the main peak, indicating some heterogeneity in the sample, however it looked consistent over 
three of the four detergents tested. AfCTD-MgPIPS gave sharper peaks, also consistent across 
three of the four detergents, with a second peak to the right of the main peak. Because this second 
peak seemed to be easily separated from the higher molecular weight peak by SEC, it was not a 
concern for crystallization. AfCTD-MmPIPS, AfCTD-MiPIPS, AfCTD-MnPIPS, and AfCTD-
MavPIPS yielded peaks that were suboptimal for all detergents tested (not shown) so were not 





Figure 2.10 Representative detergent screens of mycobacterial PIPS enzymes. Peaks from protein 
(labeled above) after size exclusion chromatography on an analytical HPLC and exchange to different 
detergents (DDM, blue; DeM, orange; OM, green; LDAO, pink). The y-axis shows UV absorbance at a 
280 nm wavelength in milli absorbtion units (mAu). The x-axis shows retention time in minutes (min). The 
shorter the retention time, the larger the eluted species.  
 
2.4.3 Initial crystallization 
 David Tomasek had previously obtained preliminary crystals from AfCTD-MabPIPS 
and AfCTD-MtPIPS (Figure 2.11 A and B), but had difficulty optimizing them. The constructs he 
was using had been synthesized to include six mutations at the interface between the PIPS 




mutations as well as an MtPIPS fusion constructs with an alternative CTD (from Archaeoglobus 
veneficus; see section 2.3.6), and I attempted to repeat his success with the new constructs and 
see if I could recapitulate his results and hopefully improve diffraction. Also, based on results from 
the mid-scale purification and detergent screens (section 2.3.3), I scaled up to purify targets in 
large-scale for initial crystallization trials of other mycobacterial PIPS fusion proteins.  
 During initial crystallization trials, proteins were purified as described in section 2.3.2. 
All targets underwent a three-step purification using DDM as the solubilizing detergent: 1) affinity 
chromatography with Nickel resin, 2) TEV cleavage followed by rebinding to Nickel resin to 
remove TEV protease and un-cleaved protein, and 3) size exclusion chromatography (SEC). After 
SEC, the appropriate fractions collected were pooled and concentrated for either LCP or vapor 
diffusion. For all initial crystallization with LCP, monoolein was used as the mixing lipid without 
any additive lipids. For some vapor diffusion crystallization trials, the detergent was exchanged 
during SEC. Crystals were set up using methods (described in section 2.3.4) with commercially 
available screens. Table 2.4 details the initial crystallization trials and any resulting crystals.  
 
Table 2.4 Results of initial crystallization trials. 





AfCTD-MtPIPS --- LCP 38 mg/ml no 
AvCTD-MtPIPS --- LCP 37 mg/ml no 
AfCTD-MvPIPS --- LCP 39 mg/ml no 
AfCTD-MvPIPS --- LCP 61 mg/ml no 
AfCTD-MvPIPS DDM to DeM Vapor diffusion 9 mg/ml no 
AfCTD-MvPIPS DDM to OM Vapor diffusion 6 mg/ml no 
AfCTD-MvPIPS DDM to OM Vapor diffusion 10 mg/ml no 
AfCTD-MvPIPS DDM to LDAO Vapor diffusion 11 mg/ml no 
AfCTD-MabPIPS --- LCP 45 mg/ml yes 
AfCTD-McPIPS --- LCP 44 mg/ml no 
AfCTD-MkPIPS --- LCP 39 mg/ml yes 





 Fusion proteins of PIPS from Mycobacterium abscessus and PIPS from 
Mycobacterium kansasii yielded initial crystals using commercial screens (Figure 2.11 C, D and 
E). The best un-optimized AfCTD-MabPIPS crystals diffracted to 14 Å and the best un-optimized 
AfCTD-MkPIPS crystals diffracted to 9 Å. The optimization of these crystals is detailed below in 
the next section of this chapter. 
 
 
Figure 2.11 Preliminary crystals of PIPS from Mycobacterium. Preliminary crystals of AfCTD-
MabPIPS (A) and AfCTD-MtPIPS (B) grown by David Tomasek with the UV image of the same drop 
shown below. C) and D) show representative MabPIPS crystals grown by me in an effort to repeat 
David’s crystallization with new cloned constructs (minimal mutations for the AfCTD-PIPS interface).  E) 
Representative preliminary crystals of AfCTD-MkPIPS grown by me. All crystals pictured were grown in 
LCP with monoolein as the mixing lipid. 
 
2.4.4 Crystal and construct optimization  
 Initial crystals were grown utilizing commercial screens and diffracted poorly, so 
required optimization. From this point on in this dissertation, I will only be dealing with PIPS 
proteins in their AfCTD fusion form, so for clarity, I will no longer be using AfCTD in protein target 
names. Crystals from MabPIPS grew in several different initial conditions: 1) 100 mM sodium 




2) 100 mM sodium citrate tribasic dehydrate, pH 5, 30% PEG 500 MME (MemMeso F8), 3) 100 
mM MES, pH 6, 30% PEG 500 MME, 100 mM sodium chloride, 100 mM lithium sulfate (MemMeso 
F10), 4) 100 mM HEPES, pH 7, 200 mM lithium sulfate, 100 mM sodium chloride, 31% PEG 400 
(MemGold II B10), and 5) 50 mM HEPES, pH 6.5, 500 mM potassium chloride, 20% PEG 400 
(MemGold II G1). Initial optimization screens were made by varying pH, salt concentration, and 
PEG concentration around the original condition. With these crystallization screens, I was able to 
see an improvement in diffraction from 14 Å of the initial crystals to between 8 and 9 Å. To optimize 
further around the most successful conditions, I made more optimization screens to test different 
PEG identities (PEG 400, PEG 500 MME, PEG 550 MME and PEG 500 DME) and different 
counter ions, for example many of the original conditions contained sodium chloride, so in a later 
stage of optimization, I tested sodium acetate, sodium formate or sodium malaonate in 
optimization screens. Along with the screens, I tried optimizing the purification, by crystallizing 
with and without the SEC step. I also tried several different protein concentrations above and 
below that of the original crystals. Unfortunately, none of these attempts improved the crystals 
more than the previous round of optimization.    
 MkPIPS crystals also originally appeared in several different conditions: 1) 100 mM 
MES, pH 6.5, 30 mM magnesium chloride, 28% PEG 400 (MemGold II B6), 2) 100 mM HEPES, 
pH 7, 200 mM sodium chloride, 29% PEG 400 (MemGold II E3), 3) 100 mM Tris, pH 8, 44% PEG 
200 (MemGold II H7) and 4) 100 mM Tris, pH 7, 200 mM sodium chloride, 30% PEG 400 (Wizard 
Cubic LCP D8). Optimization screens were made varying pH, PEG concentration and salt 
concentration around the original condition. Crystals grown from this first optimization did not 
improve, but diffracted similarly to the original condition (best diffraction at 9 Å). I tried to optimized 
the prep and use the same screens again. I tried different protein concentrations and I also 
included the lipidic substrate for PIPS enzymes, CDP-DAG, in the LCP mixing lipid (monoolein) 




LCP mix, I was able to improve diffraction to 5 Å, but the best diffracting crystals were grown 
again in commercial screens: 100 mM MES, pH 6, 100 mM sodium chloride, 100 mM calcium 
chloride, 30% PEG 500 MME (MemMeso F11). At this point, I tried to optimize again making new 
screens around this new condition, however crystals grown from these screens did not diffract at 
all. Going back to early screens and optimizing by lowering protein concentration improved 
diffraction to 4.5 Å.  MkPIPS seemed like the most promising target and my success in improving 
diffraction traditionally was limited. So we underwent optimization at the protein level, attempting 
to increase stability at the PIPS-CTD interface, as described in section 2.3.6 (Figure 2.8).  
 Many mutant MkPIPS constructs were designed to optimize crystallization (section 
2.3.6, Figure 2.8). Each of these was purified and crystallized similarly to the MkPIPS that 
provided the best diffraction, with and without CDP-DAG in the LCP mix. I did observe 
improvement of diffraction with the use of this crystal engineering approach, especially when 
changes were made to the TM2-3 loop region. Table 2.5 provides details on the best mutants that 
were crystallized and how that helped improve diffraction. The best diffracting crystals from 
MkPIPS-S79 were grown in the presence of 100 mM Sodium citrate, pH 6, 50 mM sodium 
chloride, 20 mM magnesium chloride hexahydrate and 22% PEG 400 (MemGold C4). A 
representative diffraction pattern is shown in Figure 2.12. This mutational protein engineering 
approach to ultimately led to the determination of the structure of PIPS from Mycobacterium 
kansasii (discussed further in Chapter 3).     
 
 Table 2.5 Crystallization and Diffraction results of optimization by protein engineering.  
Construct Name TM2-3 loop Lipid Mix Best diffraction 
MkPIPS-F79 LRFGGTR 2% CDP-DAG 4.5 Å 
MkPIPS-Y79 LRYGGTR 2% CDP-DAG 4.1 Å 
MkPIPS- Q77/F79/E81 QRFGETR 2% CDP-DAG 3.5 Å 








Figure 2.12 Resulting diffraction from crystals of MkPIPS-S79. Crystals of MkPIPS-S79 grown in 
100 mM Sodium citrate, pH 6, 50 mM sodium chloride, 20 mM magnesium chloride hexahydrate and 
22% PEG 400 (MemGold C4) produced the diffraction seen here. Spots of X-ray diffraction can be seen 
beyond 2.8 Å ring. Data were collected at APS NE-CAT beamline 24-ID-E using their remote system. 
 
2.5 Discussion 
 Ultimately, the many-pronged approach of using structural genomics, crystallization 
chaperones, high throughput crystallization and crystal optimization, and crystal engineering at 
the protein level successfully led to the determination of the structure of PIPS from Mycobacterium 
kansasii (discussed further in Chapter 3).  
 As shown in section 2.4.1, we saw a dramatic boost in expression of mycobacterial 
PIPS enzymes when expressed as a fusion with AfCTD (Figure 2.9). Since all our screening of 
our structural genomics approach is done in E. coli, it is logical that adding a domain that has 
already been selected based on its good expression profile in the model system would help low-




constructs, which gives us reason to believe that AfCTD may be useful more broadly as a 
crystallization chaperone for proteins outside of the CDP-AP family of enzymes. Using AfCTD 
more widely as a crystallization chaperone is currently being explored experimentally at 
COMPPÅ. From the small-scale expression results, we also saw that a few PIPS enzymes 
expressed at lower levels without being fused to AfCTD (MtPIPS, MabPIPS, McPIPS, MgPIPS, 
and MvPIPS; Figure 2.9). These were not pursued for crystallization for two reasons. First, it 
would be more difficult to prepare high enough yields for crystallization with these lower 
expressing proteins. Second, the most promising of these (MabPIPS and MtPIPS) had already 
been tested extensively in earlier structural genomics approaches to the CDP-AP enzyme family 
performed by Guiliano Sciara and David Tomasek without success of crystallization.  
 Of the ten PIPS fusion tested in mid-scale detergent exchange screening, six gave 
promising SEC peaks in at least one detergent. From these mid-scale results, PIPS from 
Mycobacterium vanbaalenii seemed to be the best target (Figure 2.10). However, it resisted 
crystallization in all crystallization methods and detergents tested. This is surprising, since it 
seems to be more stable than some of the other enzymes and less sensitive to aggregation. 
Though detergents were screened and some attempts at vapor diffusion crystallization were 
performed, this method was not thoroughly explored for the following reason. One of the aims of 
this project was to co-crystallize the lipidic substrate (CDP-DAG) to compare binding to the 
RsPIPS CDP-DAG bound structure. Ultimately, this aim seemed more achievable using lipidic 
cubic phase (LCP) with CDP-DAG incorporated into the lipid phase, so effort went mostly into 
obtaining and optimizing LCP crystals.  
 During traditional crystal optimization (described in section 2.3.5), crystals ultimately 
improved with the implementation of several different optimization approaches. Crystals seemed 
to improve when I decreased the protein starting concentration (30-35 mg/ml seemed optimal). I 




precaution against any delipidating effects it may be having on the sample. But the inclusion of 
CDP-DAG in the LCP mix helped improve the diffraction of crystals the most during this initial 
optimization stage.  
 When we turned to optimization using mutational protein engineering (described in 
section 2.3.6, Figure 2.6, Table 2.2), improvement in crystal diffraction was seen primarily when 
changes were made to the TM2-3 loop. Other attempts to change the linker region did not seem 
to have beneficial effects and my more drastic attempts to replace the TM2-3 loop and JM helix 
with the RsPIPS sequence resulted in destabilization of the protein and increased aggregation. 
This seems to confirm our hypothesis that TM2-3 loop region is important for CTD-PIPS interface 




 Work presented in this chapter was completed in reference to and as a continuation 
of work started by Guiliano Sciara, Oliver Clarke, and David Tomasek under the supervision of 
Filippo Mancia. Guiliano Sciara was a postdoctoral researcher and David Tomasek was a 
technician in Filippo Mancia’s laboratory. Oliver Clarke, at the time, was a postdoctoral researcher 
under Wayne Hendrickson and now runs his own lab at Columbia University.  Initial crystals of 
MabPIPS and MtPIPS were grown by David Tomasek, at which point I took over to optimize them. 
Genomic DNA for cloning of the 12 mycobacterial PIPS was provided by Brian Kloss from 
NYCOMPS at NYSBC, and all the cloning (original constructs and mutants) was completed by 
me in our laboratory. I was also responsible for all other protein purification, screening and 
crystallization experiments with training from Christina Chen, David Tomasek, Vasileios Petrou 
and Oliver Clarke. The design of mutants for crystallization optimization were designed with 





Structure determination and functional characterization of MkPIPS 
 
3.1 Introduction 
 Through a structural genomics and crystal engineering approach (Chapters 2), we 
were able to produce sufficient diffracting crystals to solve the structure of MkPIPS. In this chapter, 
I will present the structure determination methods and resulting structure, that has been the direct 
product of the work described in the previous chapters.  
 In this chapter, I will also present methods and results for structure determination of 
MkPIPS bound to the lipidic substrate (CDP-diacylglycerol; CDP-DAG) and the soluble substrate 
(inositol-1-phosphate; IP). Indeed, though the structure of RsPIPS was previously solved bound 
to CDP-DAG, we were still interested in visualizing substrate binding in a fully active enzyme. 
Furthermore, throughout all the previous studies with RsPIPS, we were never successful in 
obtaining a structure with bound IP. The IP binding site was putatively identified based on the 
coordination of a sulfate ion peripherally to the CDP-DAG binding pocket and on sequence 
conservation, but the precise binding mode of IP could not be determined. I pursued co-
crystallization with both substrates to better understand the molecular determinants of substrate 
binding.  
 Lastly, I will describe methods and results of our efforts to characterize the activity of 
MkPIPS. Previous characterization of the PIPS enzyme was all performed with MtPIPS, using a 
homology model based on the RsPIPS structure for targeted mutagenesis coupled to enzymatic 
characterization. Since we have been able to determine the structure of a more closely related 
PIPS enzyme from Mycobacterium, we first wanted to confirm that MkPIPS has similar activity to 




other PIPS targets and substrate binding. This characterization has laid the groundwork for more 
probing experiments that are in progress, and will be described in Chapter 4.  
  
3.2 Methods for structure determination of PIPS from Mycobacterium kansasii  
 Chapters 2 described the methods of protein production and crystallization, resulting 
in the collection of good quality X-ray diffraction data. This is the first step in protein structure 
determination by X-ray crystallography. The workflow for subsequent data analysis and model 
building is illustrated in Figure 3.1.  
 Data obtained are intensities of scattered X-ray waves, but to reliably reconstruct an 
atomic model from these data, you must also have information of the X-ray wave phases. This 
information is not directly measured, and must be calculated. This is historically referred to as the 
“phase problem.” The phases can be solved experimentally with the use of isomorphous 
replacement or anomalous diffraction, or through molecular replacement, in which a similar 
structure is provided as a reference to solve the phases (reviewed in [79-81]).  
 Solving the phases enables the reconstruction of an electron density map based on 
the experimental data. Using this electron density as a reference, the researcher can then build 
an atomic model. This atomic model will undergo several iterative rounds of refinement of the 
phases and model building to find the best fit to the experimental data, which can be validated to 
ensure it makes biological and chemical sense. The resulting atomic model can then be analyzed 
and used to probe biological and chemical questions. In sections 3.2.1 to 3.2.4, I will describe the 
methods used to acquire X-ray diffraction data and subsequently reconstruct atomic models of 





Figure 3.1 Workflow for macromolecular structure determination by X-ray crystallography. 
Presented here is a general workflow for structure determination, which starts with a good quality crystal 
(top) followed by the collection of an X-ray diffraction dataset. Once data are collected, the phase problem 
must be solved by either experimental phasing or molecular replacement using a related protein as a 
search model. Here, I solved phases only with molecular replacement, which is emphasized in this flow 
chart. Successful phasing yields an electron density map used to build an atomic model that makes 
biological and chemical sense. This atomic model undergoes rounds of refinement to improve the phases 
and the electron density map, which are followed by iterative model building to improve the accuracy of 
the atomic model. Software references in the text relevant to steps of structure determination are shown 





3.2.1 Data collection and structure determination of MkPIPS-S79 
 Crystals of the active MkPIPS-S79 fusion enzyme were grown in the presence of 0.05 
M NaCl, 0.02 M MgCl2, 0.1 M sodium citrate, pH 6, and 22% PEG 400 with 2% CDP-DAG in 
monoolein used to prepare the LCP mixture. All data were collected at NE-CAT beamline 24-ID-
E at the Advanced Photon Source at Argonne National Laboratory (Lemont, IL, USA). For the 
initial MkPIPS-F79S structure, data were indexed, integrated and scaled with XDS [82] and 
AIMLESS [83]. Data were phased with molecular replacement, using a strategy to search 
separately for two copies of the AfCTD soluble domain (PDB 4O6M, residues 1-134) and one 
copy of the TM dimer from RsPIPS (PDB 5D91, residues 8-205) using PHASER [84]. Density 
modification, including solvent flattening, histogram matching and non-crystallographic symmetry 
(NCS) averaging, was performed using PARROT [85]. The model was completed in Coot [71].  
 Diffraction appeared anisotropic, so in an attempt to improve map density, the 
STARANISO server developed by Global Phasing Ltd [86] was used to apply an anisotropic 
correction to the scaled data (without a resolution cutoff) and initial structures were refined against 
these corrected data. Using a global I/s(I) average to define the resolution cutoff produces 
spherical cutoffs for data in reciprocal space. For data that are anisotropic, this can exclude good 
quality reflections and include weak reflections (Figure 3.2). STARANISO applies a resolution 
cutoff based on local I/s(I) averages, then performs Bayesian estimation of structure amplitudes 
followed by the application of an anisotropic correction factor to the data. STARANISO produced 
a best-resolution limit of 1.97 Å and a worst-resolution limit of 5.4 Å using a I/s(I) cutoff of 1.2.  
Multiple rounds of model building in Coot and refinement with PHENIX [87] were carried out to a 
final Rwork/Rfree of 0.2284/0.2761. Complete data collection and refinement statistics can be found 





Figure 3.2 Application of anisotropic resolution cutoff by STARANISO software. Traditional 
isotropic resolution cutoffs are based on spherically averaged I/s(I) values (illustrated by the circle), which 
may include weak data (red) and exclude high-resolution data (blue). STARANISO applies an anisotropic 
resolution limit (illustrated by the ellipse) based on local I/s(I) means, allowing the inclusion of as much 
good data as possible. Figure retrieved from http://staraniso.globalphasing.org/anisocut.png. 
 
 
Table 3.1. Data collection and refinement statistics for MkPIPS-F79S 
Data Collection  
Space group P21 
Unit cell dimensions  
        a, b, c (Å) 78.338, 60.241, 85.377 
        a, b, g (°) 90, 90.911, 90 
Wavelength (Å) 0.9791 
AIMLESS  
Resolution range 49.1 - 2.25 (2.33 – 2.25) 
Total no. of reflections 72278 (7110) 
No. of Unique Reflections 37287 (3698) 
Redundancy 1.9 (1.9) 
% Completeness 98.61 (98.88) 
Mean I/s(I) 4.93 (1.40) 
Rmerge 0.1122 (0.6492) 




Rpim 0.1122 (0.6492) 
Wilson B factor 35.75 
CC1/2 0.97 (0.394) 
Resolution where I/s(I) drops below 2.0 overall 3.35 
Resolution where I/s(I) drops below 2.0 (along h) 2.32 
Resolution where I/s(I) drops below 2.0 (along k) 2.82 
Resolution where I/s(I) drops below 2.0 (along l) 2.94 
Resolution where CC1/2 drops below 0.5 overall 3.09 
Resolution where CC1/2 drops below 0.5 (along h) 2.60 
Resolution where CC1/2 drops below 0.5 (along k) 2.85 
Resolution where CC1/2 drops below 0.5 (along l) 4.02 
STARANISO  
Ellipsoidal resolution (Å) (direction) 2.78 (0.999 a* + 0.048 b*) 
 5.40 (0.524a* + 0.852c*) 
 1.97 (-0.974a* + 0.025b* + 0.225c*) 
Ellipsoidal resolution range (Å) 49.22 – 1.967 (2.037 – 1.967) 
Total no. of reflections (ellipsoidal) 71471 (290) 
No. of Unique Reflections (ellipsoidal) 37482 (183) 
Redundancy (ellipsoidal) 1.9 (1.6) 
% Completeness (ellipsoidal) 66.00 (3.27) 
Mean I/s(I) (ellipsoidal) 6.23 (0.98) 
Rmerge 0.1061 (0.64) 
Rmeas 0.1501 (0.9051) 
Rpim 0.1061 (0.64) 
Wilson B factor 25.57 
CC1/2 0.989 (0.11) 
Refinement  
Resolution 49.22  - 1.967 (2.037  - 1.967) 
No. reflections used 37477 (183) 
Reflections used for Rfree 1930 (11) 
No. of non-hydrogen atoms  5759 
        protein 5042 
        ligands 501 
        solvent 216 
Rwork 0.2284 (0.4390) 
Rfree 0.2761 (0.3061) 
R.m.s. deviations  
Bond lengths (Å) 0.006 
Bond angles (Å) 1.26 
Ramachandran plot  
        Favored regions 97.29 
        Allowed regions 2.56 
        Outliers 0.15 
Clashscore 13.60 




        protein 36.10 
        ligands 48.75 
        solvent 38.71 
 
 
3.2.2 Production of L-myo-inositol-1-phosphate 
 Inositol-phosphate used for MkPIPS co-crystallization experiments was either 
purchased from commercial sources (D-myo-inositol-3-phosphate; Cayman or Santa Cruz) or 
was produced in house at ITQB in the laboratory of Prof. Helena Santos by Dr. Carla Jorge. These 
two inositol-phosphate species are chemically equivalent (Figure 3.3). The co-crystallization 
resulting in structures reported in this dissertation used the L-myo-inositol-1-phosphate provided 
by Prof. Helena Santos. 
 The L-myo-inositol-1-phosphate is synthetized using the same method described in 
[36], using hexokinase from Thermoproteus tenax and L-myo-inositol-1-phosphate synthase 
(IPS) from Archaeoglobus fulgidus. These two recombinant enzymes are partially purified in 
house from E. coli. Glucose (Perkin Elmer Life Sciences) is incubated with T. tenax hexokinase 
for 1 hour at 70°C in the presence of ATP, magnesium chloride and Tris-HCl, pH 7.6, to form 
glucose-6-phosphate. The reaction is centrifuged, and the supernatant containing the glucose-6-
phosphate is then added to a reaction containing recombinant A. flugidus IPS and NAD+. During 
incubation for 1 hour at 85.5 °C L-myo-inositol-1-phosphate is formed. Excess nucleotides are 
removed with activated charcoal and proteins are removed by filtering the mixture through an 
Omega Nanosep filter (Pall Life Sciences) with a 10 kDa molecular weight cutoff. The resulting 
mixture is further purified by thin-layer chromatography separation. The basic mechanisms of this 





Figure 3.3 Inositol-phosphate species used for crystallization are chemically equivalent. L-myo-
inositol-1-phosphate (prepared in house) and D-myo-inositol-3-phosphate (purchased from Cayman or 
Santa Cruz) share the chemical structure pictured here (PubChem CID 440194). Chemical structure 
retrieved from https://pubchem.ncbi.nlm.nih.gov. 
 
 
Figure 3.4 Production of L-myo-insitol-1-phosphate. Hexokinase catalyzes the production of glucose-
6-phosphate from glucose and ADP. PIS then catalyzes the production of L-myo-inositol-phosphate from 





3.2.3 Co-crystallization of MkPIPS with substrates 
 To gain a more complete understanding of the enzyme mechanism and substrate 
binding, we sought to co-crystallize MkPIPS with both its natural substrates, lipidic CDP-DAG and 
soluble IP. We showed previously that L-myo-inositol-1-phosphate binds more efficiently when 
CDP-DAG is also bound (Figure 3.5) [36]. In addition, we know that a catalytically dead mutant of 
MtPIPS (D93N) is still able to bind both substrates (Figure 3.5) [36]. Thus, we reasoned that we 
would require the presence of CDP-DAG in order to observe binding of IP and that a mutant that 
does not catalyze the reaction causing turnover may be the best option to produce diffracting 
crystals containing enzymes bound to both substrates. Following this logic, we generated 
catalytically inactive mutants of several MkPIPS variants designed for crystallization (Table 2.2 in 
Chapter 2). The interpretation of the first MkPIPS structure (section 3.4.1) also suggested that the 
long C-terminus may in fact be preventing formation of the AfCTD-PIPS interface. For this reason, 
I designed truncation mutants, including MkPIPS-D24C (Table 2.2 in Chapter 2), which were also 
used for co-crystallization experiments with and without the additional mutation at the catalytic 
residue (D93N). The first MkPIPS structure determined was crystallized with 2% CDP-DAG in the 
LCP mix; however, we did not observe density consistent with CDP-DAG in the binding site. 





Figure 3.5 L-myo-[14C]inositol-1-phosphate binding to MtPIPS proteoliposomes. Quantification of 
bound L-myo-[14C]inositol-1-phosphate to proteoliposomes containing MtPIPS with no mutations (WT) 
or with a mutation of the catalytic residue (D93N) or a mutation of a residue putatively involved in inositol-
phosphate binding (R195Q) after incubation with or without CDP-DAG. Empty liposomes are used as a 
control. Figure adapted from [36].  
 
 Similar to the crystallization method described in Chapter 2 (section 2.3.4), the best 
diffracting crystals were grown in lipidic cubic phase (LCP; in meso) at 22°C, similarly to the 
method described previously [34, 36]. Purified protein was concentrated to between 30 and 35 
mg/ml using a centrifugal concentrator (Millipore) with a 100 kDa MWCO. LCP mix was prepared 
with monoolein (Sigma) at a 1:1.5 protein to lipid ratio. Crystals grown in the presence of lipid 
CDP-DAG (Avanti), CDP-DAG dissolved in chloroform was added to monoolein to a final 
concentration of 2-3% (w/w). Chloroform was evaporated off the lipid mixture under a stream of 
inert argon gas and the lipid mixture was dried overnight using a vacuum desiccator. A Mosquito 
LCP (TTP Labtech) was used to dispense a volume of 80 nl of LCP mixture onto a 96-well glass 
plate, which was covered with 750 nl of precipitant solution and sealed with a glass cover slip. 
Initial crystals appeared within 3 days, and were grown to optimal conditions up to 1 month in the 
following conditions: a) MkPIPS- 0.1 M NaCl, 0.1 M Sodium Citrate, pH 6.1, 0.04 M MgCl2, 21% 




to prepare the CDP mixture (MkPIPS-D24C-D93N bound to CDP-DAG), b) 0.1 M NaCl, 0.1 M 
Sodium Citrate, pH 6.1, 40 mM MgCl2, 29% PEG 400, 500 uM myo-inositol-1-phosphate 
(prepared in house by Carla Jorge at ITQB as described in section 3.2.2), 2.5 mM CDP (Sigma) 
(MkPIPS-S79 bound to CDP and IP).  
 
3.2.4 Data collection and structure determination of MkPIPS-D24C-D93N bound to CDP-
DAG 
 Diffraction data were collected at NE-CAT beamlines 24-ID-C at the Advanced Photon 
Source at Argonne National Laboratory (Lemont, IL, USA).  For both the structure of MkPIPS-
D24C-D93N bound to CDP-DAG, data were indexed and integrated with XDS and scaled with 
AIMLESS. Data were phased by molecular replacement strategy using the initial MkPIPS-S79 
dimer structure as a search model (section 3.2.1 for structure determination details and section 
3.4.1 for structure description), using PHASER [84]. The model was completed in Coot [71]. 
Multiple rounds of model building in Coot and refinement with PHENIX [87] were carried out to a 
final Rwork/Rfree of 0.2753/0.3004. When modeling, to limit bias, substrates were modeled at zero 
occupancy throughout early refinement. In addition, OMIT maps were calculated with PHENIX 
Polder [89] to confirm ligand density. Complete data collection and refinement statistics can be 
found in Chapter Table 3.2.  
 
Table 3.2 Data collection and refinement statistics for MkPIPS-D24C-D93N bound to CDP-DAG 
Data Collection  
Space group P21 
Unit cell dimensions  
        a, b, c (Å) 78.45, 61.37, 86.47 
        a, b, g (°) 90, 90.32, 90 
Wavelength (Å) 0.9791 
Resolution range 78.44.47 – 3.18 (3.29 – 3.18) 




No. of Unique Reflections 13745 (1139) 
Redundancy 2.0 (2.0) 
% Completeness 97.26 (81.46) 
Mean I/s(I) 5.61 (0.80) 
Rmerge 0.1103 (0.7336) 
Rmeas 0.156 (1.037) 
Rpim 0.1103 (0.7336) 
Wilson B factor 95.27 
CC1/2 0.998 (0.618) 
Resolution where I/s(I) drops below 2.0 overall 4.03 
Resolution where I/s(I) drops below 2.0 (0.83 a* + 0.56 c*) 3.27 
Resolution where I/s(I) drops below 2.0 (along k) 5.30 
Resolution where I/s(I) drops below 2.0 (-0.49 a* + 0.87 c*) 3.62 
Resolution where CC1/2 drops below 0.5 overall 3.47 
Resolution where CC1/2 drops below 0.5 (0.83 a* + 0.56 c*)) 3.17 
Resolution where CC1/2 drops below 0.5 (along k) 4.08 
Resolution where CC1/2 drops below 0.5 (-0.49 a* + 0.87 c*) 3.63 
Refinement  
Resolution 78.44.47 – 3.18 (3.29 – 3.18) 
No. reflections used 13726 (1138) 
Reflections used for Rfree 676 (63) 
No. of non-hydrogen atoms  4758 
        protein 4704 
        ligands 54 
Rwork 0.2753 (0.4493) 
Rfree 0.3004 (0.4444) 
R.m.s. deviations  
Bond lengths (Å) 0.013 
Bond angles (Å) 1.11 
Ramachandran plot  
        Favored regions 98.01 
        Allowed regions 1.68 
        Outliers 0.31 
Clashscore 15.51 
Average B-factor 86.86 
        protein 86.79 







3.2.5 Data collection and structure determination of MkPIPS-S79 bound to CDP and IP 
 All data were collected at NE-CAT beamline 24-ID-E at the Advanced Photon Source 
at Argonne National Laboratory (Lemont, IL, USA). For the structure of MkPIPS-F79S bound to 
CDP and IP, data were indexed, integrated and scaled with XDS [82] and AIMLESS [83]. Data 
were phased by molecular replacement strategy utilizing the initial MkPIPS-S79 dimer structure 
as a search model (section 3.2.1 for structure determination details and section 3. for structure 
description), using PHASER [84]. Density modification, including solvent flattening, histogram 
matching and non-crystallographic symmetry (NCS) averaging, was performed using PARROT 
[85]. The model was completed in Coot [71].  
 Diffraction was observed to be anisotropic, so in an attempt to improve map density, 
the STARANISO server developed by Global Phasing Ltd [86] was used to apply an anisotropic 
correction to the scaled data (without a resolution cutoff) and initial structures were refined against 
these corrected data. A more thorough description of STARANISO is provided in section 3.2.1. 
STARANISO produced a best-resolution limit of 2.14 Å and a worst-resolution limit of 3.38 Å using 
a I/s(I) cutoff of 1.2. Multiple rounds of model building in Coot and refinement with PHENIX [87] 
were carried out to a final Rwork/Rfree of 0.2253/0.2753. Complete data collection and refinement 
statistics can be found in Table 3.3.  
 
Table 3.3 Data collection and refinement statistics for MkPIPS-S79 bound to CDP and IP 
Data Collection  
Space group P21 
Unit cell dimensions  
        a, b, c (Å) 77.99, 60.37, 85.05 
        a, b, g (°) 90, 91.07, 90 
Wavelength (Å) 0.97918 
AIMLESS  
Resolution range 85.26 – 2.35 (2.43 – 2.35) 
Total no. of reflections 230116 (21205) 




Redundancy 6.9 (6.6) 
% Completeness 99.6 (97.1) 
Mean I/s(I) 8.3 (0.6) 
Rmerge 0.185 (3.126) 
Rmeas 0.219 (3.713) 
Rpim 0.116 (1.985) 
Wilson B factor 55.3 
CC1/2 0.997 (0.370) 
Resolution where I/s(I) drops below 2.0 overall 3.15 
Resolution where I/s(I) drops below 2.0 (along h) 2.44 
Resolution where I/s(I) drops below 2.0 (along k) 3.49 
Resolution where I/s(I) drops below 2.0 (along l) 2.71 
Resolution where CC1/2 drops below 0.5 overall 2.61 
Resolution where CC1/2 drops below 0.5 (along h) 2.35 
Resolution where CC1/2 drops below 0.5 (along k) 3.28 
Resolution where CC1/2 drops below 0.5 (along l) 2.52 
STARANISO  
Ellipsoidal resolution (Å) (direction) 3.201 (0.999 b* + 0.053 c*) 
 3.381 (b*) 
 2.142 (-0.825a* + 0.080b* + 0.559c*) 
Ellipsoidal resolution range (Å) 78.08 – 2.144 (2.221 – 2.144) 
Total no. of reflections (ellipsoidal) 51956 (138) 
No. of Unique Reflections (ellipsoidal) 26006 (69) 
Redundancy (ellipsoidal) 2.0 (2.0) 
% Completeness (ellipsoidal) 58.72 (1.57) 
Mean I/s(I) (ellipsoidal) 9.78 (1.73) 
Rmerge 0.07329 (0.4034) 
Rmeas 0.1036 (0.5705) 
Rpim 0.07329 (0.4034) 
Wilson B factor 41.06 
CC1/2 0.995 (0.594) 
Refinement  
Resolution 78.08  - 2.144 (2.221  - 2.144) 
No. reflections used 25994 (69) 
Reflections used for Rfree 1297 (3) 
No. of non-hydrogen atoms  5319 
        protein 5040 
        ligands 217 
        solvent 62 
Rwork 0.2254 (0.3266) 
Rfree 0.2753 (0.5286) 
R.m.s. deviations  
Bond lengths (Å) 0.005 




Ramachandran plot  
        Favored regions 97.15 
        Allowed regions 2.70 
        Outliers 0.15 
Clashscore 7.37 
Average B-factor 47.32 
        protein 46.67 
        ligands 63.09 
        solvent 44.42 
 
3.3 Methods of functional characterization of PIPS from Mycobacterium kansasii 
 As a continuation of our structural investigation of mycobacterial PIPS, we are 
interested in using the structures as guides to inform a more thorough functional characterization. 
Here, I present methods for preliminary functional characterization of PIPS from Mycobacterium 
kansasii. These methods are also being implemented in ongoing and future experiments, which 
will be described in Chapter 4.     
 During functional characterization, cloning, preparation of E. coli cells expressing 
MkPIPS protein, and reconstitution of MkPIPS protein into liposomes were performed by me at 
Columbia University. With these prepared materials, the functional characterization of PIPS with 
enzymatic assays using radiolabeled inositol-phosphate was instead performed in Portugal at the 
Instituto de Tecnologia, Química e Biológica (ITQB) at the Universidade Nova de Lisboa by Dr. 
Carla Jorge in the laboratory of Prof. Helena Santos, pioneers in in the functional characterization 
of PIPS and other CDP-AP enzymes [23, 35, 36, 90].  
 
3.3.1 Preparation of E. coli membranes for functional assays 
 Membranes for enzymatic assays were prepared as outlined in [36]. Cell pellets of E. 
coli cells expressing recombinant PIPS protein variants were resuspended in buffer containing 50 
mM Tris-HCl, pH 7.6, 10 mM magnesium sulfate and 5 mM b-mercaptoethanol. The resuspended 




un-lysed cells. The resulting supernatant was centrifuged for 2 hours at 4°C and 100,000g to 
isolate the membrane fraction. Pelleted membranes were resuspended once more in buffer 
containing 50 mM Tris-HCl, pH 7.6, 10 mM magnesium sulfate and 5 mM b-mercaptoethanol. 
These membranes were used in the functional assay described in section 3.3.3 
 
3.3.2 Preparation of L-myo-[14C]inositol-1-phosphate 
 Radiolabeled L-myo-[14C]inositol-1-phosphate was prepared as described in section 
3.2.2 and Figure 3.4 of this dissertation (and as previously published in [36]), but to produce the 
radiolabeled product, [14C(U)]glucose was used as starting material for the enzymatic reactions. 
[14C(U)]Glucose (Perkin Elmer Life Sciences) is incubated with T. tenax hexokinase in the 
presence of ATP, magnesium chloride and Tris-HCl, pH 7.6, to form [14C]Glucose-6-phosphate. 
[14C]Glucose-6-phosphate is then added to a reaction containing recombinant A. fulgidus IPS and 
NAD+, forming L-myo-[14C]inositol-1-phosphate. Excess nucleotides are removed with activated 
charcoal and proteins are removed by filtering the mixture through a centrifugal filter with a 10 
kDa molecular weight cutoff. The resulting mixture is further purified by thin-layer chromatography 
separation.  
   
3.3.3 Activity assay of PIPS using E. coli membrane isolates 
 PIPS activity in E. coli membranes was assessed as described previously [36]. 
Membrane isolates from E. coli expressing recombinant PIPS enzyme variants were prepared as 
described in section 3.3.1 and in [36]. Total membrane protein content of membranes was 
assayed by Bradford assay. To assay PIPS activity, 200 µg of total protein in membranes was 
added to a reaction mixture containing 6.5 µM L-myo-[14C]inositol-1-phosphate, 161 µM L-myo-




Lipids), 10 mM MgCl2 10 mM b-mercaptoethanol, 1% CHAPS, and 50 mM Bicine buffer, pH 8. 
The reaction was incubated at 37 °C for 1 hour and the reaction was stopped by the addition of 
100 mM HCl in methanol. The aqueous and organic phases of the reaction were separated using 
methanol-chloroform extraction. The radiolabeled enzymatic product (phosphatidylinositol-
phosphate) in the organic layer was quantified using scintillation counting. Relative levels of 
product formation correspond to relative activity of the PIPS enzyme in the isolated membranes. 
Activities are measured in triplicate. 
 
3.3.4 Reconstitution of MkPIPS into proteoliposomes 
 The method utilized here for preparation of liposomes and proteoliposomes was 
adapted from Rigaud, et al. [91]. E. coli polar lipid extract (Avanti) and phosphatidylcholine 
(Avanti) were mixed in a 3:1 ratio (w/w) by dissolving in chloroform. Chloroform was evaporated 
under a stream of argon gas leaving a thin layer of dry lipids. After drying overnight in a vacuum 
desiccator, lipids were resuspended in buffer containing 100 mM HEPES, pH 7.5, 1.5% (w/v) 1-
O-n-Octyl-b-D-glucopyranoside (OG; Anatrace) and 2 mM b-mercaptoethanol to make a final lipid 
concentration of 20 mg/ml. Resuspended lipid mixture was dialyzed overnight against buffer 
containing 100 mM HEPES, pH 7.5 and 2 mM b-mercaptoethanol in order to remove detergent 
and allow formation of liposomes. Preformed liposomes were distributed in 500 µl aliquots, flash 
frozen in liquid nitrogen and stored at -80°C.  
 To reconstitute protein into liposomes, aliquots were thawed, purified target protein in 
detergent and buffer (100 mM HEPES, pH 7.5) was added to make a final protein concentration 
of 0.125 mg/ml and a lipid concentration of 10 mg/ml (lipid to protein ratio of 80:1). Triton-X was 
added to a final concentration of 0.11% (w/v) and the mixture was incubated at room temperature 




added and the mixture was incubated at room temperature for 1 hour with constant agitation. 
Another 60 mg of BioBeads were added per 1 mL of mixture and incubated for 1 hour at room 
temperature with constant agitation. A final 120 mg of BioBeads per 1 mL proteoliposome mixture 
was added and was incubated overnight at 4°C. After this final incubation, the proteoliposomes 
were removed from the BioBeads by carefully pipetting, flash frozen with liquid nitrogen and 
stored at -80°C for use in enzymatic characterization assays.  
 
3.3.5 Determination of KM of MkPIPS for its substrates 
 The KM of MkPIPS for IP and CDP-DAG was determined as described for MtPIPS in 
[36]. To determine the KM of MkPIPS for IP, reactions containing 2 mM CDP-DAG, 10 mM 
magnesium chloride, 10 mM b-mercaptoethanol, 1% (w/v) CHAPS, 50 mM Bicine buffer, pH 8, 
9 µM L-myo-[14C]inositol-phosphate and different concentrations of IP with no radiolabel (ranging 
from 40 µM to 1 mM) were pre-incubated for 3 minutes at 37°C. Then, enzymatic reactions were 
initiated by adding membranes from E. coli expressing MkPIPS (200 µg total membrane protein; 
prepared as described in section 3.3.1). Reactions were stopped at different time points by adding 
1 mL of HCl in methanol. Chloroform-methanol extraction and quantification of product in the 
organic phase was carried out as described in section 3.3.3. Assays were performed in duplicate.    
 To determine the KM of MkPIPS for CDP-DAG, a similar assay was performed. 
Reactions containing 9 µM L-myo-[14C]inositol-phosphate, 91 µM IP (no radiolabel), 10 mM 
magnesium chloride, 10 mM b-mercaptoethanol, 1% (w/v) CHAPS, 50 mM Bicine buffer, pH 8, 
and different concentrations of CDP-DAG (ranging from 50 µM to 2 mM) were pre-incubated for 






3.4 Results  
 Structural genomics and crystal engineering have allowed us to produce crystals of 
sufficient quality to solve the structures of MkPIPS in several different ligand-bound states. Here 
I will present the details and interpretation of three structures, one in an apo state without the 
biological substrates bound to 3.1 Å resolution, the second crystallized in the presence of CDP-
DAG with evidence of cytidine binding to 3.5 Å resolution, and the third bound to CDP and IP to 
2.6 Å resolution. Throughout the chapter, I will compare these structures to the previously 
obtained structures RsPIPS, Af2299 and IPCT/DIPPS. Here, I will also present our initial 
functional characterization of MkPIPS by enzymatic assays using radiolabeled inositol-
phosphate.  
 
3.4.1 Structure of MkPIPS 
Anisotropic correction of data notably improved electron density maps 
 The anisotropic correction of the MkPIPS-S79 diffraction data allowed the inclusion of 
high-resolution reflections out to 1.97 Å resolution, which improved the detail and quality of the 
electron density maps (Figure 3.6 shows refinement before correction in A and after correction in 
B) beyond what is expected from the reported resolution of 3.1 Å. This improved confidence in 
the resulting model presented later in this section. After many rounds of model building and 
refinement using data with the anisotropic correction, I checked for model bias by refining a final 
model against the original data with a resolution cutoff at 2.25 Å. Fewer features were observable, 
as expected, though the model fit was still reasonable, giving me confidence that the anisotropic 






Figure 3.6 Application of anisotropic correction by STARANISO improved electron density. A) 
Electron density after initial refinement without anisotropic correction. B) Electron density of the same 
region after refinement with data with anisotropic correction applied using STARANISO.  
  
Overall architecture   
 MkPIPS-S79 fusion protein was crystallized in the presence of lipidic CDP-DAG, 
producing diffraction that allowed the determination of the structure presented in Figure 3.7 to 3.1 
Å resolution. The structure of MkPIPS reveals an overall architecture similar to PIPS from 
Renibacterium salmoninarum, as well as other CDP-AP enzymes Af2299 and IPCT/DIPPS. In 
Figure 3.7, the AfCTD chaperones have been excluded for clarity. It is a dimer, with each 
monomer being made up of an amphipathic juxtamembrane helix (JM) and six transmembrane 
helices (Figure 3.7 A and B). There are three extracellular loops (L1-2, L3-4, and L5-6; Figure 3.7 




There are also two cytosolic loops (L2-3 and L4-5; Figure 3.7 A), which both frame the substrate 
binding sites and catalytic site, as also seen in RsPIPS. L2-3 has been one of the main focuses 
of the crystal engineering attempts described in Chapter 2.   
 Another notable feature is the extended C-terminus that is seen to extend away from 
the six-helix bundle and form a sheet-like interaction with the L2-3 of the second protomer (Figure 
3.7 A). This was not observed in previous CDP-AP structures. This C-teriminus is only resolved 
in the structure to residue 210 of 232 (MkPIPS numbering).  
 Though CDP-DAG was present in the LCP crystallization mixture, density consistent 
with CDP-DAG could not be observed in the electron density maps. There was density in the 
CDP-DAG binding site, which was modeled in as citrate molecules as they were more consistent 
with the density and are present in the precipitant solution. There was also density in the putative 
IP binding site though no inositol-phosphate was present during the purification or crystallization. 





Figure 3.7 Overall architecture of MkPIPS. Overall architecture of the MkPIPS dimer with one protomer 
multicolored, (juxtamembrane helix, JM, in dark blue; transmembrane helix 1, TM1, in light blue; TM2 in 
cyan; TM3 in light green; TM4 in yellow; TM5 in orange; TM6 in red) and one protomer in grey presented 
in two views: A) Looking parallel to the plane of the membrane and B) rotated 90º looking perpendicular 
to the plane of the membrane. C-terminus, N-terminus, extracellular loops and cytosolic loops are labeled 
(L1-2 denotes loop between TM1 and TM2).  
  
AfCTD conformation 
 The structure of MkPIPS also reveals a novel organization of the fused AfCTD. Within 
each dimer, the AfCTD from each protomer has crystallized in a different orientation (Figure 3.8 




engineered fusion protein or enzyme with naturally-occurring soluble domains (Figure 3.8 B, C 
and D), which have all crystallized in a symmetric way.  
It seems that the long C-terminus may have also prevented the experimental 
recapitulation of the AfCTD-PIPS interface that was observed in the RsPIPS fusion protein. As 
previously noted, the long C-terminus extends and interacts with L2-3 of the other protomer 
(Figure 3.9 A). If you superimpose the second protomer with the structure of the RsPIPS fusion 
(Figure 3.9 B), you can see that the C-terminus of MkPIPS is clashing with the AfCTD of the 






Figure 3.8 AfCTD conformation compared to Af2299, IPCT/DIPPS and RsPIPS-fusion. The two 
AfCTDs in the MkPIPS fusion protein dimer adopt different conformations in the crystal lattice (A). This 
is novel compared to all other previously crystallized CDP-AP enzymes: Af2299 (B), IPCT/DIPPS (C), 
and AfCTD-RsPIPS fusion (D). 
 





Figure 3.9 AfCTD-PIPS interface disruption by the C-terminus. A) The long C-terminus of MkPIPS 
monomer 1 (yellow) interacts with L2-3 of monomer 2 (orange; *), which may be preventing the 
recapitulation of the AfCTD-PIPS interface observed in the RsPIPS structure. B) MkPIPS monomer 2 is 
superimposed with RsPIPS monomer (blue) showing that the MkPIPS monomer 1 C-terminal tail clashes 





Active site of MkPIPS 
 The organization of the active site of MkPIPS is also very similar to what has already 
been observed in RsPIPS. The CDP-AP signature motif is found on TM2 and TM3 at the cytosolic 
side of the enzyme, with the four conserved aspartic acid residues (D68, D71, D89, and D93) 
coordinating two Mg2+ ions (Figure 3.10 A).  The basic organization of the active site looks similar 
to that of RsPIPS, but when the two structures are superimposed, there seems to be a significant 
difference. TM1 and TM3 align very well structurally (Figure 3.10 B). When comparing only the 
backbone without side chains, RMSD between RsPIPS and MkPIPS for TM1 is 0.632 Å and for 
TM3 is 0.583 Å. However, MkPIPS and RsPIPS seem to have a significant difference in TM2, 
which changes the geometry of the active site and may also be contributing to the low activity of 
RsPIPS compared with MkPIPS and MtPIPS. When comparing only the carbon backbone, RMSD 
between RsPIPS and MkPIPS for TM2 is 1.031 Å, and when comparing only the stretch of helix 





Figure 3.10 MkPIPS active site. A) The basic organization of the MkPIPS active site is consistent with 
previous CDP-AP structures with the highly conserved aspartic acids (D68, D71, D89 and D93) are 
located on the cytosolic side of TM2 (cyan) and TM3 (light green) and act to coordinate Mg2+ ions that 
are essential for catalysis. B) Superimposing MkPIPS and RsPIPS apo structures reveals a difference in 
TM2 helix structure, which is unique among neighboring helices. C) This difference in TM2 helical 
structure seems to affect the geometry of the active site.     
 
3.4.2 Structure of MkPIPS with evidence of CDP-DAG binding 
Cytidine group coordination in MkPIPS 
Catalytically dead truncation mutant MkPIPS-D24C-D93N was crystallized in the 




of the structure presented in Figure 3.11 A to 3.5 Å resolution. In the electron density maps, I was 
only able to observe density for the cytidine group and one phosphate of the CDP in the conserved 
binding pocket (Figure 3.11 D and E), so it is modeled as cytidine-monophosphate (CMP) in the 
models presented in Figure 3.11 and 3.12. I was not able to resolve the acyl lipid tails, which were 
seen in RsPIPS to extend up into the hydrophobic groove created between TM2 and TM5. From 
what we can observe, the cytidine monophosphate coordination is consistent with the structures 
of RsPIPS and Af2299. The substrate is bound in in the conserved CDP-binding domain residing 
between TM2 and TM3 coordinated by residues of the CDP-AP signature motif (Figure 3.11 B 
and C). Though there was no density observed for the expected metals in the electron density 
map, D89 and D71 are in the correct position to coordinate the observable phosphate group and 






Figure 3.11 Cytidine group coordination in MkPIPS. A) MkPIPS-D24C-D93N crystallized in the 
presence of CDP-DAG allowed determination of this structure. Colored as in Figure 3.7, one monomer 
in grey and the other monomer with JM dark blue, TM1 light blue, TM2 cyan, TM3 light green, TM4 
yellow, TM5 orange, and TM6 red. Shows evidence of cytidine group from CDP-DAG bound below the 
active site in the correct binding site, modeled in as CMP (purple). B) and C) show a detail of this binding 
mode from different orientations shown in A. D) Density of the 2mFo-DFc map is shown in blue mesh at 
1.0 sigma around the modeled CMP. E) Density of omit map calculated by excluding the CMP in 
modeling using phenix.polder shown at 3.5 sigma in green mesh. 
 
Effect of CDP-DAG binding to MkPIPS structure 
 Superimposing this ligand-bound structure on the apo structure (presented in section 




orientation of the M69 residue on TM2 at the bottom of the hydrophobic groove (Figure 3.12 A 
and B with the density for M69 in the two datasets is shown in C and D).  In our previous probe 
of MtPIPS function, we found that if M69 was mutated to a bulkier tryptophan, function of the 
enzyme was reduced, and it if was mutated to a less bulky alanine, activity of the enzyme 
increased. This newest observation of side chain shift with ligand binding contributes evidence to 
the hypothesis that this residue may act as a rudimentary gate-keeper for substrate binding, 
however this must be tested further. 
 
Figure 3.12 MkPIPS apo and CDP-DAG bound structures superimposed. A) MkPIPS structures were 
superimposed, apo in yellow and CDP-DAG-bound in cyan revealing a difference in the sidechain 
orientation of a methionine residue on TM2 (M69; circled in red). B) Detail of the M69 residue of the 
superimposed structures. C) and D) show the density of the 2mFo-DFc map is shown in blue mesh at 1.0 
sigma for each structure.  
 
3.4.3 Structure of MkPIPS with CDP and IP 
 MkPIPS-S79 fusion protein was crystallized in the presence of soluble CDP and IP, 
producing diffraction that allowed the determination of the structure presented in Figure 3.13 A to 




and confirms the putative binding site previously identified. Density for both IP and CDP was seen 
in both monomers, but with differing quality (Figure 3.13 A, B, C, and D) with Monomer 1 having 
better quality density for bound IP (Figure 3.13 A) and Monomer 2 having better quality density 
for CDP (Figure 3.13 D).  
 
Figure 3.13 Electron density quality for substrates bound to MkPIPS-S79. The electron density 
maps used to build the model of MkPSIP-S79 bound to CDP and IP (top) revealed density for both 
ligands in each monomers, but of differing quality. IP shown in pink and CDP shown in purple. Monomer 
1 shows better quality density for IP (A) than for CDP (B) and Monomer 2 shows better quality density 
for CDP (D) than for IP (C). For each substrate, the top panel shows the 2mFo-DFc map is shown in blue 
mesh at 1.0 sigma and the bottom panel shows the omit map calculated with phenix.polder in green 
mesh contoured at 4.5 sigma (A), 3.9 sigma (B), 4.6 sigma (C) and 3.2 sigma (D). 
 
 Details of the IP binding pocket are shown in Figure 3.14. IP is bound in a polar cytosol-
facing pocket surrounded by TM3, TM4, TM5 and TM6 as well as TM5 of the other protomer. 




coordinating the inositol sugar group, while residues R94, Y133 and R137 seem to be responsible 
for binding of the phosphate group.  
 
Figure 3.14 IP binding site in MkPIPS. Overall architecture of MkPIPS bound to IP and CDP in shown 
on top for orientation. Panel below shows the details of IP binding to MkPIPS. MkPIPS is colored as 
previously established with IP in pink and with residues that seem to be important for IP binding shown 
and labeled. R155, R195, K135, S132 were previously confirmed as IP binding residues, D93 acts as 
the catalytic base. R94, Y133 and R137 seem to be playing a role in IP binding, but have not been 





 In the structure, IP and CDP are bound with the catalytic base in a central position with 
the reactive hydroxyl of IP 8 Å away from D93 and the b-phosphate of CDP 7 Å away (Figure 3.15 
A). Figure 3.15 B shows a space-fill model of the substrate binding and catalytic site with the 
substrates bound and oriented for catalysis.   
 
Figure 3.15 Substrate position relative to catalytic base D93. A) CDP (purple) and IP (pink) bind in 
adjacent pockets with the catalytic base D93 (green) in a central position. Distances of the reactive 
hydroxyl of IP and the b-phosphate of CDP are shown in black dashed line, Mg2+ shown as lime green 
spheres (density was observed for Mg2+ in these maps). B) Space fill model colored as in A with D93 in 






3.4.4 Functional characterization of MkPIPS  
 Activity of different PIPS constructs were measured using a radioactivity-based 
enzyme assay as described in Section 3.3.3. RsPIPS and MtPIPS are shown for comparison. All 
proteins measured for function were in a fusion form with AfCTD. As previously discussed, 
RsPIPS shows very low function, while MtPIPS and MkPIPS exhibit comparable activity levels, 
even when a serine mutation is introduced into the TM2-3 loop for crystallization purposes. The 
Catalytically dead version of MkPIPS (D93N) exhibits no function as expected (Figure 3.16 A).  
 
 The KM of MkPIPS for CDP-DAG and IP was measured using the method described 
in section 3.3.5. The KM of MkPIPS for IP was found to be 281 µM, showing a lower affinity 
compared to the previously measured KM of MtPIPS for IP of 133 µM. On the other hand, the KM 
of MkPIPS for CDP-DAG was measured to be 23 µM, which differs by an order of magnitude from 
the KM of MtPIPS for CDP-DAG, which was previously measured to be 238 µM (Figure 3.16 B). 
 
Figure 3.16 Initial functional characterization of MkPIPS. A) Comparison of PIPS activity measured 
by radioactive enzyme assay. RsPIPS in blue, MtPIPS in green, MkPIPS in orange, catalytically inactive 
mutant of MkPIPS (D93) in red, but at level zero for activity. B) KM of CDP-DAG and IP for MtPIPS and 




It is interesting that two similar enzymes in activity and function can have such different substrate 
affinities. This needs to be investigated further and will be discussed in Chapter 4. 
 
3.5 Discussion 
 The structures of MkPIPS presented here have confirmed PIPS topology and CDP-
DAG binding in the context of an active enzyme relevant to a pathogenic Mycobacterium. They 
have also revealed for the first time, the details of inositol-phosphate binding to PIPS, which has 
eluded us in our previous co-crystallization efforts.  
 From a crystal engineering point of view, this structure is very interesting. The lack of 
symmetry in the AfCTD soluble domains is surprising, since the crystal engineering efforts were 
aimed at stabilizing the interface between the soluble AfCTD and the PIPS enzyme. It seems that 
our efforts to optimize crystallization actually introduced more flexibility and freedom between 
domains, making this unique arrangement possible. Ultimately the fact that this fusion still 
crystallized in this novel, unexpected way gives legitimacy to the proposed use of AfCTD as a 
more universal crystallization chaperone. 
 As seen in Figure 3.9, the C-terminus may be a contributing factor in the inability of 
MkPIPS to form this stable interface; however, when I made truncations of the C-terminus 
(MkPIPS-D24C), it still crystallized in the same non-symmetric way and did not crystallize 
dramatically better without the presumably unstructured C-terminus present. The loop that the C-
terminus interacts with (L2-3) is the same loop that underwent extensive mutation in an attempt 
to optimize crystallization. From the beginning of our crystal engineering attempts, this interaction 
between L2-3 and the C-terminus of the other protomer may have been causing occlusion of 
those mutations aimed at rigidifying the interface. It is not clear if the interaction between the C-
terminus and the L2-3 of the neighboring protomer has some kind of functional role. Many other 




as long as MkPIPS (Figure 3.17). The purification of my truncation mutants makes me believe 
that the C-terminus-L2-3 interaction at least has a structural role. My shortest truncations, which 
terminated at the end of the helix as shown in the structure, were no longer stable in detergent 
during purification and were prone to aggregation. Two longer truncation variants, kept long 
enough to still intearct with the L2-3 loop based on the MkPIPS-S79 apo structure (Figures 3.7 
and 3.9) were stable in detergent. I would like to test these truncation mutants for enzyme activity 
as well to confirm whether or not the C-terminus has more than a structural role in MkPIPS.  
 
 
Figure 3.17 Comparison of PIPS C-terminus lengths. The C-terminus of sequence alignment of PIPS 
from Renibacterium salmoninarum and eleven PIPS from Mycobacterium. Sequence from MkPIPS is 
boxed in red. Sequence from RsPIPS and MtPIPS are emphasized with a red asterisk. 
 
 The structure of MkPIPS revealed a difference in catalytic site geometry, as pictured 
in Figure 3.10 C. I hypothesize that this difference in structure contributes to the higher activity of 
MkPIPS compared to RsPIPS, although this needs to be verified by other methods. It is striking 
in the comparison of PIPS enzymes that such small differences have such a large effect on 
enzyme activity.  
 As discussed in section 3.4.2, we were able to see evidence of CDP-DAG binding to 




and IP. I was not able to resolve the lipid tails in the structure. It is not clear whether they were 
not resolved due to flexibility of the acyl chains or if the substrate had been hydrolyzed during the 
crystallization process; the latter hypothesis seems unlikely to me, as the substrate was co-
crystallized with a catalytically dead mutant, but this process could have happened naturally by 
other means. Because of the lower resolution of this structure, not a substantial amount of 
information can be inferred from this absence of density.   
 Comparison of the MkPIPS apo structure to the CDP-DAG bound structure reveal a 
difference in M69 sidechain conformation (Figure 3.12). This is of particular interest as it was 
previously shown that when mutated to a bulkier residue in MtPIPS, the enzyme lost function and 
when mutated to a less bulky residue (alanine), the enzyme gained function [36]. This residue 
seems to be involved with substrate availability to the active site or ease of product release. The 
homologous residue in RsPIPS is an isoleucine, which may also contribute to the lower activity, 
if a relatively inflexible hydrophobic residue is slowing down substrate binding or product release, 
this might explain the lower activity of the enzyme. I would like to explore this further with 
functional verification.  
 We were also able to co-crystallize CDP and IP with the MkPIPS enzyme using an 
active variant (MkPIPS-S79). Additional uncharacterized residues found in the IP binding site 
(Y133, R94, R137) will be verified functionally.  As described in Figure 3.13, there seems to be 
more coordinated binding in opposite monomers of CDP and IP. This perhaps suggests some 
kind of cooperativity of binding between the dimer. We have previously shown that the presence 
of CDP-DAG increases IP binding, and it is possible that CDP-DAG binding could have an 
allosteric affect that promotes IP binding in the adjacent protomer. This should be kept in mind in 
further functional experimentation.    
 We have acquired sufficient functional data on MkPIPS to make the claim with reliable 




MtPIPS. It does seem that they have different substrate affinities. This needs to be repeated and 
clarified. It is curious that enzymes so closely related would be so different in this way, though not 
impossible and our understanding of this phenomenon will add to our understanding of CDP-AP 
enzymes in general.   
 The MkPIPS structures present the same overall architecture of RsPIPS and a similar 
CDP-binding mechanism, which are not surprising. These new structures have also revealed 
novel details about PIPS that may be useful in the application of drug development for anti-






PIPS ongoing experiments and future directions  
 
4.1 Introduction 
 We have determined the structures of PIPS from Mycobacterium kansasii (MkPIPS) 
in three different states, one without IP or CDP-DAG bound, one with CDP-DAG bound and one 
with CDP and IP bound. The details and interpretations of these structures have been described 
in Chapter 3. We have also been able to measure the activity of different MkPIPS enzymes used 
for crystallization, confirming that they are active at approximately the same level compared to 
MtPIPS, which was previously used in functional validation of the PIPS enzyme based on 
structural information of RsPIPS [36]. We have also measured the KM of MkPIPS for its substrates 
and compared these values to those previously measured for MtPIPS. There are still many 
outstanding questions surrounding this enzyme and many hypotheses generated from the 
enzyme that we would like to pursue, but are beyond the scope of the work presented here. Some 
of these experiments are already in progress and hope to be completed soon and some are set 
as more long term goals for the project that will be continued after I am no longer working on the 
project.  
   
4.2 Functional characterization of PIPS and testing of structure-based hypotheses 
 One of the most important ongoing pursuits is to functionally confirm some of the 
structure-based hypotheses generated by these three structures. This is essential to finish the 
work outlined in this dissertation. To begin, we would first like to repeat the KM measurements of 
MkPIPS for its substrates on the same construct tested as well as using other active mutants. 




the result of mutations that were introduced during crystal engineering. This is an essential first 
step for our functional characterization.  
 We would also like to test several mutants to confirm the role of different structural 
elements. I would like to test the relative activity of MkPIPS C-terminus truncation mutants. These 
will hopefully give use some insight into any functional role, if any, the C-terminus may be playing. 
I would also like to test activity of several mutants of MkPIPS and RsPIPS to confirm the role of 
the key methionine residue in CDP-DAG binding (M69 in MkPIPS and I67 in RsPIPS). I have 
already designed and cloned MkPIPS mutants to recapitulate the MtPIPS results, which showed 
increased activity when with mutation to alanine (M69A) and decreased activity when mutated to 
tryptophan (M69W). I have also designed and cloned a MkPIPS mutant of this residue to 
isoleucine (M69I). If this mutant loses function, we will gain insight as to whether this is a 
contributing factor in the low activity of RsPIPS. Conversely, I have also designed and cloned 
RsPIPS point mutants of the homologous residue (I67) to see if mutating it will allow gain of 
function in this barely functional enzyme (I67M, I67A). I have also designed chimeric RsPIPS and 
MkPIPS mutants with the entire TM2 of the other species. If RsPIPS with TM from MkPIPS has a 
functional gain even if the point mutants do not, this will help us understand the determinants of 
enzyme activity. This may also point to the general geometry of the active site being a more 
important determining factor than any single residue. We will also confirm the role of residues 
R94, Y133, and R137 in inositol-phosphate binding. I have already designed and cloned mutants 
of the residues (R94A, R94Q, Y133F, Y133A, R137A, R137Q) to test for enzyme activity and 
inositol-phosphate binding using established assays.  
 To further characterize substrate binding, we will determine the Kon and Koff 
measurements, compared to other PIPS enzymes. With or previously established enzyme 




for CDP-DAG. We would like to work with our Portuguese collaborators to develop a method to 
be able to measure this for the lipidic substrate as well.   
 Most of these experiments are already in progress and we hope they are completed 
in the next month by our wonderful collaborators Prof. Helena Santos and Dr. Carla Jorge at ITQB 
in Portugal. 
 
4.3 Further structural characterization 
 I am satisfied with the progress we have made on the structural characterization of a 
PIPS enzyme more closely related to PIPS from Mycobacterium tuberculosis. MkPIPS shares 
86% identity with MtPIPS and is a much better model for use in structure-based drug design and 
in silico inhibitor screening, especially now that we know IP binding details. However, as far as 
understanding the catalysis of the enzyme, I believe there is still more to learn. None of the 
structures we were able to solve showed very much movement or difference in structural state. 
Also, in the structure of MkPIPS bound to both IP and CDP (Chapter 5, section 5.4) the geometry 
between the catalytic base and the substrates seems a bit far, requiring some other intermediate 
state to achieve catalysis. This has been difficult to achieve by crystallography, but we would like 
to attempt to resolve intermediate states by single-particle cryogenic electron microscopy (cryo-
EM). Recent advances in cryo-EM technology has made the resolution of smaller membrane 
proteins possible [92]. As a dimer, the MkPIPS fusion is around 80 KDa, which is still around the 
current limit for structure determination by cryo-EM, but may still be worth pursuing, as it is a well-
expressed, detergent-stable protein. Using cryo-EM, we could potentially inspect MkPIPS 
incorporated into a near-native lipid environment such as a lipid nanodisc in the presence of 
substrates, to determine intermediate structural states during catalysis. One concern is the 
flexibility between the MkPIPS enzyme and the AfCTD. Further optimization to stabilize the 




pursuit is beyond the scope of this current project, but I think could add to our knowledge of this 
enzyme and its catalysis.  
 
4.4 Structure-based in silico inhibitor screening toward drug development 
 The long-term goal of this work would be in the application of in silico PIPS inhibitor 
prediction toward the aim of anti-tuberculosis drug development. In close collaboration with 
Jerémie Vendôme from Schrödinger, whose expertise lies in computational protein structure and 
binding partner prediction, in silico docking and inhibitor prediction experiments have previously 
been attempted using the MtPIPS homology model. A subset of 2 million small molecules was 
selected from an in-house virtual library based on chemical properties (size: < 350 Da, solubility: 
logP < 3.5, and commercial availability). In this preliminary screening with Glide [93, 94], 
molecules were run through several iterations of docking with increasing levels of scrutiny. 
Compounds were then filtered by docking score and clustered by chemical similarity. This yielded 
a set of over 300 compounds with docking score similar to that of docked IP in 21different 
chemical clusters. Of these, 76 compounds were purchased from commercial vendors and tested 
in a single point inhibition assay with MtPIPS in proteoliposomes by Dr. Carla Jorge at ITQB in 
Portugal. Fourteen of the tested compounds showed more than 25% inhibition of enzyme activity 
with 2mM potential inhibitor included in the reaction. The most promising potential inhibitors from 
this screening were further characterized, however this line experimentation did not yield potent 
competitive inhibitors.   
Considering the limitations of the MtPIPS homology model, as previously discussed, 
we would like to repeat these experiments using the newest MkPIPS models with a structure-
informed IP binding mode as a control. The use of a virtual screen is expected to substantially 
reduce the chemical space, thus providing a manageable list of compounds to screen with in vitro 




binding site of MkPIPS. Targeting the CDP-DAG binding site of PIPS may yield promising 
inhibitors, but have complications further down the drug-development pipeline, since it is a 
conserved substrate among all CDP-APs. Inhibitors selected computationally can then be 
screened in using established enzymatic assays.  
Further down the road, we can test the effectiveness of a given inhibitor on M. 
tuberculosis viability and growth, the inhibitor can be tested on M. tuberculosis in culture. In 
collaboration with Paul Elkington at the University of Southampton, who is an expert in M. 
tuberculosis infection, this can be attempted in a cell culture model of tuberculosis infection, 
including a growth assay of M. tuberculosis expressing a fluorescent reporter [95]. In this assay, 
growth of the mycobacteria with and without the inhibitor can be monitored with both fluorescence 
and optical density. Testing on M. tuberculosis alone will evaluate inhibitor viability separately 
from added complications of delivery into mammalian cells. To evaluate the effect of the drug on 
mycobacterium in a model of infection, cultured primary human bronchial epithelial cells (HBECs) 
encapsulated in a 3D hydrogel sphere [96] can be infected with M. tuberculosis and monitored 
with and without the inhibitor/drug for cell viability and M. tuberculosis growth.  
 
4.5 Conclusions 
In the next few months, we will work with our collaborators at ITQB in Portugal, Prof. 
Helena Santos and Dr. Carla Jorge, to complete experiments to further functionally characterize 
MkPIPS as well as test structure-based hypotheses about substrate binding and catalysis that 
have been generated with the structural results described in this dissertation. We would also like 
to pursue further structural characterization by cryo-EM to capture intermediate catalytic states of 
the structure to better understand the function of PIPS. Looking forward, we would like to use the 
structural information generated in this dissertation for in silico inhibitor prediction toward the aim 





RodA-PBP2: Background and Significance 
 
5.1 Antibiotic resistance is a rising problem 
 The development and implementation of antibiotics is often cited as one of the most 
important innovations of the modern era. Antibiotics have drastically improved human lifespan 
and quality of life. They have also paved the way for advancements in medicine, as essential 
support therapeutics for surgical procedures, organ transplantation and cancer chemotherapy 
[97]. Though their benefits are undeniable, we have witnessed a pharmaceutical arms race in 
which bacterial evolution has been matched against our ability to discover new antimicrobial 
compounds (Figure 5.1), a phenomenon which was anticipated but widely disregarded. When 
Alexander Fleming accepted his Nobel Prize in 1945 for the discovery of Penicillin [98], he warned 
“[T]here is the danger that the ignorant man may easily underdose himself and by exposing his 
microbes to non-lethal quantities of the drug make them resistant.” The wide use of antibiotics in 
medicine and agriculture, often irresponsibly, and the waning production of drug development 
pipelines have led to a mounting public health crisis. Currently, about 700,000 people per year 
die from drug resistant infections, a trend that only seems to be worsening [99].   
 Antibiotic resistance has also forced the use of drugs previously avoided due to more 
severe side effects. For example, Colistin is an antibiotic originally implemented to treat gram-
negative bacterial infections, but as other antibiotics were developed, waned in popularity 
because of a risk of kidney toxicity [100]. Recent emergence of resistant bacterial strains such as 
Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, paired with the 
steady rise of nosocomial or hospital-acquired infections have necessitated the use of Colistin as 
a last resort. To make matters worse, resistance to Colistin itself is being reported with more 





Figure 5.1 Timeline of antibiotic resistance emergence. This timeline shows when antibiotics were 





 therapies to treat these resistant infections, the problem of antibiotic resistance could become 
devastating. The Review on Antimicrobial Resistance [99] has projected that if current trends 
hold, deaths caused by antibiotic resistant disease will outpace deaths from cancer by 2050.  
 Antibiotic resistance is generally achieved through the mutation of genes coding for 
drug targets and other compensatory proteins, or by the introduction of new genes by horizontal 
gene transfer (HGT), a mechanism in which bacteria physically pass DNA plasmids. The most 
obvious mechanism is the mutation the drug target, preventing binding and inhibition. Genetic 
changes can also prevent influx or increase efflux of the drug, provide alternative pathways to 
compensate for inhibited target proteins, produce proteins that chemically alter and inactivate the 
antibiotic, or prevent bacterial proteins from processing an antibiotic from a pro-drug form [102].  
 Bacteria have many biological resources to fight antibiotics, so we must also approach 
the problem of antibiotic resistance at many levels. Recommendations to fight antibiotic resistance 
are many pronged. They including approaches to keep the drugs we have effective, such as 
programs to reduce misuse or overuse of antibiotics. They also include incentives for diagnostic 
innovation and drug discovery [99]. The success of the latter is dependent on a more thorough 
understanding of bacterial biology and essential processes that can be exploited and targeted by 
antimicrobial drugs. Resistance against ß-lactam antibiotics are a microcosm of this phenomenon 
and help introduce the rationale for our interest in structural and functional investigation of the 
RodA-PBP2 complex.  
 
5.2 ß-lactam antibiotics and resistance 
 ß-lactam antibiotics make up a class of bactericidal drugs, which include, for example, 
penicillins, carabapenems, monobactams and cephalosporins. ß-lactams are used against a 
broad spectrum of bacterial infections and are among the most commonly prescribed antibiotics. 




chemical structures (Figure 5.2). ß-lactam antibiotics bind to the transpeptidase domain of 
penicillin binding proteins (PBPs) and act to disrupt cell wall biosynthesis, particularly the 
biosynthesis, maintenance and remodeling of peptidoglycan. This disruption acts to destabilize 
the cell wall and kill the bacterium [103]. Peptidoglycan is a common structural element among 
most bacteria, so advancements in understanding the biology of PBPs will have applications to 
infections involving most bacteria.  
 To survive the effects of a ß-lactam drug, bacteria can become resistant by expressing 
ß-lactamases, which degrade the antibiotic, reducing its ability to bind to its target protein. In turn, 
chemists synthesized compounds, which were resistant to ß-lactamase, such as methicillin, or 
use a combination therapy with ß-lactamase inhibitors, which tend to be from the same antibiotic 
family. However, bacteria have found a way around this using HGT to acquire alternate penicillin 
binding proteins, which mitigate the effects of ß-lactam antibiotics or by upregulating the 
expression of PBPs to compensate for any inhibited enzymes. This has been observed in many 
cases, but one of particular interest is that of methicillin-resistant Staphylococcus aureus (MRSA), 
which has traditionally plagued hospitals but is now becoming more common in the broader 
community [104]. To better understand this phenomenon, we must better understand the drug 





Figure 5.2 ß-lactam antibiotics. Examples of ß-lactam antibiotics with the common ß-lactam ring 
highlighted in blue. This is compared to the endogenous substrate of PBPs in the biosynthesis of 
peptidoglycan, the peptide terminus D-Ala-D-Ala with the similar chemical structure highlighted in purple.  
 
5.3 Role of PBP proteins in peptidoglycan synthesis 
 All bacteria have a cell wall, which serves as an external barrier or envelope. This is 
an incredibly important component of the bacterium, first, because it acts as the primary protective 
barrier and second, because it is responsible for detection and communication with host proteins, 
immune system and therapeutics. The cell wall varies between types of bacteria giving them 
unique structural characteristics and pathogen-host interaction profiles [105].  
 Peptidoglycan is a key component of the cell wall in almost all gram-negative and 
gram-positive bacteria [106], with the exception of some atypical bacteria such as members of 
Mycoplasmataceae [107, 108]. Peptidoglycan is made up of strands of repeating sugar units, N-
acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc). The sugar strands are 
covalently conjugated to peptides, which form linkages between sugar strands, forming a mesh-




cell and is essential for growth and viability. In gram-positive bacteria, it forms a thick coat over 
the single lipid bilayer, and in gram-negative bacteria, it forms a thinner coat between the inner 
and outer lipid bilayers in what is called the periplasm or periplasmic space (Figure 5.3). Any 
disruption of peptidoglycan biosynthesis, whether by genetic mutation, inhibition with antibiotics 
or degradation by lysozyme, results in bacterial cell lysis. Therefore, enzymes contributing to the 
peptidoglycan biosynthetic pathway can be exploited as antibiotic targets [106, 109].  
 
 
Figure 5.3 Structure of peptidoglycan. Comparison of peptidoglycan in the cell walls of gram-positive 
bacteria (A), gram-negative bacteria (B). (C) Shows a detailed structure of the peptide linkage catalyzed 
by transpeptidase penicillin-binding proteins (PBP). Panel (C) adapted from [110].  
  
 During peptidoglycan synthesis, first a hydrophilic peptidoglycan precursor (UDP-




undecaprenyl phosphate (UndP). The lipid-linked precursor (undecaprenyl-pyrophosphoryl-
MurNAc-pentapeptide or Lipid I) is modified further to undecaprenyl-pyrophosphoryl-MurNAc-
(pentapeptide)-GlcNAc (Lipid II) by addition of a GlcNAc moiety. Lipid II is then flipped across the 
membrane to the periplasm where enzymes with a transglycosylase (TG) activity polymerize the 
sugar chains and enzymes with a transpeptidase (TP) activity form linkages between peptides on 
different sugar strands, creating the characteristic mesh structure [109].  
 Penicillin binding proteins (PBPs) have long been implicated in the synthesis of 
peptidoglycan. There are many different genes encoding for membrane-bound PBPs in bacteria. 
They vary by species, but they are mainly categorized into low molecular mass (LMM) PBPs and 
high molecular mass (HMM) PBPs. LMM-PBPs are less defined in their biological roles, but have 
been implicated in peptidoglycan remodeling during cell division as some members of the sub-
type have been identified as having carboxypeptidation and peptide bond hydrolysis activities 
[111]. HMM-PBPs are known to be essential and have enzymatic functions related to the 
transpeptidation and transglycosylation of peptidoglycan. HMM-PBPs can be further categorized 
into class A and class B. Class A HMM-PBPs have been characterized as dual function enzymes, 
with both glycosyltransferase and transpeptidase activity. Class B PBPs have been shown to 
have only transpeptidase activity [112]. Class B PBPs are essential components of larger protein 
complexes responsible for either cell shape, growth and elongation (elongasome) and cell division 
(divisome) [113-115]. Beyond its contribution to bacterial biology generally, understanding the 
protein-protein interactions involving penicillin-binding proteins may be of broader application, 
since the disruption of protein-protein interfaces may be a promising strategy for future antibiotic 
development [116]. Some components of these larger complexes are described in the next 





Figure 5.4 Steps of peptidoglycan biosynthesis. After Lipid II is flipped across the membrane, it 
undergoes transglycosylation and transpeptidation, forming cross-links between peptide strands. Figure 
adapted from [117].  
 
5.4 PBPs are functional partners of SEDS proteins 
 Transmembrane enzymes referred to as SEDS proteins are characterized by and 
named for their roles in cellular processes such as shape, elongation, cell division and sporulation. 
Bacterial proteins FtsW, RodA and SpoVE are SEDS proteins that share sequence homology and 
participate in peptidoglycan synthesis during different growth and maturation processes. RodA 
participates in elongation before cell division, SpoVE participates in sporulation and FtsW 
participates in cell division [118].  
 Since the proteins involved in sporulation are not essential and are more easily 
genetically manipulated, they have been key characterizing the role of these and homologous 
proteins in cell processes [119]. SpoVE, a sporulation SEDS protein in Bacilis subtilis, has been 
shown to form a direct functional complex with a HMM type B PBP protein, SpoVD. A recombinant 
fusion of these two proteins was also functional in vivo and could complement a sporulation defect 
of a double knockout strain (∆spoVE/∆spoVD) [119]. It was also shown that the introduction of a 
loss-of-function point mutation into either individual protein, ablated function of the complex, 
suggesting cooperative function. This complementation experiment was recapitulated with a 




class B PBP is conserved and widely applicable [119]. Since the characterization of the 
SpoVE/SpoVD protein-protein functional interaction, other SEDS proteins, FtsW and RodA, have 
been shown to interact directly with class B PBPs in the divisome and elongasome respectively 
[119-121]. 
 Though SEDS proteins are understood to be important for peptidoglycan synthesis, 
having a role in key bacterial processes, and interact with class B PBPs, their precise functional 
characterization has been a bit of a debate. FtsW, for example, has been implicated as the Lipid 
II flippase, and has been demonstrated in vitro to promote the movement of Lipid II across a 
bilayer [122], [123]. However, a homologous protein RodA, has been recently characterized as a 
glycosyltransferase, functioning in complex with a class B PBP (PBP2) to complete the first step 
of peptidoglycan synthesis [124]. Additionally, a preprint of an article now available gives evidence 
that FtsW also functions as a glycosyltransferase [125]. There are two hypothesized models in 
the field (demonstrated in Figure 5.5 using RodA as an example), one in which SEDS proteins 
function as dual purpose enzymes in complex with class B PBPs to flip lipid II across the 
membrane and then polymerize peptidoglycan and another in which MurJ acts as the lipid II 





Figure 5.5 Two models of SEDS-PBP function. A) Model of RodA as having a sole glycosyltransferase 
function with MurJ acting as the Lipid II flippase. B) A model of RodA as having a dual function, acting to 
flip Lipid II across the membrane before accomplishing its glycosyltransferase reaction. These models 






5.5 Crystal structure of RodA 
 A crystal structure of Thermus thermophilus RodA to 2.9 Å resolution was recently 
published [126] using evolutionary coupling-enabled molecular replacement (EC-MR) to build an 
ab initio model used to solve the phases. Protein residues that interact structurally tend to co-
evolve to maintain structural and functional integrity. In this method, a 3D model is constructed 
computationally informed by the analysis of sequence co-variation across orthologs. By looking 
at residue pairs or clusters that appear to co-vary, you can infer what residues are spatially related 
[127, 128]. The computed model can then be used as a search model for molecular replacement 
to solve the phases of the crystallographic data. 
  This structure reveals a ten transmembrane (TM) topology, with a putative lipid 
substrate-binding site between TM2 and TM3 and a central hydrophilic cavity open to the 
periplasmic side of the membrane. Within the central cavity, an absolutely conserved salt bridge 
was identified (E108/K111). If either of the corresponding residues were mutated to alanine in E. 
coli or B. subtilis, the cells lost their elongated shape, suggesting complete malfunction of the 
RodA enzyme. A mutant that swapped the salt bridge residues (E114K/K117E in E. coli; 
E117K/K120E in B. subtilis) also showed an altered morphological phenotype and a loss of 
peptidoglycan synthesis activity, suggesting that the maintenance of the salt bridge alone is not 
important, but that the glutamate residue is essential for catalytic activity.  
 The paper also proposes a PBP2 interacting domain located between TM8 and TM9 
also based on evolutionary co-variance between RodA and PBP2. Residues hypothesized to 
interact with PBP2, were mutated in E. coli and B. subtilis RodA. These mutants exhibited 
morphological changes compared to wild type in E. coli but not B. subtilis and these mutations do 
not seem to affect peptidoglycan synthesis in vivo. This is a significant step	 toward the 
characterization of this protein-protein interface, which however remains far from being 




the flipping of Lipid II. Other reports have suggested that FtsW, a RodA homolog, is a Lipid II 
flippase [122], however the mechanism is not clarified by this structure. The authors of this paper 
seem to reject the hypothesis of RodA as a flippase [126], however this has yet to be 
experimentally demonstrated. The structure also did not fully resolve an important extracellular 
loop (ECL4) containing the putative catalytic residues for the glycosyltranferase activity.  
 This structural information is a great step forward, but we are interested in better 
characterizing the RodA-PBP2 interface and further characterizing how this enzyme complex 
functions in the context of peptidoglycan biosynthesis. Understanding this interface might also 




Figure 5.6 Structure of RodA from Thermus thermophilus. Architecture of RodA reveals ten 
transmembrane helices (TM1-10) and 5 extracellular loops (ECL1-5) with a cone shaped central cavity. 







5.6 Crystal structure of PBP2 from Helicobacter pylori  
 The structure of PBP2 (class B) from H. pylori (HpPBP2; PDB 5LP4) illustrates the 
characteristic fold of class B PBPs containing a nonpenicillin-binding domain and a transpeptidase 
domain [129]. HpPBP2 is made up of a three-part N-terminal domain (the nonpenicillin-binding 
domain) containing a helical “head,” a three beta-strand “anchor”, and a mostly helical “linker” 
region. Following the N-terminal domain is the transpeptidase domain, containing a catalytic site 
with three conserved sequence motifs: 1) S-x-x-K, 2) S-x-N/D, and 3) K-T/S-G. There is also a 
disulfide bond of note near the active site of HpPBP2, which is of interest since there is evidence 
that class B PBP SpoVD may be regulated by disruption of the disulfide bond by disulfide 
reductase StoA in B. subtilis [130].  
 The structure of the soluble domain of HpPBP2 in complex with the soluble domain of 
the elongasome scaffolding protein MreC was also solved (PDB 5LP5), indicating that MreC binds 
PBP2 at N-terminal domain, causing a rearrangement of the N-terminal domain in which the 
anchor domain swings away from the head domain to accommodate MreC binding [129]. Key 
hydrophobic interactions mediate PBP2-MreC binding. Both forms of crystallized PBP2 and MreC 
exclude the single pass TM helix at the N-terminus of the protein, making them easier to 
crystallize, but leaving off perhaps an important part of the story, especially when looking at 
protein-protein interactions with other membrane-embedded enzymes. The position of MreC 
binding would potentially be close to where the N-terminal TM helix would be reaching into the 
membrane for both enzymes and also where the RodA protein is hypothesized to interact with 
the PBP2. The HpPBP2 paper emphasizes that the interactions between elongasome proteins 
have a transient nature, so it can be noted that these different interactions with PBP2 are not 
necessarily mutually exclusive.  However, the membrane undoubtedly plays a major part in this 
story, adding more restrictions on protein-protein interactions, which are missing in this recent 




  In Chapters 6 and 7, I present preliminary structural and functional data of a RodA-
PBP2 fusion protein, in a lipid nanodisc environment, using single particle cryo-electron 
microscopy (cryo-EM). We hope to contribute to the understanding of protein-protein interactions 
in the elongasome toward the development of novel drug intervention strategies. 
 
Figure 5.7 Structure of PBP2 from Heliobacter pylori. A) The structure of PBP2 from H. pylori in its 
apo state. The transpeptidase domain in green, the linker domain in yellow, the head domain in blue and 
the anchor domain in red. B) The structure of H. pylori PBP2 bound to two MreC molecules, showing a 





5.7 RodA-PBP2: Significant work presented in this thesis 
 In Chapters 6 and 7 of this dissertation, I will present the approach, results and 
interpretation of our structural and functional studies of the RodA-PBP2 fusion enzyme. I have 
used structural genomic approaches and protein engineering to generate promising preliminary 
data toward structure determination of a RodA-PBP2 protein fusion in a lipid nanodisc by cryo-
EM. I will also discuss our strategy moving forward to better resolve the structure of this protein 






Structural characterization of RodA-PBP2 by cryo-EM 
 
6.1 Introduction 
 As described in Chapter 7, SEDS proteins function in complex with type B penicillin 
binding proteins (bPBPs) to synthesize the peptidoglycan mesh that forms a crucial component 
of the bacterial cell wall [119, 120]. The role of SEDS proteins is not entirely understood. It is 
thought that SEDS proteins function either solely as a glycosyltransferase, catalyzing the transfer 
of sugar-peptide groups from one Lipid II peptidoglycan precursor molecule to another [124-126], 
or that it functions as both a Lipid II flippase, moving Lipid II from the inner to the outer leaflet of 
the bacterial membrane, and a glycosyltransferase [122, 123]. A crystal structure of RodA (Figure 
5.6), a SEDS protein involved in bacterial cell growth and elongation, has recently become 
available [126] and structures of type b PBPs are also available (Figure 5.7) [129, 131, 132]. 
These structures alone do not definitively resolve the understanding of the function of the SEDS-
PBP protein complex.  
 Before the RodA structure became available, we were working to solve the structure 
of a SEDS protein by crystallography, using a structural genomics approach. The success of this 
approach was limited, so we pursued structural investigation of SEDS proteins in complex with 
PBPs by designing fusion proteins to be studied by cryo-EM. In this Chapter, I will describe the 
approach we have taken in our preliminary studies of a RodA-PBP2 fusion protein by cryo-EM.   
 
6.2 Structural genomics: SEDS proteins 
 Initially, we were interested in structurally characterizing a SEDS protein alone using 
crystallography as the main structural method. We initiated the project using the NYCOMPS 




begin, 189 SEDS targets were identified using the E. coli gene coding for FtsW as a seed and 
were then cloned into NYCOMPS expression vectors containing decahistidine tags at either the 
N or C terminus, separated from the target gene by a TEV cleavage site. These targets were 
tested for expression in small scale by Brian Kloss and Michael Loukeris at the NYSBC facility. 
The results from these initial small scale expression experiments can be found in Table 6.1. 
 
Table 6.1 List of SEDS genes cloned and tested for expression by NYCOMPS 
# Bacterial Species GenInfo identifier MW (Da) expression  
1 Pseudomonas aeruginosa PAO1 15599609 45283 - 
2 Vibrio cholerae O1 biovar El Tor str. N16961 15640965 42423 - 
3 Vibrio cholerae O1 biovar El Tor str. N16961 15642399 45173 - 
4 Lactococcus lactis subsp. lactis Il1403 15672650 47593 - 
5 Lactococcus lactis subsp. lactis Il1403 15672866 45283 - 
6 Streptococcus pyogenes M1 GAS 15674690 49133 - 
7 Neisseria meningitidis MC58 15676333 47923 - 
8 Bacillus subtilis subsp. subtilis str. 168 16078549 45723 - 
9 Bacillus subtilis subsp. subtilis str. 168 16078585 41653 - 
10 Escherichia coli str. K-12 substr. MG1655 16128082 46933 - 
11 Haemophilus influenzae Rd KW20 16272006 42203 - 
12 Haemophilus influenzae Rd KW20 16273063 44733 - 
13 Salmonella enterica subsp. enterica serovar 
Typhimurium str. LT2 
16763517 46933 - 
14 Listeria monocytogenes EGD-e 16803111 45393 + 
15 Listeria monocytogenes EGD-e 16804725 42753 - 
16 Streptococcus agalactiae 2603V/R 22536925 47813 - 
17 Shewanella oneidensis MR-1 24375705 45723 - 
18 Streptococcus mutans UA159 24379181 48143 - 
19 Staphylococcus epidermidis ATCC 12228 27467730 42313 - 
20 [Pseudomonas syringae] pv. tomato str. DC3000 28871544 45833 - 
21 Vibrio parahaemolyticus RIMD 2210633 28897233 45173 - 
22 Enterococcus faecalis V583 29376951 45613 + 
23 Bacillus cereus ATCC 14579 30022000 41653 - 
24 Bacillus cereus ATCC 14579 30022036 44513 - 
25 Bordetella pertussis Tohama I 33593955 45063 - 
26 Geobacter sulfurreducens PCA 39997176 41653 - 
27 Desulfovibrio vulgaris str. Hildenborough 46580909 42863 - 
28 [Bacillus thuringiensis] serovar konkukian str. 97-27 49478445 41323 - 
29 [Bacillus thuringiensis] serovar konkukian str. 97-27 49479964 44623 - 
30 Legionella pneumophila subsp. pneumophila str. 
Philadelphia 1 
52842821 44733 - 
31 Lactobacillus acidophilus NCFM 58337140 44733 - 
32 Vibrio fischeri ES114 59712809 42753 - 
33 Neisseria gonorrhoeae FA 1090 59801870 48913 + 
34 Aeromonas hydrophila subsp. hydrophila ATCC 7966 117617598 42973 - 
35 Chloroflexus aurantiacus J-10-fl 163846283 42533 - 
36 Chloroflexus aurantiacus J-10-fl 163846339 48033 - 
37 Enterobacter cloacae subsp. cloacae ATCC 13047 296101252 46933 - 




39 Lactobacillus plantarum WCFS1 380032893 44073 - 
40 Bacillus cereus ATCC 10987 gi|42779081:3707436-3708527 41323 - 
41  Bacillus cereus ATCC 10987 gi|42779081:3745139-3746317 44513 - 
42  Bacillus cereus E33L gi|52140164:3848917-3850098 44623 - 
43  Oenococcus oeni PSU-1 gi|116490126:1177396-1178571 44403 - 
44  Streptococcus pneumoniae TIGR4 gi|194172857:1001278-1002507 46383 + 
45  Salmonella enterica subsp. enterica serovar 
Paratyphi A str. ATCC 9150 
gi|56412276:150220-151464 46933 - 
46  Escherichia coli str. K-12 substr. MG1655 gi|556503834:98403-99647 46933 - 
47  Klebsiella pneumoniae subsp. pneumoniae MGH 
78578 
gi|152968582:110142-111416 48033 - 
48  Bacillus cereus ATCC 10987 gi|42779081:3745139-3746317 44513 - 
49  Bacillus cereus E33L gi|52140164:3848917-3850098 44623 - 
50  Oenococcus oeni PSU-1 gi|116490126:1177396-1178571 44403 - 
51  Francisella tularensis subsp. holarctica LVS complete 
genome 
gi|89255449:1541019-1542224 45503 - 
52  Clostridium perfringens str. 13 DNA gi|18308982:2127383-2128507 42533 + 
53  Burkholderia mallei ATCC 23344 chromosome 1 gi|53723370:2656512-2657804 48693 - 
54  Francisella philomiragia subsp. philomiragia ATCC 
25017 
gi|167626225:310865-312073 45613 - 
55  Burkholderia multivorans ATCC 17616 chromosome 
1 
gi|161523180:3090798-3092081 48363 - 
56  Ralstonia eutropha H16 chromosome 1 gi|113866031:3539445-3540686 46823 - 
57  Bacillus halodurans C-125 DNA gi|57596592:2688845-2689945 41653 - 
58  Bacillus halodurans C-125 DNA gi|57596592:3396381-3397577 45173 - 
59  Bacillus halodurans C-125 DNA gi|57596592:3397902-3399047 43303 - 
60  Bordetella parapertussis strain 12822 gi|33594723:4057347-4058540 45063 - 
61  Mycobacterium avium subsp. paratuberculosis str. 
k10 
gi|41406098:21303-22712 52983 + 
62  Listeria innocua Clip11262 complete genome gi|16799079:2851181-2852311 42753 - 
63  Colwellia psychrerythraea 34H gi|71277742:1761680-1762795 42203 + 
64  Xylella fastidiosa Temecula1 gi|28197945:2194251-2195522 47923 - 
65  Staphylococcus saprophyticus subsp. saprophyticus 
ATCC 15305 DNA 
gi|73661309:824266-825471 45503 - 
66  Staphylococcus saprophyticus subsp. saprophyticus 
ATCC 15305 DNA 
gi|73661309:1744571-1745806 46603 + 
67  Shewanella frigidimarina NCIMB 400 gi|114561188:4537404-4538618 45833 - 
68  Pediococcus pentosaceus ATCC 25745 gi|116491818:1153312-1154520 45613 - 
69  Pelobacter propionicus DSM 2379 gi|118578449:2757286-2758386 41653 - 
70  Pelobacter propionicus DSM 2379 gi|118578449:3625852-3626976 42533 - 
71  Mycobacterium vanbaalenii PYR-1 gi|120401028:3747365-3748870 56503 - 
72  Shewanella woodyi ATCC 51908 gi|170724370:5497839-5499053 45833 - 
73  Xanthomonas citri subsp. citri Aw12879 gi|471265562:4246768-4248144 51773 - 
74  Citrobacter koseri ATCC BAA-895 gi|157144296:3054755-3055999 46933 - 
75  Streptococcus pneumoniae TIGR4 gi|194172857:1001278-1002507 46383 + 
76  Shigella flexneri 2a str. 301 chromosome gi|344915202:97021-98265 46933 - 
77  Salmonella enterica subsp. enterica serovar 
Paratyphi A str. ATCC 9150 
gi|56412276:150220-151464 46933 - 
78 Escherichia coli str. K-12 substr. MG1655 gi|556503834:98403-99647 46933 - 
79  Escherichia fergusonii ATCC 35469 chromosome gi|218547440:120372-121616 46933 - 
80  Bacillus licheniformis ATCC 14580 gi|163119169:651745-652893 43413 - 
81  Bacillus licheniformis ATCC 14580 gi|163119169:1657454-1658665 45723 - 
82  Bacillus licheniformis ATCC 14580 gi|163119169:1694224-1695324 41653 - 
83  Listeria innocua Clip11262 complete genome gi|16799079:1075784-1076992 45613 - 
84  Delta proteobacterium NaphS2 ctg_1101087565921 gi|301063213:31728-32837 41983 - 
85  Delta proteobacterium NaphS2 ctg_1101087568010 gi|301064529:66080-67183 41763 - 
86  Burkholderia cenocepacia MC0-3 chromosome 1 gi|170731356:583204-584487 48363 - 
87  Burkholderia thailandensis E264 chromosome I gi|83718394:1261591-1262883 48693 - 




89  Idiomarina loihiensis L2TR gi|56459112:450156-451385 46383 - 
90  Arthrobacter aurescens TC1 gi|119960487:1869535-1870836 49023 - 
91  Mycobacterium gilvum PYR-GCK gi|145220606:3159397-3160917 57053 - 
92  Streptosporangium roseum DSM 43021 gi|271961609:3119932-3121257 49903 - 
93  Nitrosomonas europaea ATCC 19718 gi|30248031:1076630-1077793 43963 + 
94  Haemophilus ducreyi strain 35000HP complete 
genome 
gi|33151282:187253-188431 44513 - 
94 Pseudomonas aeruginosa PAO1 gi|110645304:c4483364-4482261 41910 - 
96 Thermotoga maritima MSB8 gi|15642775:865408-866430  38940 - 
97 Helicobacter pylori 26695 gi|15644634:c798936-797791  43450 - 
98 Lactococcus lactis subsp. lactis Il1403 gi|15671982:915962-917206  47080 - 
99 Clostridium acetobutylicum ATCC 824 gi|15893298:1395591-1396712  42570 + 
100 Clostridium acetobutylicum ATCC 824 gi|15893298:c2216615-2215500 42350 - 
101 Caulobacter crescentus CB15 gi|16124256:1712006-1713163  43890 - 
102 Escherichia coli str. K-12 substr. MG1655 gi|556503834:c666313-665201  42240 + 
103 Listeria monocytogenes EGD-e gi|16802048:c442872-441622 47300 - 
104 Listeria monocytogenes EGD-e gi|16802048:c2498238-2497069  44330 - 
105 Corynebacterium glutamicum ATCC 13032 gi|58036263:c46669-45344  50050 + 
106 Corynebacterium glutamicum ATCC 13032 gi|58036263:c2285432-2283780  62040 - 
107 Streptococcus agalactiae 2603V/R gi|22536185:609766-610971  45650 - 
108 Pseudomonas putida KT2440 gi|1002825811:c5469997-5468873  42680 + 
109 Bacteroides thetaiotaomicron VPI-5482 gi|29345410:c4444260-4442944  49720 + 
110 Enterococcus faecalis V583 gi|29374661:c2425951-2424764  44990 - 
111 Bacillus cereus ATCC 14579 gi|30018278:c1184689-1183529  44000 - 
112 Bacillus cereus ATCC 14579 gi|30018278:c4119449-4118271 44660 - 
113 Mycobacterium bovis AF2122/97 gi|31791177:c2395436-2393862  59180 - 
114 Bordetella pertussis Tohama I gi|33591275:379684-380820  43120 - 
115 [Bacillus thuringiensis] serovar konkukian str. 97-27 gi|49476684:1050478-1051743  47850 - 
116 [Bacillus thuringiensis] serovar konkukian str. 97-27 gi|49476684:c1203016-1201856 44000 - 
117 Vibrio fischeri ES114 gi|172087630:c815431-814310 42570 - 
118 Salinibacter ruber DSM 13855 gi|83814055:736130-737269 43230 - 
119 Salinibacter ruber DSM 13855 gi|83814055:2968103-2969365  47740 - 
120 Enterobacter cloacae subsp. cloacae ATCC 13047 gi|296100371:3119688-3120800  42240 + 
121 Borrelia burgdorferi B31 gi|15594346:756354-757670  49720 - 
122 Shewanella oneidensis MR-1 gi|414561716:c1210706-1209603  41910 + 
123 Salmonella enterica subsp. enterica serovar 
Typhimurium str. LT2 
gi|16763390:700908-702020  42240 + 
124 Escherichia coli str. K-12 substr. MG1655 gi|556503834:665201-666313  42240 - 
125 Bacillus cereus E33L gi|52140164:1209883-1211043  44000 - 
126 Bacillus cereus ATCC 10987 gi|42779081:1335625-1336785  44000 - 
127 Bacillus cereus ATCC 10987 gi|42779081:3942627-3943805 44660 - 
128 Klebsiella pneumoniae subsp. pneumoniae MGH 
78578 
gi|152968582:753548-754660  42240 + 
129 Bacillus licheniformis ATCC 14580 gi|163119169:3849343-3850512  44330 + 
130 Pseudomonas putida F1 gi|148545259:4908630-4909844  45980 - 
131 Listeria innocua Clip11262 gi|16799079:2542895-2544070 44550 - 
132 Mycobacterium avium subsp. paratuberculosis str. 
k10 
gi|41406098:2095083-2096903  68200 - 
133 Burkholderia mallei ATCC 23344 gi|53723370:166630-167778 43560 - 
134 Porphyromonas gingivalis W83 gi|34539880:1473049-1474506  54890 - 
135 Burkholderia cenocepacia J2315 gi|206558403:527424-528572 43560 - 
136 Novosphingobium pentaromativorans US6-1 gi|359398414:33387-34583 45320 + 
137 Agrobacterium radiobacter K84  gi|222084201:2379212-2380366 43780 - 
138 Haemophilus ducreyi strain 35000HP gi|33151282:1679925-1681049  42680 - 




140 Listeria innocua Clip11262 gi|16799079:2850081-2851184 41910 + 
141 Erwinia carotovora subsp. atroseptica SCRI1043 gi|50118965:1474394-1475506  42240 + 
142 Synechococcus elongatus PCC 7942 gi|81298811:1121152-1122417  47850 - 
143 Rhizobium etli CFN 42 gi|86355669:2973760-2974914  43780 - 
144 Mycobacterium vanbaalenii PYR-1 gi|120401028:31347-32759  53240 - 
145 Marinobacter aquaeolei VT8 gi|120552944:2696338-2697480  43340 - 
146 Marinobacter aquaeolei VT8 gi|120552944:2738945-2740144 45430 + 
147 Acidovorax sp. JS42 gi|121592436:3854870-3856042  44440 - 
148 Flavobacterium johnsoniae UW101 gi|146297766:1666170-1667405  46750 + 
149 Sphingomonas wittichii RW1 gi|148552929:4334004-4335221  46090 + 
150 Gluconacetobacter diazotrophicus PAl 5 gi|162145846:2400286-2401440  43780 + 
151 Methylobacterium radiotolerans JCM 2831 gi|170746450:2493848-2495014  44220 + 
152 Mycobacterium marinum M gi|183980035:21391-22800  53130 - 
153 Mycobacterium marinum M gi|183980035:3893457-3895088  61270 - 
154 Nostoc punctiforme PCC 73102 gi|186680550:5988085-5989287 45540 - 
155 Nostoc punctiforme PCC 73102 gi|186680550:6396338-6397651  49610 - 
156 Phenylobacterium zucineum HLK1 gi|197103466:2583493-2584644  43670 - 
157 Pedobacter heparinus DSM 2366 gi|255529916:951603-952868  47850 - 
158 Sphingobium chlorophenolicum L-1 gi|334343657:1543525-1544727 45540 - 
159 Pseudomonas protegens Pf-5 gi|70728250:6221477-6222580  41910 + 
160 Dyadobacter fermentans DSM 18053 gi|255033817:2454596-2455879 48510 - 
161 Dyadobacter fermentans DSM 18053 gi|255033817:4269345-4270499  43780 - 
162 Desulfovibrio salexigens DSM 2638 gi|242277482:3866146-3867261  42350 - 
163 Mycobacterium neoaurum ATCC 25795 contig_2 gi|662767947:157055-158470  53350 - 
164 Hydrocarboniphaga effusa AP103 245_2 gi|392952762:492834-493919  41250 - 
165 Phenylobacterium zucineum HLK1 gi|197103466:2635963-2637147  44880 - 
166 Shewanella frigidimarina NCIMB 400 gi|114561188:823006-824112  42020 - 
167 Streptococcus pneumoniae TIGR4 gi|194172857:758037-759260  46310 + 
168 Bacillus cereus ATCC 10987 gi|42779081:1137545-1138801  47520 + 
169 Escherichia fergusonii ATCC 35469 gi|218547440:2535245-2536357  42240 + 
170 Campylobacter jejuni RM1221 gi|57236892:1100159-1101322 44110 - 
171 Campylobacter jejuni RM1221 gi|57236892:1334487-1335587  41800 - 
172 Porphyromonas gingivalis W83 gi|34539880:635984-637240  47520 - 
173 Burkholderia multivorans ATCC 17616 gi|161523180:3398263-3399411 43560 - 
174 Novosphingobium pentaromativorans US6-1 gi|359401704:50355-51467 42240 - 
175 Cronobacter sakazakii ATCC BAA-894 gi|156932229:2642248-2643360  42240 + 
176 Ralstonia eutropha H16 gi|113866031:131861-133003  1 43340 - 
177 Streptomyces avermitilis MA-4680 gi|1012131129:3699662-3701029  51590 - 
178 Xanthomonas axonopodis pv. citri str. 306 gi|21240774:781974-783092  42460 - 
179 Thermus thermophilus HB27 gi|46198308:703026-704087  40370 + 
180 Synechococcus elongatus PCC 6301 DNA gi|56750010:1298874-1300058  44880 - 
181 Cupriavidus metallidurans CH34 gi|94308945:63631-64773  43340 - 
182 Arthrobacter aurescens TC1 gi|119960487:3491614-3494277  99110 + 
183 Mycobacterium gilvum PYR-GCK gi|145220606:835362-836774  53240 - 
184 Shewanella woodyi ATCC 51908 gi|170724370:4515416-4516522  42020 + 
185 Caulobacter segnis ATCC 21756 gi|295687459:1577472-1578629  43890 - 
186 Mycobacterium intracellulare ATCC 13950 gi|379744720:2397503-2399200  63690 - 
187 Sphingopyxis alaskensis RB2256 gi|103485498:1711804-1712910  42020 - 
188 Ruegeria pomeroyi DSS-3 gi|564825954:1246216-1247379  44110 - 
189 Mycobacterium chubuense strain DSM 44219 gi|860424691:12631-14043 53240 - 
(+) indicates positive expression in at least one expression vector. 




 The targets that expressed positively for the NYSBC scientists were re-tested for 
expression by me at Columbia University. The best performing targets from these results were 
purified in mid-scale and tested for stability in different detergents for crystallization. The most 
promising hits were scaled up even further and purified for crystallization experiments. Detailed 
results from these preliminary trials can be found in section 6.7, however ultimately, we were 
unable to obtain crystals. For this reason, we decided to pursue a different approach inspired by 
the observation made by Jonathan Dworkin’s research group at Columbia University that a 
functional SEDS-PBP complex could be designed as a fusion [119]. Danger of a free complex 
becoming dissociated in detergent and compromising protein yields makes purification of a fusion 
protein preferable. For this reason, we have not pursued the complex without the fusion.   We 
were also aware of the fact that having with these fusion proteins would increase the molecular 
weight of the target, and introduce an extra-membrane feature of the soluble PBP transpeptidase 
domain, ultimately making the target more suitable for structural studies using cryo-EM.     
 
6.3 Design of SEDS-PBP fusion proteins 
 Jonathan Dworkin’s group at Columbia University has made recombinant fusions of 
SEDS-PBP proteins (SpoVE-SpoVD and FtsW-PBP3), which have been demonstrated to be 
functional in vivo [119] (these findings are described in more detail in Chapter 5, section 5.4). In 
collaboration with Jonathan Dworkin, we designed similar SEDS-PBP fusion proteins by matching 
each best expressing, detergent-stable SEDS protein from our initial structural genomics trials 
with its species-matched PBP partner. Fusions were designed with the PBP linked to the C-
terminus of the SEDS protein by a flexible linker of the amino acid sequence GSGSGS (Figure 
6.1). The resulting constructs were again tested for expression in small scale, and scaled up for 





Figure 6.1 Design of SEDS-PBP fusion proteins.  The design of the SEDS-PBP fusion proteins is 
shown here. The full length PBP (in green) is fused to the C-terminus of the SEDS protein (in blue) using 
a flexible linker (red) of the sequence GSGSGS.  
 
 
6.4 Structural studies of RodA-PBP2 by cryo-EM 
 Recent advances in the field of cryogenic electron microscopy (cryo-EM) such as the 
development and implementation of direct detectors and other computational methods have led 
to what has been coined the “resolution revolution” [133]. Achieving high resolution structures by 
Cryo-EM is now possible for macromolecules that were previously too small for this technique 
[133, 134]. SEDS proteins by themselves, which are only around 40-50 kDa, would still be too 
small and featureless to be successfully resolved by cryo-EM, but as fusions with PBPs they are 
now a suitable size for cryo-EM given the recent advancements in the field (110-130 kDa).  
 Briefly, the basic pipeline for single particle cryo-EM starts with a similar protein 
preparation as described for X-ray crystallography; however, once you obtain a pure, stable 
protein, instead of attempting to grow crystals, the protein in solution is prepared on grids. Initial 




high contrast images for assessment of sample quality, protein purity, and homogeneity that can 
be used to compute initial low resolution 3D reconstructions [135]. After assessment with negative 
stain, the use of the lower contrast and more time consuming cryo methods can be optimized to 
obtain high resolution structures [39]. For cryo-EM, protein is flash frozen and data are collected 
from an electron microscope in multiple frame movies. The individual frames in these movies can 
then be aligned to correct for beam-induced movement of the microscope stage or sample itself. 
Defocus determination and correction for aberrations from the microscope using the contrast 
transfer function (CTF). Individual protein particle images can be picked from corrected 
micrographs and used for 2D and 3D volume reconstruction [136]. This data collection and 
processing pipeline is outlined in Figure 6.2.  
 
Figure 6.2 Structure determination by single particle TEM and Cryo-EM. The experimental pipeline 
for structure determination by cryo-EM starts with protein purification. Initial lower resolution 2D and 3D 
models can be obtained using negative stain procedure in which protein is applied to grids and stained 
with chemicals such as Uranyl Formate (UF), causing protein particles to show light on a dark 
background. After negative stain assessment of protein quality, purified protein sample can be frozen on 
grids for cryo-EM. Micrographs are collected as many-framed movies, which are aligned and CTF 
corrected. Individual particle images are picked and aligned into 2D classes, which are then used to 
reconstruct a 3D volume or structure. Figure adapted from [136]. 




 For membrane proteins, detergent micelles can often contribute a high background to 
electron micrographs obtained [137], so other membrane mimetics are used to reduce 
background while also keeping your membrane protein stable. Amphipols are one example. They 
make up a class of amphipathic molecules, which act similar to detergent in stabilizing membrane 
proteins in solution by coating the hydrophobic regions (Figure 6.3 A) [138]. Another example is 
lipid nanodiscs using membrane scaffolding protein (MSP; Figure 6.3 B) [139]. In both methods 
for reconstitution of protein into amphipols or nanodiscs, the protein is purified as usual in 
detergent, then either amphipol or a mixture of MSPs and phopspholipids are added to the pure 
protein. Detergent is them removed by dialysis or the use of biobeads, resulting in a stabilized 
membrane protein without a high detergent micelle background.    
 After large scale purification, my best SEDS-PBP fusion target was RodA-PBP2 from 
E. coli, so structure determination by cryo-EM was pursued using this target. RodA-PBP2 was 
reconstituted into both amphipol and nanodisc, and screened with both negative stain and cryo-
EM. After optimization of grid preparation, we have collected a dataset of RodA-PBP2 on a Titan 





Figure 6.3 Detergent alternatives: amphipol and nanodisc. To reduce background on micrographs 
resulting from empty detergent micelles, we have used alternative membrane mimetics in our cryo-EM 
studies. A) Amphipol is an amphipathic molecule similar to detergent. You do not need excess amphipol 
in the solution to maintain a micelle once it is formed, so background is reduced. B) Nanodiscs can also 
be formed by incubating purified protein in detergent with phospholipids and membrane scaffolding 
proteins (MSPs). Biobeads are added to remove detergent, allowing the formation of the nanodisc made 
up of your membrane protein of interest surrounded by phospholipids contained by a belt of MSPs. Figure 
adapted from [139].  
 
 
6.5 Functional characterization of RodA-PBP2 fusion protein in nanodisc 
 Since we are working with an artificially fused protein complex, confirming that it still 
functions as expected becomes ever more so crucial. In collaboration with David Roper at the 




biosynthesis and antibiotic resistance [140-142], we have confirmed that the E. coli RodA-PBP2 
fusion is functional and that it can complete both the glycosyltransferase reaction as well as the 
transpeptidase reaction. We have not yet been able to assay a flippase activity, but we hope that 
this will also be possible in the near future.  
 
6.6 Methods 
6.6.1 Protein purification and crystallization trials of SEDS proteins 
 Protein expression and purification for small-scale expression tests and mid-scale 
detergent screening as well as large-scale purification of non-fusion SEDS proteins were 
performed as described in Chapter 2 (Section 2.3.2). During small scale expression tests, targets 
were transformed into our usual BL21 PLysS E. coli strain, as well as an E. coli strain provided 
by our collaborator Jonathan Dworkin, referred to as CAM33. Detergent screens were performed 
as described in Chapter 2 (section 2.3.3) with the addition of two more detergents: n-Nonyl-β-D-
Maltopyranoside (NM; included in SEC buffer at concentration of 0.5% (w/v)) and n-Octyl-β-D-
Glucopyranoside (OG; included in SEC buffer at a concentration of 1% (w/v)). Crystallization trials 
were carried out as described in Chapter 2 (section 2.3.4).  
 
6.6.2 Cloning of SEDS-PBP2 fusion proteins 
 The PBP partners of the best expressing SEDS proteins were identified (Table 6.2) 
and amplified from genomic DNA from the following bacterial strains: Enterococcus faecalis V583, 
Klebsiella pneumoniae subsp. pneumoniae MGH 78578, Escherichia coli str. K-12 substr. 
MG1655, Streptococcus pneumoniae TIGR4, and Escherichia fergusonii ATCC 35469. PBPs 
were cloned by Gibson assembly [73, 74] into the NYCOMPS expression vectors containing the 
genes for SEDS proteins already tested for expression. The details of these constructs can be 




of this chapter (Figure 6.1).  
 
Table 6.2 SEDS-PBP fusion proteins cloned. 
Bacterial species SEDS UniProt ID PBP UniProt ID MW (kDa) 
Enterococcus faecalis Q820T8 Q836V7 126.8 
Enterococcus faecalis Q820T8 Q830D1 122.8 
Klebsiella pneumoniae A0A0H3GLD1 A0A0W8ASI8 112.0 
Escherichia coli P0ABG7 P0AD65 111.8 
Streptococcus pneumoniae A0A062WN05 P14677 128.2 
Streptococcus pneumoniae A0A062WN05 A0A0Y0HFB8 119.7 
Streptococcus pneumoniae A0A062WN05 A0A0H2URT5 126.5 
Escherichia fergusonii B7LLH8 B7LLH7 111.7 
 
6.6.3 Protein purification of SEDS-PBP2 fusion proteins 
 Large-scale purification of RodA-PBP2 protein was performed similar to the protocol 
outlined in Chapter 2 (section 2.3.2), with some minor differences. In early purification attempts, 
RodA-PBP2 was not very stable and could not be left overnight for binding to nickel resin or for 
dialysis. Because of this instability over time, cleavage with TEV protease was omitted from the 
purification protocol. To increase purity in lieu of cleaving the 10x His tag as a second purification 
step, I insolated membranes and washed them with a high salt concentration before purification. 
Furthermore, to avoid protein precipitation, I performed the purification protocol in one day without 
any overnight incubation steps.  
 To prepare membranes, I used the following protocol.  E. coli cells expressing the 
target protein are grown and harvested as described in Chapter 2 (section 2.3.2). These cells are 
resuspended in Lysis Buffer (5 mL per gram of E. coli cells) containing 20 mM HEPES, pH 7.5, 
200 mM sodium chloride, 20 mM magnesium sulfate, RNase, DNase, PMSF, Complete protease 
inhibitor cocktail (Roche) and 1mM TCEP. Cells are lysed by pressure using the Emulsiflex C3 
(Avestin). Lysed cells are centrifuged 34,000 rpm and 4°C for 30 minutes. Supernatants are 




HEPES, pH 7.5, 500 mM sodium chloride, PMSF, Complete protease inhibitor cocktail (Roche) 
and 1mM TCEP) using a glass homogenizer. The washed membranes are again centrifuged at 
34,000 rpm and 4°C for 30 minutes. Supernatants are again discarded and the membrane fraction 
is resuspended in Lysis Buffer at the same volume as in the first step of the membrane preparation 
protocol using a glass homogenizer, resulting in a membrane resuspension at a concentration of 
~30 mg prepared membrane per mL of lysis buffer. The membranes can then be used 
immediately for subsequent protein purification or stored at -80°C for future use.  
 For protein purification, DDM is added to prepared membranes to a final concentration 
of 1% (w/v) to solubilize and extract the target proteins from the membrane. Solubilization is 
carried out for 1.5 hours at 4°C with gentle agitation or rotation. Samples were then spun at 34,000 
rpm at 4°C for 30 minutes to separate the insoluble fraction. The supernatant is added to Ni-NTA 
resin (Qiagen), which had been pre-equilibrated with buffer containing 20mM HEPES, pH 7.5, 
200 mM NaCl and 0.1% DDM. Imidazole is added to a final concentration of 40mM to reduce non-
specific binding to the nickel resin. Samples were incubated for 1-2 hours at 4°C with gentle 
agitation or rotation to facilitate protein binding to the resin. Samples were incubated on ice to 
settle the resin. The supernatant is removed and discarded. The remaining resin is washed with 
10 column volumes (C.V.) of wash buffer (20 mM HEPES, pH 7.5, 200 mM NaCl, 60 mM 
Imidazole, 0.1% DDM) and eluted with 3-4 C.V. of elution buffer (20 mM HEPES, pH 7.5, 200 mM 
NaCl, 300 mM Imidazole, 0.05 % DDM). Eluted protein is exchanged to buffer without imidazole 
(20 mM HEPES, pH 7.5, 200 mM NaCl, 0.05 % DDM) using a G-25 or PD-10 desalting column 
(GE Healthcare). Protein concentration is measured with a NanoDrop spectrophotometer 
(Thermo Fisher Scientific) using the calculated extinction coefficient of the target protein. The 
resulting protein is then reconstituted into amphipol or lipid nanodiscs.  
  




 Amphipol A8-35 (anatrace) is added to purified protein at a ratio of 1:3 (protein to 
amphipol; w/w), by weighing out the appropriate amount of Amphipol and dissolving in a small 
amount of buffer before adding to the protein solution. The solution with amphipol is incubated for 
4-5 hours at 4°C with rotation. After incubation, 100 mg of BioBeads (BioRad) per 1 mL of buffer 
containing detergent are added to the protein-amphipol mixture to remove detergent. The mixture 
with Bio-Beads is incubated overnight at 4°C with rotation. In the morning, the sample is removed 
from Bio-Beads by careful pipetting and the resulting protein in amphipol is subjected to size 
exclusion chromatography in a detergent-free buffer (containing 20 mM HEPES, pH 7.5 and 200 
mM NaCl) to remove excess amphipol, assess protein quality, and collect fractions of pure, stable 
protein. The resulting protein could be used for grid preparation for negative stain or cryo-EM 
experiments.  
 
6.6.5 Preparation of Membrane Scaffolding Proteins for nanodisc formation 
 E. coli One Shot BL21 Star competent cells (ThermoFisher Scientific) are transformed 
with pMSP1E3D1 (Addgene) and plated on a LB Agar plate containing 35 µg/ml Kanamycin and 
grown overnight at 37°C. A single colony from the resulting plate is used to inoculate 50 mL of LB 
containing 35 µg/ml Kanamycin. The culture is grown overnight at 37°C. 25 mL of the starter 
culture is added to 800 mL of 2xYT containing 35 µg/ml Kanamycin and grown at 37°C until the 
OD600 is between 1 and 1.2, when the incubator temperature is reduced to 28°C and 0.4 mM 
IPTG is added. Cells are grown for an additional 4 hours at this temperature. Cells are harvested 
at 4000 rpm at 4°C, supernatant removed, and the resulting cell pellets are stored at -80°C or 
used immediately for protein purification.   
 Cell pellets are resuspended in 15 mL pre-chilled lysis buffer (per 800 mL of bacterial 




RNase, DNase, PMSF, Complete protease inhibitor cocktail (Roche) and 1mM TCEP. Cells are 
lysed on ice by sonication at an amplitude of 35 W/cm2 for 20 minutes, alternating 30 seconds on 
and 30 seconds off. The lysed cells are then centrifuged at 34,000 rpm for 30 minutes at 4°C.  
 Supernatant is passed through a column of pre-equilibrated Ni-NTA resin (2 mL of 
nickel resin per 800 mL bacterial culture). The resin is washed with 3 C.V. of Cholate Buffer (20 
mM HEPES, pH 7.5, 0.3M sodium chloride and 50mM sodium cholate) and then washed with 10 
C.V. of Wash Buffer (20 mM HEPES, pH 7.5, 200 mM sodium chloride, 20 mM Imidazole) and 
then the eluted with 4 C.V. Elution Buffer (20 mM HEPES, pH 7.5, 200 mM sodium chloride, 300 
mM Imidazole). The eluted protein is dialyzed against 1 L of Dialysis Buffer (20mM Hepes pH 7.5, 
150mM sodium chloride) in the presence of TEV protease (1 mg TEV protease per 800 mL 
bacterial culture). Dialysis is carried out overnight at 4°C. Resulting protein is concentrated to 
about 10 mg/ml and stored in aliquots for future use.  
 
6.6.6 Preparation of lipids for nanodisc formation 
 For RodA-PBP2 reconstitution into nanodiscs, I use E. coli polar lipid extract (Avanti 
Polar Lipids) as the source of phospholipid. To prepare the lipid to add to the nanodisc reaction, 
lipid from the manufacturer in powder form is weighed into a glass vial. Buffer containing 20 mM 
HEPES, pH 7.5 and 150 mM NaCl is added to make a 10 mM lipid solution.  The amount of 
required lipid is calculated from the average molecular weight provided by Avanti Polar Lipids. 
The lipid mixture is then sonicated on a low setting with a tip sonicator or a water bath sonicator 
until the lipid solution is nearly clear and opalescent. This can be used immediately or stored in 
aliquots at -20°C for future use. If using a thawed aliquot, the lipid must be sonicated to the correct 
clarity once more.  
 




 Alternatively, the protein can be reconstituted into lipid nanodiscs using the prepared 
MSP as described in section 6.6.5 and lipids prepared as described in section 6.6.6 of this 
chapter. For RodA-PBP2, pure desalted protein is added to E. coli polar lipid extract and “medium” 
MSP 1E3D1 at a molar ratio of 1:285:5 (protein:lipid:MSP). The reaction mixture is incubated for 
2 hours at 4°C with gentile agitation and protected from light. After the incubation, 100 mg of Bio-
Beads (BioRad) per 1 mL of nanodisc mixture is added to remove the detergent and initiate 
nanodisc formation. The mixture with Bio-Beads is incubated overnight at 4°C with gentile 
agitation. In the morning, the mixture is removed from Bio-Beads by careful pipetting. To remove 
excess lipids and empty nanodiscs, the protein incorporated into nanodiscs is then added to fresh 
Ni-NTA resin, which had been pre-equilibrated with buffer containing 20mM HEPES and pH 7.5, 
200 mM NaCl. No imidazole is added. Binding is carried out for 2 hours at 4°C with gentle agitation 
or rotation. After binding, the nickel resin is washed with 10 column volumes (C.V.) of wash buffer 
(20 mM HEPES, pH 7.5, 200 mM NaCl, 60 mM Imidazole) and eluted with 3-4 C.V. of elution 
buffer (20 mM HEPES, pH 7.5, 200 mM NaCl, 300 mM Imidazole) both without detergent. The 
resulting protein in nanodisc is subjected to size exclusion chromatography in a detergent-free 
buffer (containing 20 mM HEPES, pH 7.5 and 200 mM NaCl) to assess protein quality, and collect 
fractions of pure, stable protein in nanodisc.  
 
6.6.8 EM and cryo-EM sample preparation, data collection, and data processing. 
 For negative stain experiments described here, 5 µl of purified protein sample 
reconstituted into amphipol at 0.01 mg/ml was applied to carbon grids (Carbon Type-B on 300 
mesh Cu; Ted Pella, Inc.) and incubated for 60 seconds. Filter paper was used to blot the excess 
liquid away. Grid was incubated in a solution of 2% Uranyl Formate (UF; w/v) for 30 seconds and 
washed with distilled deionized water several times and dried completely. These grids were 




Simons Electron Microscopy Center (SEMC) housed at the New York Structural Biology Center 
in New York, NY. Leginon [143] and Appion [144] computational tools were used to visualize and 
process data through the SEMC servers.  
 For cryo-EM, grids were prepared using a Vitribot (FEI) plunge freezer. 3 µl of purified 
protein reconstituted into amphipol or lipid nanodiscs at concentrations ranging from 0.15 to 0.8 
mg/ml was applied to C-Flat grids (CF-1.2/1.3-3Cu-50; Electron Microscopy Sciences) or gold 
grids (Ultra AU Foil R 1.2/1.3 300 Mesh; QuantaFoil), incubated for 30 seconds, blotted with filter 
paper for times ranging from 2.5 to 4.5 seconds and flash frozen in liquid ethane and stored in 
liquid nitrogen. Prepared grids were imaged with one of the following microscopes: Tecnai F20 
(FEI) housed at SEMC, Tecnai T12 (FEI) housed at SEMC, Tecnai F20 (FEI) housed at Columbia 
University, Tecnai Polara F30 (FEI) housed at Columbia, Titan Krios (FEI) housed at SEMC, or 
the Titan Krios (FEI) housed in the Midlands Regional Cryo-EM Facility at the University of 
Leicester in Leicester, UK. Data were collected and visualized with either Leginon or EPU. Frame 
alignment and dose weighting were performed with MotionCor2 [145] and CTF estimation was 
performed using Gctf [146]. 2D particle alignment, 3D reconstruction and refinement were carried 




6.7.1 Small scale expression of SEDS protein homologs 
 After the initial small-scale expression screening performed at NYSBC (section 6.2 of 
this chapter, Table 6.1), I confirmed expression of the positive targets in small-scale at our 
laboratory at Columbia University. From their original 189 targets, I retested 37 in two different E. 
coli cell strains (BL21 PLysS and CAM33) for expression. Of these, the best expressing targets 




expression and cleavage tests are shown in Table 6.3. Targets that expressed well and were 
successfully cleaved with TEV were scaled up for detergent screening.  
 
Table 6.3 Small scale expression and TEV cleavage tests for SEDS protein homologs. 
My ID Bacterial species MW 
(kDa) 
Expression in BL21* Expression in 
CAM33 
TEV 
B2-N Listeria monocytogenes 45.4 + + n/a 
B10-N Enterococcus faecalis 45.6 +++ + + 
C9-N Neisseria gonorrhoeae 48.9 - + n/a 
D8-N Streptococcus pneumoniae 46.4 +++ + - 
E5-C Burkholderia mallei 48.7 - - n/a 
F1-C Mycobacterium avium 53.0 +++ + - 
F3-C Colwellia psychrerythraea 42.2 + +  
F6-N Staphylococcus 
saprophyticus 
46.6 +++ + - 
G3-C Streptococcus pneumoniae 46.4 + + n/a 
G3-N Streptococcus pneumoniae 46.4 - - n/a 
H9-N Nitrosomonas europaea 44.0 - - n/a 
A8-N Escherichia coli 42.2 +++ + + 
A11-N Corynebacterium 
glutamicum 
50.0 - + n/a 
B2-N Pseudomonas putida 42.7 - - n/a 
B3-N Bacteroides 
thetaiotaomicron 
49.7 - - n/a 
C4-N Shewanella oneidensis 41.9 + - n/a 
C4-C Shewanella oneidensis 41.9 - - n/a 
C6-N Escherichia coli 42.2 +++ + + 
C10-N Klebsiella pneumoniae 42.2 +++ - + 
D10-C Listeria innocua 41.9 - - n/a 
D11-N Erwinia carotovora 42.2 +++ - + 
E4-C Clostridium perfringens 42.5 - - n/a 
F5-C Pseudomonas protegens 41.9 - - n/a 
F6-C Staphylococcus 
saprophyticus 
46.6 - - n/a 
G1-N Streptococcus pneumoniae 46.3 +++ - + 
G2-N Bacillus cereus 47.5 + - n/a 
G3-N Escherichia fergusonii 42.2 +++ + + 
G9-C Cronobacter sakazakii 42.2 - - n/a 
B2-N* Pseudomonas putida 42.7 + + n/a 
B3-N* Bacteroides 
thetaiotaomicron 
49.7 - - n/a 
C2-N* Enterobacter cloacae 42.2 + + n/a 
C5-N* Salmonella enterica 42.2 - - n/a 
D11-C* Erwinia carotovora 42.2 - - n/a 
E10-C* Bacillus halodurans 45.2 + + n/a 
H1-N* Thermus thermophilus 40.4 + + n/a 




G2-N* Bacillus cereus 47.5 - - n/a 
(+) indicates some expression detected (expression column), and successful cleavage (TEV column). 
(-) indicates no expression detected (expression column), or unsuccessful cleavage (TEV column). 
(+++) indicates best expression, which were tested for cleavage with TEV.  
 
6.7.2 Mid-scale expression, detergent screening, and crystallization trials of SEDS 
protein homologs 
 Proteins with the best expression and successful TEV cleavage were scaled up, 
purified in mid-scale and tested for stability in different detergents. Seven targets were identified 
as promising for mid-scale expression and the best expressing targets (B10-N, G3-N, C6-N and 
C10-N) were prioritized for detergent screening. Of these four, B10-N and G3-N were successfully 
screened for stability in detergents (Figure 6.4). B10-N resulted in the highest yields and the nicest 
looking peaks from size exclusion chromatography.  The yields of the other two targets (C6-N and 
C10-N) were too low. Since these were the highest expressing targets, it was reasoned that the 
others of less priority would also be too low and were not pursued for mid-scale screening.   
 
 
Figure 6.4 Mid-scale detergent screening for SEDS homologs. SEDS proteins that expressed well 
in small-scale expression tests and successfully cleaved with TEV were scaled up and tested for stability 
by exchanging to buffers with different detergents. This shows two of these targets, B10-N from 
Enterococcus faecalis (left) and G3-N from Streptococcus penumoniae (right). The top panel shows all 





 SEDS protein homolog B10-N from Enterococcus faecalis yielded the best expression 
and stability results. This protein was purified in large-scale for crystallization trials. First, this 
protein was purified using DDM as the solubilizing detergent and set up in LCP using two different 
lipid mixes. First, I used protein at a concentration of 34 mg/ml mixed with monoolein at a protein 
to lipid ratio of 1:1.5. Second, I used protein at a concentration of 20 mg/ml mixed with 7.8 MAG 
at a protein to lipid ratio of 1:1.2. I also purified this protein in DDM and exchanged to DeM on 
SEC. I set up vapor diffusion crystal trays with this protein at a concentration of 10 mg/ml. 
Unfortunately, none of these crystallization attempts yielded any crystals.  
  
6.7.3 Small scale expression of SEDS-PBP fusion proteins 
 Fusion proteins designed (as described in section 6.3 and cloned as described in 
section 6.6.2 of this chapter) were tested for expression in small scale. Many of the targets 
expressed, but the best expressing target was the RodA-PBP2 fusion protein from Escherichia 
coli. Details of the expression tests can be found in Table 6.4.  
 
Table 6.4 Small scale expression of SEDS-PBP fusion proteins.  
Bacterial species SEDS UniProt ID PBP UniProt ID MW (kDa) expressed 
Enterococcus faecalis Q820T8 Q836V7 126.8 - 
Enterococcus faecalis Q820T8 Q830D1 122.8 + 
Klebsiella pneumoniae A0A0H3GLD1 A0A0W8ASI8 112.0 + 
Escherichia coli P0ABG7 P0AD65 111.8 +++ 
Streptococcus pneumoniae A0A062WN05 P14677 128.2 + 
Streptococcus pneumoniae A0A062WN05 A0A0Y0HFB8 119.7 + 
Streptococcus pneumoniae A0A062WN05 A0A0H2URT5 126.5 - 
Escherichia fergusonii B7LLH8 B7LLH7 111.7 + 
(+) indicates some observed expression. 
(-) indicates no observed expression. 






6.7.4 Negative stain of RodA-PBP2 
 RodA-PBP2 was purified in large scale and reconstituted into amphipol. Size exclusion 
chromatography (SEC) of the resulting sample (Figure 6.5 A) resulted in many different peaks, 
but from SDS-PAGE analysis of the collected SEC fractions (Figure 6.5 B), all the peaks seem to 
contain the target protein (expected molecular weight of 112 kDa).  A fraction from the dominant 
peak was deposited on grids and treated with Uranyl Formate to negative stain the sample. Data 
was collected on the JEM-1230 (JEOL) microscope at SEMC (a representative micrograph is 
shown in Figure 6.5 C). The resulting 2D class averages (Figure 6.5 D) seem to show different 
oligomeric states, with some appearing to be a monomer, with a bulbous micelle around the 
transmembrane RodA and a smaller soluble protrusion (PBP2), and others that appear to be two 
such structures closely associated.  
Negative stain results from RodA-PBP2 in amphipol seemed promising, but when 
frozen in on grids for cryo-EM, the protein appeared aggregated and the resulting data provided 
very poor 2D classes that did not recapitulate the classes seen from the negative stain. For this 





Figure 6.5 Negative stain of RodA-PBP2 in amphipol. RodA-PBP2 was purified and resonstituted into 
amphipol. The resulting SEC profile is shown in A. The yellow bar indicates the fraction used for negative 
stain and the peak is annotated with a red asterisk. B) SDS-PAGE of the resulting fractions of the SEC 
profile in A. Again the peak used for negative stain is indicated with a red asterisk. C) A resulting 
micrograph of RodA-PBP2 stained with Uranyl Formate. D) 2D classes resulting from the negative stain 
data collection. Possible monomer (red) and dimer (blue) classes are indicated.  
 
6.7.5 Cryo-EM of RodA-PBP2 
 RodA-PBP2 was purified, reconstituted into nanodiscs, and run on size exclusion 
chromatography. The resulting SEC elution profile reveals two main overlapping peaks. The peak 
further to the right was taken for cryo-EM studies in an attempt to characterize a monomeric 
protein (Figure 6.6 A). SDS-PAGE analysis of the resulting peak suggests successful 
incorporation into nanodiscs, as the MSP protein is clearly seen on the gel in the same fractions 




screening on a Tecnai F20 or collection on the Tecnai Poalra F30, allowed us to optimize the 
sample concentration and freezing conditions enough to justify collection on the Titan Krios 
microscope at the Midlands Regional Cryo-EM Facility at the University of Leicester in Leicester, 
UK. A representative micrograph from this collection is shown in Figure 6.6 C and resulting 2D 
class averages in Figure 6.6 D. Secondary structural elements of the protein can already be 
discerned looking at the 2D class averages. Comparing these 2D classes to the available 
structures (Figure 6.7 A), it does resemble what would be expected for the RodA-PBP2 complex.      
 These data were processed further using primarily cryoSPARC. We were able to 
reconstruct a preliminary 3D volume, however we were not able to refine the density beyond the 
point shown in Figure 6.7 B and C. The distribution of particle views included in this 3D 
reconstruction (Figure 6.7 D; as supplied by cryoSPARC) shows heavy clustering and suggests 
that there is preferred orientation of our particles frozen on the grids. We are actively engaged in 
solving this problem and pursue a higher quality 3D reconstruction of this protein complex by cryo-
EM. The details of our ongoing work and how we plan to solve this problem will be discussed in 





Figure 6.6 Reconstitution of RodA-PBP2 into nanodisc and cryo-EM collection. A) Size exclusion 
chromatography profile of RodA-PBP2 after nanodisc incorporation. Yellow bar indicates the fraction that 
was taken for subsequent cryo-EM grid preparation. B) SDS-PAGE analysis of fractions collected from 
the SEC run shown in A. The red asterisk indicates the same fraction that was taken for cryo-EM grid 
preparation. C) Representative micrograph from the Titan Krios data collection (left) with diagnostics 
including drift, defocus estimation (Def) and power spectrum (right). D) Resulting 2D classes calculated 






Figure 6.7 Preliminary 3D reconstruction of RodA-PBP2. A) Simple composite of available structures 
of RodA (PDB 6BAR) and PBP2 (PDB 5LP5) of what is expected for the RodA-PBP2 complex.  B) 
Preliminary 3D reconstruction of RodA-PBP2 from cryo-EM data using cryoSPARC with a slice through 
the nanodisc region to show the volume corresponding to TM helices from RodA-PBP2. This volume is 
rotated 90° to achieve the view in C. D) Distribution by view of particles used to build and refine the 
volume shown in B and C as calculated by cryoSPARC, which seems to indicate there is preferred 





 We have taken a structural genomics approach to determine the structure of a SEDS 
protein. While this was not especially fruitful, we used our results from these experiments to guide 
a secondary approach in our design of fusion complexes of SEDS proteins with their functional 
PBP partners. The best fusion target, RodA-PBP2 from E. coli was reconstituted into amphipol 
and nanodisc for the use in cryo-EM analysis and we have collected a data set on a Titan Krios, 
which has yielded a preliminary 3D reconstruction (Figure 6.7 B and C).  
 What I have described above is, in my opinion, a very promising start toward 
determining the structure of the RodA-PBP2 complex by cryo-EM. Indeed, our preliminary 
structure appears to be forming a stable complex, and is not too flexible to be resolved by cryo-
EM. Furthermore, even in its preliminary stage, it seems to resemble the expected folds of the 
RodA and PBP2 proteins. Ultimately, we are most interested in understanding how these two 
proteins interact in a complex and how they achieve their joint function. This will require a higher 
resolution structure. In order to achieve this, we must solve some of the problems we have 
encountered, such as preferred particle orientation. I will discuss our plans for future experiments 








Ongoing experiments and Future Directions: RodA-PBP2 
 
7.1 Introduction 
 As presented in Chapter 6, we have been able to reconstruct a preliminary 3D density 
map from cryo-EM data of the RodA-PBP2 fusion protein incorporated into nanodiscs. However, 
the resulting data seem to show a preferred orientation for particles when frozen on grids, which 
represents a commonly observed issue with this technique [149, 150]. To achieve a high 
resolution structure, we must solve this problem. This project is still in its preliminary stages, so 
substantial work must still be done to solve the structure as well as further probe structure-function 
relationship of the fusion protein. In this Chapter, I will describe this ongoing work and our long 
term goals.  
  
7.2 Resolving the issue of RodA-PBP2 preferred orientation 
 Preferred particle orientation is a classic problem in cryo-EM and methods 
development to compensate for preferred orientation have the focus of much research [149-151]. 
One way we hope to solve the preferred orientation issue of RodA-PBP2 is to collect data with a 
tilt as described in Tan, et al. in [150]. This allows the collection of a larger number of particle 
views, which expands the sampled Fourier space (Figure 7.1). However, there are some 
limitations to using this approach. Resolution in data collected with tilt is usually lower because of 
the thicker ice the beam has to pass through. The data processing is also more labor intensive 
as well because the defocus at every particle is different, so CTF correction must be undertaken 
at a single particle level. This can also introduce errors, which are another limiting factor for 
resolution. Despite these limitations and concerns, we have recently collected a dataset on the 





Figure 7.1 Resolving preferred particle orientation with tilt. In the event of observed preferred 
orientation, one way to resolve the issue is to collect with a tilt (a). This will produce a variety of views 
that are not seen when collection is undertaken at 0° tilt (b), and ultimately allowing you to sample more 
Fourier space, resulting in a more reliable 3D reconstruction (c). Figure adapted from [150]. 
 
 If the use of tilt does not solve the preferred orientation, other ways to solve the issue 
would be to include additives or surfactants in the protein solution before freezing grids that will 
insulate the particles in the thin aqueous layer from the forces present at the air-water interface 
that could be influencing the particle orientation. Additives that are commonly used for this 
purpose include detergents and glycerol [149]. There are many other approaches that can be 
taken at the sample preparation level, such as adjusting the pH of the buffering solution or using 
different blotting paper on the plunge freezer.  Something as simple as freezing the protein on 
different grids with support films or simply at a higher concentration might help the preferred 
orientation issue. These are all things we plan to try and we are continuing to test grid preparation 
conditions and assess quality with data collection on the Tecnai F20 microscope. The end goal 
of this optimization is to determine a high-resolution structure of the RodA-PBP2 complex in order 
to assess protein-protein interactions and generate structure-based hypotheses. These 
hypotheses will then be tested with a functional readout.   
 




 We have been collaborating with David Roper at the University of Warwick, who has 
a working biochemical assay to assess glycosyltransferase and transpeptidase activity of purified 
proteins, including our RodA-PBP2 enzyme reconstituted into nanodisc. The assays performed 
by David Roper’s group are well established and described in [140, 152-155]. These are gel-
based techniques in which fluorescently labelled Lipid II variants are incubated with the purified 
enzyme, RodA-PBP2. The discrete glycan products of increasing size can be separated on a 9% 
acrylamide gel to see the processive glycosyltransferase and transpeptidase activity of the 
enzyme. b-lactam antibiotics can also be included to confirm specificity of the reaction. They have 
already been able to perform these assays on purified RodA-PBP2 fusion protein in nanodisc and 
assess baseline function (data not shown here), and this assay among others that are yet to be 
determined, will be used to further probe function of the complex as informed by the structural 
information obtained.  
 We are also collaborating with Jonathan Dworkin at Columbia University medical 
center, who has been working to characterize the SEDS-PBP protein complex genetically using 
Bacilis subtilis as a model [119]. We will also be working with his group to test functional 
hypotheses in vivo using his established bacterial systems.  
 
7.4 Conclusions  
 We are currently working to solve the issue of preferred orientation observed in the 
RodA-PBP2 cryo-EM data. We are experimenting using tilt during data collection and we are 
currently optimizing our grid preparation to increase the variety of particle orientation in thin 
vitreous ice. We hope that these efforts will soon yield a high-resolution structure of the RodA-
PBP2 complex that will inform biochemical functional investigation of the purified enzyme as well 




understanding of these incredibly important enzymes and inform the future of antibiotic research 






Structural basis for catalysis at the membrane-water interface 
 
One of the overarching interests of Dr. Mancia’s laboratory is membrane embedded 
enzymes and how they interact with both lipidic and water-soluble substrates during catalysis.  
Both PIPS and the RodA-PBP2 complex fit into this broader category of enzymes that catalyze 
reactions at the membrane-water interface. Understanding their structure and function add to the 
broader understanding of this enzymatic process combining substrates of different chemical 
character. In this Chapter, I present the review published in Biochimica et Biophysica Acta [156] 
for which I am primary contributor. This work describes our current structural knowledge of this 
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